Building a better bypass with emphasis on bilateral internal mammary grafting by Kieser, T.M. (Teresa)
BUILDING A BETTER BYPASS WITH EMPHASIS ON 
BILATERAL INTERNAL MAMMARY GRAFTING
Teresa Mary Kieser
Pictures by Jean Prieur 
Picture Captions
Cover:  ‘Three Sisters, Canmore Alberta’
Chapter 1: ‘Erasmus’
Chapter 2: ‘Boats in waiting’
Chapter 3: ‘Take-o’
Chapter 4: ‘View from Sulphur Mountain, Ban, Alberta’
Chapter 5:  ‘Hermit Crab’
Chapter 6: ‘Florentine Fields’
Chapter 7: ‘Stargazer Lilies’
Chapter 8: ‘Flow…’
Chapter 9: ‘Reection’
Chapter 10: ‘View from Piazzale San Michelangelo, Florence’
Chapter 11: ‘Sunset over Brentwood Bay, Vancouver Island, British Columbia’
Chapter 12: ‘Erasmus’
Chapter 13: ‘Almaty, Kazakhstan’
Chapter 14: ‘Lily pads, Lac Bataille, Gatineau, Quebec’
Chapter 15: ‘Sunset, San Lucia’
Chapter 16: ‘Jack Frost’
Chapter 17: ‘Artwork, Erasmus Medical Centre’
Chapter 18: ‘Lake Louise, Alberta’
Chapter 19: ‘Charyn Canyon, Kazakhstan’
Chapter 20: ‘Young elk grazing in the Rockies, Alberta’
Chapter 21: ‘Tulips, close and far’
Chapter 22: ‘Five Sails, San Lucia’
Chapter 23: ‘Betwixt Heaven and Earth’
Layout and Printing: Optima Grasche Communicatie (www.ogc.nl)
BUILDING A BETTER BYPASS WITH EMPHASIS ON 
BILATERAL INTERNAL MAMMARY GRAFTING
Het optimaliseren van een bypass: 
 nadruk op het gebruik van twee interne thoracale slagaderen
Thesis
To obtain the degree of Doctor from the
Erasmus University Rotterdam
By command of the
Rector Magnicus
Prof. Dr. H.A.P. Pols
And in accordance with the decision of the Doctorate Board
The public defense shall be held on
Thursday the 8th of October 2015 at 15:30am
By
Teresa Mary Kieser
Born the 29th of January 1952 in 
London Ontario, Canada
DOCTORAL COMMITTEE
Promotor: Prof. dr. A.P. Kappetein
Other Members: Prof. dr. A.J.J.C Bogers
 Prof. dr. F. Zijlstra
 Prof. dr. R.J. Klautz
TABLE OF CONTENTS
Part 1 INTRODUCTION
Chapter 1 General introduction 13
Chapter 2 Aim and Outline 19
PART 2 RATIONALES FOR USE OF BILATERAL INTERNAL MAMMARY 
ARTERY GRAFTING IN THE MAJORITY OF CORONARY 
ARTERY BYPASS GRAFT PATIENTS
Chapter 3 Coronary artery bypass grafting: Part 1 – the evolution over the 
rst 50 years
27
Head SJ, Kieser TM, Falk V, Huysmans HA, Kappetein AP
Eur Heart J 2013;34:2862-2872
Chapter 4 Coronary artery bypass grafting: Part 2 – optimizing outcomes 
and future prospects
47
Head SJ, Börgermann J, Osnabrugge RLJ, Kieser TM, Falk V, Taggart DP, Puskas 
JD, Grummert JF, Kappetein AP
Eur Heart J 2013;34:2873-2886
Chapter 5 The radial artery: neither gold, nor silver, but bronze? 67
Kieser TM
J Thorac Cardiovasc Surg 2004;127:607-608
Chapter 6 Bilateral internal mammary artery grafting in CABG surgery: an 
extra 20 minutes for an extra 20 years…
73
Kieser TM
EuroIntervention 2013;9:899-901
PART 3 PATIENT’S AGE OF BENEFIT FOR BILATERAL INTERNAL 
MAMMARY ARTERY GRAFTING
Chapter 7 Outcomes associated with bilateral internal thoracic artery 
grafting: the importance of age
79
Kieser TM, Lewin AM, Graham MM, Martin BJ, Galbraith PD, Rabi DM, Norris 
CM, Faris PD, Knudtson ML, Ghali WA
Ann Thorac Surg 2011;92:1269-76
PART 4 REDUCING THE RISKS ASSOCIATED WITH BILATERAL 
INTERNAL MAMMARY ARTERY GRAFTING
Chapter 8 Transit-time ow predicts outcomes in coronary artery bypass 
graft patients: a series of 1000 consecutive arterial grafts
91
Kieser TM, Rose S, Kowalewski R, Belenkie I
Eur J Cardiothorac Surg 2010;38:155-162
Chapter 9 Adhesive-enhanced sternal closure to improve postoperative 
functional recovery: a pilot, randomized controlled trial
101
Fedak PWM, Kieser TM, Maitland AM, Holland M, Kasatkin A , LeBlanc P, Kim 
JK, King KM
Ann Thorac Surg 2011;92:1444-50
Chapter 10 Toward zero: deep sternal wound infection after 1001 
consecutive coronary artery bypass procedures using arterial 
grafts: implications for diabetic patients
111
Kieser TM, Rose MS, Aluthman U, Montgomery M, Louie T, Belenkie I
J Thorac Cardiovasc Surg 2014;148:1887-95
PART 5 COMPLETENESS OF REVASCULARIZATION AND BILATERAL 
INTERNAL MAMMARY ARTERY GRAFTING
Chapter 11 Arterial grafts balance survival between incomplete and 
complete revascularization: a series of 1000 consecutive 
coronary artery bypass graft patients with 98% arterial grafts
123
Kieser TM, Curran HJ, Rose MS, Norris CM, Graham MM
J Thorac Cardiovasc Surg 2014;147:75-84
Chapter 12 Arterial grafting and complete revascularization: challenge or 
compromise?
135
Kieser TM, Head SJ, Kappetein AP
Curr Opin Cardiol 2013;28:1-8
PART 6 FACILITATING SURGICAL USE OF BILATERAL INTERNAL 
MAMMARY ARTERY GRAFTING
Chapter 13 Quicker yet safe: skeletonization of 1640 internal mammary 
arteries with harmonic technology in 965 patients
147
Kieser TM, Rose MS, Aluthman U, Narine K
Eur J Cardiothorac Surg 2014;45(5):142-50
Chapter 14 Skeletonization of the internal mammary artery with the 
harmonic hook blade
159
Kieser TM, Narine K
CTSNet Video published on July 12 2012 Website: http://www.ctsnet.org/
sections/videosection/videos/vg2012_KieserT_Harmonic
PART 7 SPECIAL TECHNIQUES IN THE USE OF ARTERIAL GRAFTING
Chapter 15 Sequential coronary bypass grafts 169
Kieser TM, FitzGibbon GM, Keon WJ
J Thorac Cardiovasc Surg 1986;91:767-772
Chapter 16 Iatrogenic Aortic Root and Left Main Dissection in CABG 
Surgery: An Unconventional Fix
177
Kieser TM, Spence FP, Kowalewski R
CTSNet Video published on Nov 3 2014 Website:
http://www.ctsnet.org/article/iatrogenic-aortic-root-and-left-main-
dissection-cabg-surgery-unconventional-x
PART 8 GENERAL DISCUSSION AND CONCLUSIONS
SUMMARY
EPILOGUE
Chapter 17 General Discussion and Conclusions 183
Chapter 18 Summary English (summary of each part) 193
Chapter 19 Nederlandse Samenvatting (summary Dutch) 201
Chapter 20 PhD portfolio 211
Chapter 21 List of publications 217
Chapter 22 About the author 225
Chapter 23 Acknowledgements 229

PART 1
INTRODUCTION

General Introduction
“I shall pass this way but once; any good that I can 
do or any kindness I can show to any human being; 
let me do it now. Let me not defer nor neglect it,  
for I shall not pass this way again.”
Etienne de Grellet
Quaker Missionary
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Introduction
The coronary artery bypass graft (CABG) operation has been a mainstay for the treat-
ment of coronary artery disease (CAD) for more than 50 years. It is hoped that this body 
of work presents evidence for and facilitates the use of the very best ‘substitute’ coronary 
arteries available – the internal mammary arteries – right and left.
Coronary artery disease is a chronic disease; it is not curable. The diagnosis of athero-
sclerosis is a life sentence. A chronic disease that causes only minor limitation of activities 
is compatible with a good and happy life but a disease which carries with it the possibil-
ity of sudden death is not. Damocles an envious courtier of King Dionysius II willingly 
accepted a change of place with his king, until he realized that above his head hung a 
huge sword, held by a single hair of a horse’s tail. Cicero (3 Jan 106 BC – 7 December 43 
BC) in his Tusculanae Disputationes, V. 62, asked: ‘Satisne videtur declarasse Dionysius 
nihil esse ei beatum, cui semper aliqui terror impendeat?’ or ‘Does not Dionysius seem 
to have made it suciently clear that there can be nothing happy for the person over 
whom some fear always looms?’ [1]
The spectre of CAD has plagued mankind for centuries. Just after William Harvey 
(1578-1657) discovered the circulation of blood, Professor Homan (1660-1742) at the 
University of Halle noted that CAD started in the ‘reduced passage of the blood within 
the coronary arteries’. [2] As physicians and surgeons, all we can hope to do is to amelio-
rate, palliate or reduce the progression of this disease. The treatment has come a long 
way since the early diagnosis. However, as there is always room for improvement; it is the 
wish of this author to convince readers of the value and possibility of a way to remove 
the ‘sword of Damocles’ or at the very least - use more than one horse hair to secure it.
The surgical treatment of obstructive CAD, CABG involves the addition of ‘new routes 
to Rome’ in the form of either vein from the leg or arteries from the chest and/or arms. 
Although the preferred conduit in use for more than 50 years, the saphenous vein does 
not stand up to the test of time. At 12.5 years post-operatively, 60% of saphenous vein 
grafts are occluded or severely diseased [3], whereas 95% of internal mammary arteries 
(IMA) are well patent at 10 years. [4] The preferred use of the saphenous vein as a bypass 
conduit continues despite an ever increasing body of evidence that arterial grafting - 
especially with the IMA - confers not only longevity to the bypass, but also to the patient. 
It was in 1986 that Floyd Loop in the New England Journal of Medicine reported that use 
of just one internal mammary artery conferred not only increased patient survival, but 
also a better quality of cardiac-disease free life. ‘ After an adjustment for demographic 
and clinical dierences by Cox multivariate analysis, he found that patients who had only 
vein grafts had a 1.61 times greater risk of death throughout the 10 years, as compared 
with those who received an internal mammary artery graft. In addition, patients who 
received only vein grafts had 1.41 times the risk of late myocardial infarction (P<0.001), 
1.25 times the risk of hospitalization for cardiac events (P<0.0001), and 1.27 times the 
risk of all late cardiac events (P<0.0001), as compared with patients who received IMA 
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grafts.’[5] Then in 1999, Bruce Lytle and colleagues produced convincing evidence that 
‘Two internal thoracic artery grafts are better than one.’ He found that after reviewing 
10,124 patients over a mean follow-up of 10 postoperative years that ‘survival for the 
bilateral IMA group was 94%, 84% and 67%, while for the single IMA group it was only 
92%, 79%, and 64% at 5, 10, and 15 postoperative years, respectively (P < 0.001).’ [6]
We come now to the reason for this thesis: contemporary CABG is performed with 
bilateral IMA grafts in only 4% of patients in North America, 12% in Europe and 30% 
in Japan. Why is this? Reasons are many and varied; the basis of this thesis contains 
research intended to counteract rationale opposing more liberal use of bilateral internal 
mammary grafting.
‘I will give thanks unto thee: for I am fearfully and wonderfully made: wonderful are thy 
works; and that my soul knoweth right well.’ (English Revised Version of Psalm 139:14). 
We are wonderfully made indeed. Coronary artery bypass grafting is ‘reconstructive’ in 
nature, unlike ‘ablative’ surgery as in excision/removal of a left atrial myxoma. Recon-
structive surgery requiring ‘extra parts’ is advantaged if these ‘spare parts’ are close-by. 
Internal mammary arteries or ‘internal thoracic arteries’ are situated in the thorax right 
next to the heart. They are so close that one end can even be ‘left attached’, thereby 
reducing the amount of eort for their use. They are also the only artery in the human 
body endowed with nitric oxide secreting properties, which protects them from the 
development of atherosclerosis. The Almighty is probably wondering why after His 
creation of such beautiful conduits situated right next to the heart, that all too often 
we go to the farthest corner of the human body –  the ankle –  to procure the inferior 
saphenous vein.
In the recent 2014 Guidelines for myocardial revascularization [7], it is recommended 
that ‘Bilateral IMA grafting should be considered in patients <70 years of age’. If these 
guidelines were to be followed, so many lives could be improved. For example, if the 
average age of patients undergoing CABG is approximately 65 years of age [8], then 
performance of BIMA grafting in patients 70 years and younger would lead to more than 
50% of patients undergoing CABG with BIMA grafting – more than 10 times the current 
rate in North America, and 5 times the rate in Europe.
Why then do we not as surgeons as part of our treatment of this most lethal disease, 
give patients the very best ‘fresh start’ that we are able? This body of work seeks to dispel 
every fear, remove every refutation against more frequent use of internal mammary 
arteries; it hopes to empower surgeons with the ability to do this condently and safely 
in their practice.
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Aim and outline
The goals for this thesis are 1) to encourage the use of bilateral internal mammary artery 
(BIMA) grafting more frequently so that many more patients receive the ‘BIMA benet’ 
and 2) to ensure that an increase in bilateral IMA grafting is achieved with accuracy and 
no greater morbidity than that which is achieved with one IMA and the rest of bypasses 
with a saphenous vein.
Revascularization of diseased coronary arteries may be accomplished in one of two 
ways: by percutaneous coronary intervention (PCI) or by coronary artery bypass graft 
surgery (CABG). The principal dierence between the two procedures involves the length 
of coronary artery needed to be addressed to improve blood ow to the heart. PCI with 
placement of stents must open all signicantly obstructed areas along a coronary artery 
whereas in CABG, a surgeon needs only a ‘postage-stamp’ size of disease-free artery in 
order to perform an anastomosis. However as with everything in life, there are pros and 
cons to both approaches. PCI is quicker and requires no surgical incision from which 
a patient must recover. CABG is a major surgical procedure with all the inherent risks 
associated with a median sternotomy and the use of a heart-lung machine (or not, in the 
case of o-pump CABG). Patients are naturally drawn to the less invasive PCI but recent 
publications, most notably the recent 5 year SYNTAX trial results have clearly shown an 
advantage for CABG for the majority of patients needing revascularization [1]. ‘Pay me 
now or pay me later’ is a saying that comes to mind…
Coronary artery bypass grafting (CABG) has remained the cornerstone treatment for 
obstructive coronary artery disease for more than 50 years. Chapters 3 and 4 outline 
the past and the present/future of the CABG procedure, respectively. Chapters 5 and 
6 are commentary articles on the benet of bilateral IMA grafting. Chapter 7 addresses 
the possibility of an age cut-o as to the survival benet of BIMA use.
BIMA grafting is technically more challenging – all the more reason to use an intra-
operative assessment of graft function to ensure bypasses are functioning to the best of 
a surgeon’s ability before the patient leaves the operating room. (Chapter 8) Operative 
revascularization is more invasive compared to that with PCI but cementing a sternum 
solid within 24 hours of operation may possibly reduce the relative invasiveness of 
CABG, especially when the revascularization rate for CABG is so much lower than PCI. 
(Chapter 9)
BIMA grafting is denitely associated with an increase in deep sternal wound infec-
tion, one of the most dreaded complications of CABG surgery and commonest reason 
for not performing BIMA grafting. However if many preventive measures/procedures are 
used meticulously and consistently on every patient, the risk for this complication can 
be reduced to almost zero. (Chapter 10)
Complete revascularization has been found to improve the survival of patients un-
dergoing CABG surgery; however it is not always possible to completely revascularize a 
patient. For example if coronary arteries are very small, diusely diseased or are mostly 
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in scar tissue it may not be possible or even advisable to perform bypasses to such arter-
ies. We have shown that if total arterial grafting (with the majority of arterial grafts of 
internal mammary artery origin) is used, there is no dierence in midterm survival if a 
patient is incompletely revascularized by inability to bypass one of three artery systems. 
This is a valuable point as there is only a nite amount of arterial conduit available and 
there may not be enough to perform all bypasses desired. (Chapter 11 and 12)
BIMA grafting does take increased operative time but harmonic ultrasound technol-
ogy used to skeletonize IMAs helps shorten this time. (Chapter 13 and 14) Chapter15 
discusses sequential bypass grafts and the inherent risk of losing the second anastomo-
sis in preference to the rst, a serious problem if the second anastomosis is to the more 
important artery. Chapter 16 presents a rare complication of CABG surgery but from 
this problem, an operative technique has been developed that is applicable to similar 
patients with prohibitively calcied coronary arteries.
To summarize: It is the author’s wish to 1) refute every reason used as to why BIMA 
grafting is not performed more frequently and 2) to establish credible studies and 
guides to encourage their use.
23
Aim and outline
REFERENCES:
 1. Head SJ, Davierwala PM, Serruys PW, Redwood SR, Colombo A, Mack MJ, Morice MC, Holmes 
DR Jr, Feldman TE, Ståhle E, Underwood P, Dawkins KD, Kappetein AP, Mohr FW. Coronary artery 
bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: 
nal ve-year follow-up of the SYNTAX trial. Eur Heart J 2014;35(40):2821-30

PART 2
RATIONALES FOR USE OF BILATERAL 
INTERNAL MAMMARY ARTERY GRAFTING 
IN THE MAJORITY OF CORONARY ARTERY 
BYPASS GRAFT PATIENTS

Chapter 3
Coronary artery bypass grafting:  
Part 1 – the evolution over the rst 50 years
Head SJ, Kieser TM, Falk V, Huysmans HA, Kappetein AP
Eur Heart J 2013;34:2862-2872
Chapter 3
28
REVIEW
Clinical update
Coronary artery bypass grafting: Part 1—the
evolution over the first 50 years
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Surgical treatment for angina pectoris was first proposed in 1899. Decades of experimental surgery for coronary artery disease finally led to the
introduction of coronary artery bypass grafting (CABG) in 1964.Now that we are approaching 50 years of CABGexperience, it is appropriate to
summarize the advancement of CABG into a procedure that is safe and efficient. This review provides a historical recapitulation of experimental
surgery, theevolutionof the surgical techniquesand theutilizationofCABG.Furthermore,dataoncontemporaryclinical outcomesarediscussed.
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Introduction
In 1899, Francois Franck proffered the first surgical treatment for
angina pectoris; he believed that ligation of sympathetic pain pathways
would result in relief of angina.1 Several decades later, a number of
groups started performing surgical sympathectomy that indeed
resulted in relief of angina, yet this was found to be inconsistent.
Moreover, mortality remained high during follow-up, and although
patients no longer experienced symptoms, the consequences of the
underlying coronary artery disease (CAD) continued.
To specifically address reduced myocardial perfusion, several ex-
perimental surgical techniques were designed to supply external
blood to the myocardium (Figure 1). Thorel in 1903 suggested that
pericardial adhesions to the myocardium could provide blood to is-
chaemic areas,2 which was confirmed in 1932 by Moritz et al.3 Peri-
cardial abrasion was performed either mechanically or with the use
of irritants (e.g. beef bone, aleuronat, talc) to initiate formation of
adhesions.4,5 Simultaneously, numerous tissues were used as ‘collat-
erals’ and sutured to the ventricle:1,6 in 1935, Beck used the pectoral
muscle,7 in 1936 O’Shaugnessy the great omentum,8 in 1937 Lezius
the lung,9 and in 1954 Key used a pedicle of jejunum.10
The internalmammaryartery (IMA) formedan areaof interest early
on, particularly after the report of Fieschi in 1939. He ligated the right
IMA at the second intercostal space to increase blood flow to the
coronary circuit through smaller anastomotic collaterals from the
IMA bed.4 Although angina was significantly reduced in up to 95% of
patients,11 a study with sham controls proved no benefit of ligating
the IMA.12 It was not until the work by Arthur Vineberg in 1946 that
the use of the IMAwas starting to show promising results.13 He skele-
tonized the left IMA and tunneled the artery next to the left anterior
descending (LAD) coronary artery—without using any anasto-
mosis—in a tract in the ventricular wall he made with a tonsil-type in-
strument. Remarkably, in 71% of dogs with ischaemic heart disease
spontaneous anastomosis developed;14 probably because dogs have
greater capacity to form collaterals.15 Beck in 1946 moved away
from the IMA and focused on the coronary sinus; in dogs he used a
segment of the carotid artery as a graft between the descending
aorta and coronary sinus creating a systemic-cardiac arteriovenous
fistula,16 which for obvious reasons failed to help patients. Prophetic-
ally,Murray in1954 suggested that onewouldneeddirect anastomosis
to the LAD to provide the best results, and like Beck he also favoured
the carotid artery.17 Thereafter, Goetz and colleagues in 1960 per-
formed an IMA-right coronary artery anastomosis using a nonsuture
technique with a tantalum ring as a connector device.18
One of the most crucial developments was that of coronary angi-
ography byMason Sones;19 he demonstrated the formation of collat-
erals after the Vineberg operation, but, more importantly, was able
to evaluate native coronary arteries and identify lesions that required
* Corresponding author. Tel: +31 10 70 35784, Fax: +31 1070 33993, Email: a.kappetein@erasmusmc.nl
Published on behalf of the European Society of Cardiology. All rights reserved.& The Author 2013. For permissions please email: journals.permissions@oup.com
European Heart Journal (2013) 34, 2862–2872
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Fifty years of CABG
targeted therapy. Coronary angiography was quickly considered to
be mandatory to select patients and plan the procedure. Its use
during follow-up resulted in the recommendation to perform revas-
cularizationoncoronaryarterieswith.75%stenosis toensuregood
patency rates.20
These advancements finally led to the ‘modern’ coronary artery
bypass grafting (CABG) procedure of the mid-1960s (Figure 2A).
Vasilii Kolesov is believed to have been the first to perform a
sutured anastomosis of an IMA to the LAD on February 25th,
1964.21 Later that year, on November 23rd, a team led by Michael
DeBakey performed a saphenous vein aorta-coronary bypass with
a continuous suture technique.22 Although not the first to perform
this operation, Rene´ Favaloro was the first to systematically
perform CABG with reproducible results.23 He is considered the
‘father’ of bypass surgery and is acknowledged for his tremendous
contribution in the field of surgical revascularization.20,24
From initial experiences
to the standard of care
Quickly it became clear that given the limited possibilities of medical
therapy at the time, surgical revascularization could be very beneficial
for patients with CAD. In a review of .10 000 CABG procedures
performed before 1971 at 16 selected centres, 70–95% of patients
had improved their symptomatic status and 60–70% became asymp-
tomatic.25 However, operative mortality was as high as 10% in some
large series.20,25 Skepticismwas additionally fueled by a perioperative
myocardial infarction (MI) rate of 15%.26 With growing experience,
the rate of mortality andMI reduced significantly,27 but still remained
high in some all-comers series; respectively 7 and 14%.28 Selection
of patients appeared of paramount importance, as mortality was sig-
nificantly higher in patients who suffered a recent MI with/without
severe left ventricular dysfunction,29,30 or who underwent concomi-
tant procedures.28
The controversial early data unmasked the need for comparative
effectiveness analyses of CABG and medical therapy in the form of
randomized clinical trials. While it was unquestionable that surgery
relieved angina, it remained unclear whether there would also be a
benefit in reducing long-termmortality and preventing future MI, es-
pecially since the introduction of b-blockers had in the meantime
optimized medical therapy. Several retrospective and prospective
(randomized) studieswereperformedbutwereunable to showa sig-
nificant survival benefit of CABG over optimal medical therapy in
patients with stable angina,31–34 with the exception of patients
with left main disease.35,36 However, these studies were heavily criti-
cized for their (i) selectionbias, (ii) useof historical controls, (iii) com-
parability of study groups and (iv) small sample size.37 The results
from three large trials formed the basis for clinical decision making:
the Veterans Administration (VA) Cooperative Study (n ¼ 686),38
theEuropeanCoronarySurgeryStudy (n ¼ 767)39 and theCoronary
Artery Surgery Study (n ¼ 780) (CASS).40 Although the individual
trials did not consistently show superiority of CABG over medical
therapy in terms of long-term survival, they provided much of the
Figure 1 Experimental surgery for coronary artery disease that preceded the introduction of coronary artery bypass grafting. Different surgical
methods have been applied: (A) ligation of the right internal mammary artery to increase blood flow to the coronary circuit through collaterals, (B)
pericardial abrasion with the use of irritants to form adhesions, and (C ) suturing different tissues to the myocardium as collaterals.
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basis for a later meta-analysis of seven trials that reported a survival
benefit with CABG at 5 (OR ¼ 0.61, 95% CI 0.48–0.77), 7 (OR ¼
0.68, 95% CI 0.56–0.83) and 10 years (OR ¼ 0.83, 95% CI 0.70–
0.98) of follow-up.41 Besides the relief of symptoms, the benefits of
CABG now included an improved prognosis after which it evolved
as the standard of care for the treatment of CAD on the grounds
of evidence-based recommendations rather than expert opinion.
The costs involved with CABG procedures were criticized for its
possible impact on health care budgets. However, apart from
prolonging life, compared with medical therapy, CABG also signifi-
cantly improves the quality of life for at least up to 5 years.42,43 In
the MASS-II trial, angina-free survival at 5-year follow-up was 54.8%
for patients in the medical therapy group vs. 74.2% in the CABG
group (P, 0.001).44 Although initial hospitalization costs are
indeed higher for patients undergoing CABG, these are counterba-
lanced by the long-term benefits of the treatment. Compared with
other therapies, the benefit of CABG on quality-adjusted-life-years
proved favourable.45,46
Utilization of coronary artery
bypass grafting
After the successful introduction of CABG, the procedure remained
in a state of relative experimental therapy outside of a fewpioneering
centres.47–49 In the beginning of the 1970s, larger experiences were
published which resulted in a growing interest in surgical revascular-
ization. At one point, it was even anticipated to become the ‘most
frequently performed operation in America’.22
In the 1960s, .35% of total deaths per 100 000 population in the
USAwere the result of ischaemic heart disease,whichwas somewhat
lower in European countries (e.g. United Kingdom 29% and the
Figure 2 Timeline of developments that led to the first ‘modern’ coronary artery bypass grafting (A) and facilitated continuous improvements in
surgical technique and outcomes during the first 50 years (B).
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Netherlands25%).50 Theoption of surgical revascularizationwas a
long awaited solution for patients with CAD, and like any disruptive
technology was quickly adopted with widespread enthusiasm. The
annual number of CABG procedures in the USA increased rapidly
to 30 000–40 000 in 1974 and exceeded 60 000 in 1976.34,51 By
1976, it was estimated that already more than 300 000 patients
had undergone CABG.34 The annual rate continued to grow to
114 000 procedures/year in the USA alone by 1979.52
Andreas Gru¨ntzig introduced percutaneous coronary interven-
tion (PCI) in1978,53whichprovidedanalternative treatment strategy
for symptomatic CAD. Nevertheless, the annual CABG rate contin-
ued togrowto191 000CABGprocedures/year in 1983 in theUSA.54
When the indications for PCI quickly developed first for acute MI55
and later for stable single- and multivessel disease with the develop-
ment of bare-metal stents, PCI rates started to grow exponentially
and already by 1986 more than 133 000 PCIs were performed annu-
ally in the USA.56 Continuous technical advancements of PCI (e.g.
drug-eluting stents) and adjuvant medical therapy (e.g. P2Y12 recep-
tor antagonists) allowed a broader range of clinical scenarios to
be treated percutaneously. As a result, CABG more and more
became reserved for patients with complex lesions.
Despite the dramatic increase in PCI procedures during the
1990s,57 there was also an expansion of the number of CABG pro-
grams thereby increasing the absolute rate of CABG per popula-
tion.58,59 In an analysis of European countries, the annual rate of
CABG increased from 137 000 to 225 000 procedures/year
between 1992 and 2000.58 In the USA, there was also a constant in-
crease in the number of CABG procedures, although the age- and
gender-adjusted rate per 100 000 population finally leveled out at
100–150 procedures/year.59,60 Approaching the turn of the millen-
nium and a stage of market saturation, the utilization of CABG
started to decline. Community-based studies in Olmsted andWash-
ington State showed a significant shift in the PCI-to-CABG ratio;
while the increase in the number of revascularizations stagnated,
the number of PCIs continued to rise as the number of CABGs
declined.59,60 Through 2001–2008, the number of revascularization
procedures in theUSAhave declined from5569 to 4748 per 100 000
population due to a significant reduction of CABG (1742 to 1081;
P, 0.001) but not PCI (3827–3667; P ¼ 0.74).61 This has been pre-
dominantly the result of the absence of a survival benefit with CABG
in randomized trials performed during the 1990s and 2000s. Results
from theBARI trial showed that 71.0 and73.5%patientswerealive10
years after PCI and CABG, respectively (P ¼ 0.18), and survival free
of MI was comparable (63.9% vs. 63.6%, respectively; P ¼ 0.97).62 In
larger pooled analyses with 5-year follow-up, there were also no dif-
ferences in survival or the compositeof death orMI.63,64More recent
results from the SYNTAX trial andASCERT study have contradicted
these findings and may initiate another shift in the PCI-to-CABG
ratios in favour of CABG.65,66
Over 50 years, the increase in the number of CABG procedures
has shown significant inter-country variation. Between 1985 and
2006, there was a 6% increase in CABG procedures in the USA,
while there was a staggering 915% increase in Germany
(Figure 3A).67,68 The average annual number of CABG procedures
per100 000 is 62.2 in contemporaryWesternpractice, but differs sig-
nificantly by country ranging from 29.3 to 135.4 procedures in Spain
and Belgium, respectively (462% variation) (Figure 3B).68 When
considering age-standardized death rates from ischaemic heart
disease, the ratioofCABGperdeath varies evenmore from0.17pro-
cedures/death in Hungary to 1.40 procedures/death in Germany
(817% variation) (Figure 3C). This variation may be the result of
a myriad of reasons, including, but not limited to: patient and/or
physician preferences, the number of centres performing CABG,
differences among private and public sectors, thresholds for revascu-
larization and import/export of patients to best practices in more
developed countries.
Research
A simple entry of ‘CABG OR coronary bypass’ in PubMed yields 59 732
publications in peer-reviewed journals through 1964–2012
(Figure 4). Over the past 10 years, this search results in consistently
2300–2500publications annually. Thebodyof evidenceoriginating
from this research has (i) produced a technical evolution of the pro-
cedure, (ii) focused on complications that are associatedwithCABG,
(iii) provided an estimate of the incidence in which these complica-
tions occur and (iv) identified predictors of short-and long-termout-
comes. These data have led to continuous quality improvements and
have been incorporated in clinical decision-making and guideline-
directed treatment recommendations.
An evolution of the technique
Myocardial protection
Initially, CABGwas almost exclusively performedwith the use of car-
diopulmonary bypass (CPB) and the anastomoses were performed
on the arrested heart. Myocardial protection during the period of
induced ischaemia was found to be of utmost importance as opera-
tivemyocardial injurywasdirectly resulting in left ventricular dysfunc-
tion, thereby impacting prognosis.69 The work by Follette, Buckberg
and colleagues in the 1970s demonstrated the deleterious effects of
induced ischaemia and reperfusion injury and triggered a whole new
field of research.70 Improved CPB techniques, advanced anaesthesia
techniques, shorter-operating times and more refined suturing all
contributed to reducing the amount of myocardial injury.71
However, the introduction of myocardial protection is believed to
be the single most important contribution to CABG.71 Operative
mortality and morbidity were significantly reduced in the early
1970s by using potassium cardioplegia to lower myocardial energy
demands during the ischaemic period (Figure 2B).72 In the 1980s,
advanced myocardial protection methods aimed at providing
oxygen, optimizing the metabolic rate, reducing calcium influx, re-
versing acidosis, avoiding edema and replenishing substrates.70
Over the years, two different types of cardioplegia have been ex-
tensively investigated; blood and crystalloid cardioplegia. Warm
blood cardioplegiamay have an advantage over crystalloid cardiople-
gia as it resembles the normal physiology, which could result in less
myocardial injury andbetter clinical outcomes.However, administra-
tion of blood cardioplegia is more complex than for crystalloid cardi-
oplegia: (i) it can be cold, normothermic, or warm, (ii) it can be
administered antegrade or retrograde and (iii) should it be given con-
tinuous or intermittent, and atwhat interval betweendoses? Crystal-
loid cardioplegia is less expensive and provides better intraoperative
visibility.73 The most recent meta-analysis summarized data from 36
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Figure 3 The utilization of coronary artery bypass grafting around the world. The increase in coronary artery bypass grafting procedures per
100 000 population has differed significantly between countries (A), as well as the number of coronary artery bypass grafting procedures that are
performed in contemporarypractice (2006) (B). Thesedifferences are independent of theprevalenceof ischaemic heart disease (C ).Dataoriginated
from the Organization for Economic Co-operation and Development68 and from Rothlin.67 AUS, Australia; CAN, Canada; CZE, Czech Republic;
DNK, Denmark; FIN, Finland; FRA, France; DEU, Germany; HUN, Hungary; ISL, Iceland; IRL, Ireland; ITA, Italy; LUX, Luxembourg; NLD, Nether-
lands;NZL,NewZealand;NOR,Norway; POL, Poland; PRT, Portugal; ESP, Spain; SWE, Sweden;CHE, Switzerland;GBR,UK;USA,United States of
America.
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randomized trials and was unable to identify a clear advantage of one
cardioplegic over the other for endpoints of death (RR ¼ 0.95, 95%
CI 0.60–1.51), MI (RR ¼ 0.80, 95% CI 0.55–1.19), or low cardiac
output syndrome (RR ¼ 0.69, 95%CI 0.48–1.04).74 The debate con-
tinues and until large randomized trials show a particular benefit it
appears that surgeons should continue using their own preferred
strategy, in which they have experience and that allows proper myo-
cardial protection in their cases.
The clinical impact of other measures of myocardial protection
remain debated: whetherCPB flow should be non-pulsatile or pulsa-
tile to mimic the physiological blood flow,75 whether direct and
remote ischaemic preconditioning through a number of brief
periods of ischaemia proves to have a clinical benefit by increasing
the tolerance of the myocardium to sustain a large period of ischae-
mia,76 aswell as theuseofprophylacticoradjunctivepharmacological
agents to minimize ischaemia and/or reperfusion injury.77,78
Grafts
In the early yearsof coronary surgery, the saphenous vein graft (SVG)
was used in the majority of cases;28 in 1979 in the USA, it was used in
87% of CABG procedures.52 However, in 1978 FitzGibbon et al.79
demonstrated that venous bypass grafts fail early: 11% of 1400 vein
grafts were occluded at 2–3 weeks postoperatively. At 1 year,
failure rates of up to 20% have been reported,80,81 and only 60% of
SVGs are open at 10-year follow-up.82,83 This failure rate is particu-
larly influenced by graft thrombosis (early failure), intimal hyperplasia
(late failure) and atherosclerosis (late failure).84
Although the first ever CABG was performed using an IMA graft,
IMA grafting was only done in few centres. Favaloro et al. were
particularly interested in this technique, and by the end of 1967 had
already performed 248bilateral IMAgraft procedures.20 Throughout
the historyofCABG, theClevelandClinic has provided seminalwork
demonstrating data in favourof IMAgrafting.They reportedexcellent
graft patency and significantly better survival in patients receiving an
IMA graft to the LAD instead of SVGs only.85 Second, they demon-
strated for the first time that bilateral IMA grafting proved superior
to single IMA grafting in reducing rates of reoperation and long-term
mortality.86,87 The excellent patency of the IMA graft triggered a
search for additional arterial grafts to revascularize non-LAD myo-
cardial territories. Experimental surgeries were performed using
the splenic artery,88 subscapular artery,89 intercostal artery,90 lateral
femoral circumflex artery,91 inferior mesenteric artery92 and ulnar
artery.93 In 1978, the use of Gore-Tex grafts was suggested,94 but
because of the high thrombogenicity and disappointing patency
rates this technique was quickly abandoned. The most promising ar-
terial conduits besides the IMA were the right gastroepiploic artery
(GEA),95 inferior epigastric artery (IEA)96 and radial artery.97
TheGEA and IEAwere introduced in 1987 and 1990, respectively,
and showed goodpatency results in several studies.98However, their
use has never been fully integrated into clinical practice because of a
number of technical issues, including the need for an additional lapar-
otomy, limited graft length, variation in size and small distal diameter.
Differences in biological characteristics when compared with the
IMA graftmake them also less suitable.99,100Data fromCABGproce-
dures performed in 1992 in the UK showed that in only 3% of cases
one of these grafts was usedmainly when the IMA or SVGswere not
available.101
The radial artery is the best and most commonly used arterial al-
ternative (or addition) to the right IMA graft. Its use was first investi-
gated byCarpentier in 1971,97 butwas discarded after high early graft
occlusion rates of 30% were reported.71 The unexpected finding of
patent grafts after .15 years renewed the interest in the radial
Figure 4 Peer-reviewed articles published since the introduction of coronary artery bypass grafting. The searchwas performed using an entry of
‘CABG OR coronary bypass’ in PubMed.
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artery during the early 1990s,102 although concerns remained with
regard to its susceptibility for spasm and intimal hyperplasia.103,104
Refined operative techniques aim at minimizing endothelial damage
and adjunctive medical therapy are applied to reduce vasoreactivity.
As a result, 5-year patency rates of.90%have been reported,105 but
are strongly dependent on the graft territory and the degree of sten-
osis of the native coronary. The best results with the radial artery are
achieved in high-grade stenosis (.90%), when the graft is harvested
as a pedicle, when pharmacological dilatation is applied locally and
when postoperative administration of vasodilator therapy is per-
formed.105–107
Contemporary data on international use of grafts are available
from the SYNTAX trial that included 1541 patients who underwent
CABGat85 sites in 18 countries between2005 and2007.108 In 95.2%
of patients, an arterial graft was anastomosed to the LAD, and in
97.1% at least one arterial graft was used. Bilateral IMA grafting was
only performed in 22.7%. Complete arterial revascularization was
performed in 15.6%. Abdominal arteries were not used at all, and
the radial artery was used in 12.8% of patients.
Invasiveness
Since its introduction, CABG has been performed with and, to a
lesser degree, withoutCPB, even though on-pumpCABG is referred
to ‘conventional CABG’. The use of CPB and cardioplegic arrest pro-
vides a more stable and bloodless operative field, but are associated
with a systematic inflammatory response, increased red cell damage
and stroke frommanipulation and clamping of the ascending aorta.109
With the development of heparin-coated circuits in 1983,110
CPB-associated systemic inflammation became less of an issue.
Off-pump CABG (OPCAB) avoids the use of CPB altogether and, if
performed in a no-touch technique, by avoiding aortic manipulation
has the potential to reduce the risk of stroke. The benefit of OPCAB
is, however, offset by a more challenging technical demand. Surgical
series from the early 1980s reported excellent results,111,112 which
encouraged further implementation. The introduction of the
Octopus stabilizer in 1996 marked a significant improvement in the
operative technique and reduced the technical difficulty.113 Further-
more, the use of distal anastomotic connector devices was investi-
gated already in 1979 but interest was renewed with the advent of
off-pump procedures, as it would omit difficult suturing on a
beating heart.114 Series reporting increased rates of repeat revascu-
larization have hampered widespread use of distal connector
devices,115 although recent favourable results have been reported
as well.116 Off-pump coronary artery bypass grafting is performed
particularly in developing countries to reduce the procedural costs.
However, numerous large randomized trials have not proven an
early or long-term clinical advantage ,and there appears to be no
benefit of off-pump CABG with respect to quality of life.117–120
In 1994, a number of centres were performing LIMA-to-LAD min-
imally invasive CABG (MIDCAB) through a left mini thoracotomy
using video-assisted LIMA harvesting.121,122 Growing experiences
have shown excellent results for the LIMA to LAD similar to CABG
through a sternotomy. Reported early patency rates range from 94
to 99% and perioperative mortality is 0.8% for the largest
series.123,124 Survival at 5 and 7 years for all-comers populations are
reported as 91.9% (95% CI 90.1–93.8%) and 89.4% (95% CI 86.7–
92.1%), respectively.123 Familiarity with video-assisted procedures
furthermore reduced surgical trauma through robotic-assisted
totally endoscopic CABG.125 Initially, it was performed on-pump
and patency results were inferior compared with those achieved
with the standard MIDCAB technique; more recent results with
advanced computer-assisted technology, better endoscopic stabili-
zers, and without the use of CPB have shown excellent results with
up to 100% LIMA to LAD patency and very low conversion rates.126
The patient population
Disease specifics
The principal indication for CABG utilization was (chronic) stable
angina,41 whether by single-, double,- or three-vessel disease. The
benefit of revascularization became more evident in patients with
complex coronary disease as outcomes with medical therapy grad-
ually worsened with increasing complexity, while outcomes after
CABG were consistent.41 In patients with left main disease the
benefit of CABG was largest.
For many years CABG was the only revascularization strategy
proven to be effective and has therefore been used for a number of
clinical scenarios. In the 1960s and 1970s, patients with acute MI
often did not survive to reach the hospital or died early thereafter.127
Acute MI was therefore considered a contraindication for CABG.128
In very selected cases, emergency CABG was performed and did
show increasingly improved results when compared with medical
therapy.129 However, with the advent of fibrinolysis and PCI to
acutely treat the culprit lesion,130,131 early survival of patients with
acute MI significantly improved. Since the early 1990s, PCI has been
the treatment of choice while the need for CABG has been limited
to a minority of acute MI cases with a disease pattern too complex
for PCI. Patients requiring additional bypasses for non-culprit
lesions do undergo subsequent elective CABG.
In the initial CABG trials, patients with severe left ventricular (LV)
dysfunction were excluded. However, the dismal prognosis of such
patients treatedmedically led to explore the impact ofCABGon long-
term survival in patients with severe LV dysfunction. A prognostic
benefit was first confirmed by registry data.132,133 Utilization of
CABG forLVdysfunction subsequently increasedbutwas limitedprin-
cipally to patients who would suffer from angina, with limited hypoki-
nesia and with an expected improvement of ventricular function.
Interestingly, the impact of CABG on improving LV dysfunction in
patients with ischaemic heart failure has not been adequately
addressed over the years and continues to remain under debate.134
Guideline recommendations are similar to what they were half a
century ago, although recent results from the randomized STICH
trial shed new light on this discussion: in the intention-to-treat analysis
there was no difference in the primary endpoint of all-cause mortality
at 5-year follow-up (41 vs. 36% for medical therapy and CABG, re-
spectively; P ¼ 0.12).135 CABG was associated with significantly
reduced rates of the secondary endpoint of all-causemortality or hos-
pitalization (HR ¼ 0.81, 95% CI 0.71–0.93; P ¼ 0.003). Moreover, a
per-protocol analysis excluding crossed-over patients showed that
CABGwas superior tomedical therapy also for the primary endpoint
(HR ¼ 0.76, 95% CI 0.62–0.92; P ¼ 0.005). It is crucial to assess the
percentage of myocardial ischaemia as a trigger for revascularization,
with a proposed cut-off of 12% ischaemia.136
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Patient specifics
The early populations that underwent CABG included patients at
a mean age of 50–55 years, the majority were males, smoking
history was frequent28,41,137,138 and diabetes and hypertension
were present in 10–30 and 20–50%, respectively.138,139 Evalu-
ation of patient subgroups who underwent coronary angiography
demonstrated that male patients were more likely to undergo
CABG than women and Caucasians more than blacks.140 As
expected from theworseningWestern lifestyle that involves less ex-
ercise, amplified dietary intake, more stress and sleep deprivation,
patients referred for CABG are becoming increasingly higher risk.
Over the last two decades, the mean age of patients undergoing
CABG has increased to about 60–65 years of age.141,142 An ever in-
creasing number of patients present with co-morbidities; between
2000and2009 in theUSA,e.g. the rateofdiabetes in theCABGpopu-
lation has grown from 33 to 40%, hypercholesterolemia from 60 to
84% andCOPD from17 to 23%.Other risk factors such as hyperten-
sion, renal failure requiring dialysis, previous stroke and prior PCI all
have increased in prevalence.141 Interestingly, it appears that CABG
remains underutilized in black patients as well as in women.143
In those patients requiring revascularization, the trendof thefirst 50
years has led to utilization of CABG particularly in patients with stable
angina, complex CAD, not too high risk and with an expected long-
term benefit for IMA grafts.144–146 Patients with concomitantmoder-
ate/severe aortic stenosis ormitral valve regurgitation require surgical
intervention according to the current guidelines. However, advance-
ments in percutaneous valvular therapies (transcatheter aortic147,148
andmitralvalve149 techniques)mayallowan increasingnumberofhigh-
risk patients tobe treated percutaneously by theHeart Teamand con-
sequently undergo PCI for concomitant CAD.150
Postoperative clinical outcomes
Outcomes
The periprocedural risk of elective CABG has constantly declined
despite an ageing population. Owing to the invasiveness of CABG,
several procedural risks require consideration (Table 1). Mortality
is considered operation-related if it occurs within 30 days after
surgery. Even though the patient population is becoming older and
of higher operative risk,193 mortality continues to decline in contem-
porary practice; currently, operativemortality forelectiveCABG is in
the range of 1–3%. One of the most devastating complications is
stroke.194 Approximately 1–3%of patients suffer an intraprocedural
or early postoperative stroke, which are predominantly ischaemic in
nature.195,196 Other important complications are postoperative MI
or injury, renal failure, delirium, deep sternal wound infection,
mediastinitis and atrial fibrillation. Re-exploration for bleeding is
required in 2–6% of patients and increases the risk for these
complications.163,164
Complications are associated with increased morbidity, longer
postoperative stays, higher costs, and increase the risk of early or
delayedmortality. The risk may be reduced by adopting (and consid-
ering early in the decision-making process) lesser-invasive surgical
techniques and/or by applying intraoperative quality assessments.197
Determinants of short-term outcomes
Many of the procedural complications associated with CABG can be
anticipated on the basis of the preoperative patient history, charac-
teristics and demographics.198 These factors can be divided into
the categories of: factors with an impact on howwell a patient toler-
ates the invasiveness of CABG (e.g. age, COPD, renal function),
factors that identify the progression of disease (e.g. acute coronary
syndrome, left ventricular function, NYHA and CCS classification),
factors that impact procedural complexity (e.g. previous surgery,
emergent surgery, the presence of acute ischaemic mitral regurgita-
tion), and factors that influencepostoperative recovery (e.g. diabetes,
neurological impairment, reduced mobility). To provide an estimate
of the operative risk based on these factors, several generic risk
models have been developed.199–202 These can be helpful tools
during decision making;203 in some instances, it may be more appro-
priate to referpatients to the interventional cardiologist for PCI145 or
continue with medical therapy only. The additive and logistic Euro-
SCORE have been used most frequently in Europe,200,204 and have
recently been updated to the EuroSCORE II (Figure 5A).205 The
Society of Thoracic Surgeons (STS) score is the standard risk
model in the USA and its popularity is increasingly recognized in
Europe as well (Figure 5B).151,201 The existing risk models have
been severely criticized over the recent years for a number of
reasons,198,206–208 including (i) models have become outdated
because of dynamic trends in patient risk, (ii) (lack of) inclusion of
risk factors, (iii) the majority of models have been developed to
predict mortality but do not predict postoperative complications
(e.g. stroke) and (iv) suboptimal methodology for model develop-
ment. Therefore, risk estimation by such models should not be
taken as gospel, but rather used as guidance and interpreted accord-
ing to the individual patient.
Notonly patient-related factors areessential in this regard. A great
number of studies have been devoted to assess volume–mortality
interactions, where the number of cases per surgeon and/or hospital
influences CABG outcomes. As one would expect, the expertise of
higher-volume surgeonswould bebeneficial to the qualityof thepro-
cedure, particularly in complex and/or critical situations. Similarly,
the quality of perioperative care in high-volume centres would
likely be improved when compared with low-volume centres,
thereby reducing the risk of adverse events. Although these assump-
tions have shown to be genuine in several large studies,209,210 results
have been challenged.211–213 Compared with other major complex
surgeries, the impact of volume on outcomes after CABG is
limited.214 More important than volume itself are quality measures
and being a low-volume centreby itself does not necessarily preclude
quality.214–216 Other factors independent of the patient, operator,
and/or hospital, have also shown to impact postoperative complica-
tions; for example the duration of red-cell storage in patients requir-
ing blood transfusions.217
Long-term clinical outcomes
Outcomes
In the early randomized trials (patient inclusion 1972–1984) compar-
ingCABGwithmedical therapy, long-term survival at 5 and 10years of
follow-up was 90 and 74%, respectively.41 Remarkably, in later trials
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comparing CABGwith PCI, the long-term survival did not significantly
improve. The BARI trial included 1829 patients through 1988–1991
and reported 5- and 10-year survival rates nearly identical to earlier
trials: 89 and 74%, respectively.62 The most recent 5-year follow-up
data originates from the SYNTAX and FREEDOM trials.65,195 Again,
survival was similar with 89% in SYNTAX and 89% in FREEDOM. It
should, however, be noted that these trials included patients with
impaired LV function and either complex leftmain and/or three-vessel
disease (SYNTAX), or diabetics with complex disease (83% three-
vessel disease, FREEDOM); compared with the first randomized
trials where only 50% had three-vessel disease, impaired LV function
was an exclusion criteria and patients were generally lower risk.41 In
large registries that include ‘real-world’ ‘all-comers’ data, 5-year
survival has been estimated at 78–82%.66 ,218,219 To summarize, it
appears as if the improvements in patient care (pre-, operative, and
post-operative) have kept an even pace with the increase in patient
morbidity, resulting in similar rates of survival today as in previous
years with lower risk patients.
Data from the PREVENT IV trial showed that the rate of SVG
failure was a dramatic 25% at 1 year.220 The high graft failure rate
was associated with an increased risk of MI during follow-up, which
in turn is associatedwith increasedmortality, left ventricular dysfunc-
tion and reduced quality of life. In a pooled analysis of four rando-
mized trials by Daemen et al., the risk of non-fatal MI at 5 years
after CABG was 7.6%.64 Even though SYNTAX and FREEDOM
included more complex patients, the rates of MI were somewhat
lower (3.8 and 6.0%, respectively), suggesting a continuous improve-
ment in long-termoutcomes afterCABG. The occurrence ofMImay
require repeat revascularization; however, caution is advised when
interpreting repeat revascularization rates because the decision to
treat is a less well-defined, subjective endpoint.
After the perioperative phase, the risk of stroke after CABG
remains constant at approximately 0.5–0.8% per year.154 At 5-year
follow-up, the rate of stroke is 2.5–5%.65,195,221,222 Longest follow-
up is available from the MASS II trial, where the 10-year stroke rate
was 8.4%.223 These data are consistent with a limited number of pro-
spective observational studies.224,225 There is little evidence regard-
ing the severity of strokes, but results from the FREEDOM trial
suggest that strokes were severely disabling in 55% of diabetic
patients with a stroke at any time during follow-up.195 In addition,
results from the SYNTAX trial show that 68% of patients who suf-
fered a stroke and survived had long-term residual deficits.196
Several observational studies226,227 and randomized studies have
shown that health-related quality of life is significantly improved
with CABG. At 3months after randomization in the VACooperative
Study, subjective improvement was reported in 79.8% of patients
who underwent CABG compared with only 58% of the medically
managed patients (P, 0.01).228 At longer follow-up of 5 years, it
was found that more patients in the CABG group were free from
chest pain (54.8% vs. 32.9%; P, 0.01). Data from the CASS trial
support these findings, but showed that differences in freedom
from angina and the activity level between surgery and medical
therapywere less by 10-year follow-up because late surgerywas per-
formed in almost 40% of patients randomized to medical therapy.43
With regard to psychobehavioural endpoints, specific attention has
been given to depression during the perioperative period and long-
term follow-up after CABG. Up to 47% of patients present with
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depression at baseline, which has a significant impact on long-term
freedom from cardiovascular events and death.229–231
Determinants of long-term outcomes
There are a number of factors that have a significant impact on long-
termoutcomes. Postoperative complications such as stroke,156 renal
failure,174 atrial fibrillation,186 and myocardial injury232 diminish
patient survival as well as quality of life. Procedural factors including
graft patency and completeness of revascularization are critical to
ensure reduction in angina pectoris and preservation of the left ven-
tricle. The degree of periprocedural blood loss as measured by the
need for (and number of) red blood cell transfusions has been
found to be an independent predictor of long-term survival.233 Fur-
thermore, life expectancy is significantly reduced by non-coronary
disease patient-related factors such as advanced age, the presence
of co-morbidities and pshychobavioral deficits. Finally, life-long
optimal medical therapy and other secondary prevention measures
after CABG positively impact the incidence of late events after
CABG, although secondary prevention including antiplatelet
therapy has been underused after CABG.
The choiceof graft is oneof themost important procedural factors
to consider. Grafting the LIMA to the LAD undoubtedly is the best
treatment option to prolong survival,85 but there are several grafts
that can be used for other myocardial territories: the SVG, the
right IMA and the radial artery. Bilateral IMA grafting with the left
and right IMA produces the best long-term survival,234 but may not
always be feasible and/or safe; it increases the risk of sternal wound
complications particularly in obese and diabetic patients. Recent evi-
dence suggests that under such circumstances the radial artery pro-
vides better long-term patency and survival than the SVG.105,235–239
Complete revascularization is usually the goal of CABG, as incom-
plete revascularization may be associated with reduced survival
during follow-up. However, results are not uniform; there is a differ-
ence in appropriateness of incomplete revascularization.240 Where
incomplete revascularization of distal lesions and/or small vessels
with little myocardium at risk may be categorized as appropriate in-
complete revascularization,241 leaving a large area of viable myocar-
dium in patients with more complex disease would result in
inappropriate incomplete revascularization and subsequently lead
to detrimental outcomes.
Procedure-specific risk models have been developed to predict
long-term mortality based on preoperative patient characteris-
tics.218,242–244 Naturally, the procedural and post-procedural
factors as discussedearlierwill havea significant impact, but recogniz-
ing the impact of preoperative risk factorsmay be helpful in assessing
the risk–benefit ratio of surgical revascularization. It is advised to use
these during multidisciplinary Heart Team decision-making. Clearly,
the life expectancy of older patients or patients with severe co-
morbidities is limited, and CABG with several months of rehabilita-
tion may not be the best treatment recommendation.
Conclusions
Surgical treatment for CAD has shown substantial improvements
that finally led to the introduction of CABG. During the first 50
years of performing CABG, the technique has evolved into a
refined, safe, andefficientprocedure thateven in contemporaryprac-
tice shows a continuous reduction in postoperative complications. It
has been an extensively investigated topic that has accumulated a
body of evidence in favour of performing CABG for a wide range
of clinical scenarios, and provided crucial data that is weighted
during decision making and can be integrated in risk–benefit ratios
to optimize treatment recommendations. However, there are still
a number of procedural advancements that may be considered to
improve short- and long-term outcomes. In an accompanying manu-
script, we discuss inmore detail off-pumpCABG, clampless/anaortic
CABG,minimally invasiveCABGwithorwithout extending tohybrid
procedures, arterial revascularization, endoscopic vein harvesting,
intraprocedural epiaortic scanning, graft flow assessment, and
improved secondary prevention measures.
Conflicts of interest: none declared.
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Sincefirst introduced in themid-1960s, coronaryarterybypass grafting (CABG)hasbecomethe standardof care forpatientswith coronaryartery
disease. Surprisingly, the fundamental surgical technique itself did not changemuch over time.Nevertheless, outcomes afterCABGhave dramat-
ically improved over the first 50 years. Randomized trials comparing percutaneous coronary intervention (PCI) toCABGhave shownconverging
outcomes for select patient populations, providingmore evidence forwider use of PCI. It is increasingly important to focus on the optimization of
the short- and long-termoutcomes of CABGand to reduce the level of invasiveness of this procedure. This reviewprovides an overview on how
new techniques and widespread consideration of evolving strategies have the potential to optimize outcomes after CABG. Such developments
include off-pumpCABG, clampless/anaortic CABG, minimally invasive CABGwith or without extending to hybrid procedures, arterial revascu-
larization, endoscopic vein harvesting, intraprocedural epiaortic scanning, graft flow assessment, and improved secondary preventionmeasures.
In addition, this review represents a framework for future studies by summarizing the areas that needmore rigorous clinical (randomized) evalu-
ation.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords Coronary artery bypass grafting † Off-pump † Anaortic † Minimally invasive † Hybrid revascularization † Arterial
grafting † Endoscopic vein harvesting † Epiaortic scanning † Graft flow measurement † Secondary prevention †
Guidelines † Heart team
Introduction
Coronary artery bypass grafting (CABG) was first introduced in the
mid-1960s and evolved rapidly as the standard of care for patients
with extensive coronary artery disease.1 However, the introduction
of percutaneous coronary intervention (PCI) led to a reconsider-
ation of therapeutic strategies.2 Improvements in stent design, adju-
vant medical therapy and technical skills quickly turned PCI into a
very attractive alternative treatment option for patients with acute
coronary syndromes and less complex coronary disease.3–7 The
broader use of PCI is reflected by declining CABG rates over the
last decades,8 even though recent long-term results from the
SYNTAX,9 ASCERT,10 and FREEDOM11 trials showed significantly
better survival rates after CABG than after PCI. Despite converging
outcomes between the two treatments in select patient populations,
coronary surgery currently remains the standard of care for most
elective patients, including those with diabetes and/or complex left
main or three-vessel disease.9,12
Although short-term outcomes have dramatically improved over
the first 50 years, surprisingly, technical aspects of theCABGproced-
ure did not change significantly. Particularly in an era of increasing and
sometimes overuse of PCI, several aspects of CABG should be
improved to further optimize short- and long-term outcomes,
while at the same time improving the appeal of CABG which is
regarded as an overly invasive attractive treatment option by some.
A number of advancements have been proposed, but adoption
rates for these techniques are low.
This review provides a summary of how CABG outcomes can be
optimized by adoption of new developments. These developments
include off-pump, clampless/anaortic, and minimally invasive CABG
*Corresponding author. Tel: +31 (0)10 70 35784, Fax: +31 (0)10 70 33993, Email: a.kappetein@erasmusmc.nl
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European Heart Journal (2013) 34, 2873–2886
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Optimizing outcomes of CABG
withorwithout extending tohybridprocedures, arterial revasculariza-
tion, endoscopic vein harvesting, intraprocedural epiaortic scanning
and graft flow assessment and improved secondary prevention mea-
sures. Furthermore, this review represents a framework for future
studies by summarizing the areas that need more rigorous clinical
evaluation.
Operative techniques
Off-pump surgery
In 2001,25%of CABGprocedureswere performed off-pump.13 In
theWestern world, the contemporary rate of off-pump CABG pro-
cedures is 20%, while in Asia the majority of procedures is per-
formed off-pump.14 Theoretically off-pump CABG could reduce
morbidity—particularly stroke—and evenmortality by avoiding car-
diopulmonary bypass that is associated with formation of microem-
boli, an increased blood–brain barrier permeability and aortic
manipulation during cross-clamping and cannulation.15
Numerous risk-adjusted studies have found that the off-pump
technique appears favourable in terms of both hard and surrogate
endpoints.16,17 A meta-analysis of propensity score-adjusted
studies that included.120 000 patients demonstrated the superior-
ity of the off-pump techniquewith respect to 11 selected short-term
outcomes, particularly for mortality as the most important one
(OR ¼ 0.69; 95% CI: 0.60–0.75; P, 0.0001) and for stroke (OR ¼
0.42; 95% CI: 0.33–0.54; P, 0.0001).18 In addition, the most
recent meta-analysis of 59 randomized trials on a total of 8961
patients comparing on-pump with off-pump CABG demonstrated
a 30% (95% CI: 1–51%) relative risk reduction for stroke.13
However, some studies have shown increased rates of mortality and
repeat revascularization during the follow-up;19,20 probably caused
by reduced graft patency after off-pump vs. on-pump CABG.21,22
Although single-centre prospective angiographic studies have
shown similar excellent graft patency rates with off-pump and
on-pump CABG,23 the 1-year results from the ROOBY trial
showed a 27% higher risk of graft occlusion in the off-pump group
(95% CI: 9–48%); graft patency was 87.8% in the on-pump and
82.6% in the off-pump patients (P, 0.001).24 These results were
criticized for the lack of sufficient experience that contributing
surgeons had with off-pump procedures.25 However, several other
trials involving highly experienced surgeons and a meta-analysis
pointed in a similar direction as the findings from the ROOBY
trial.25–27 Off-pump CABG has also been associated with increased
rates of incomplete revascularization, and could result in reduced
long-term survival.28
The CORONARY trial showed no benefit of off-pump CABG
over on-pump CABG at 30 days or 1 year in 4752 randomized
patients.29,30 Although there appears to be a significant benefit of
off-pump over on-pump CABG in patients at high-operative risk31
and in patients with atherosclerotic aortas,32 the hypothesis that
off-pumpCABG is beneficial for ‘all-comers’maybe toooptimistic.33
Despite the encouragement to a general use of off-pump techniques,
it has been recommended specifically for high-risk patients.34
However, even this recommendation was recently challenged by
the results of the GOPCABE trial, which did include elderly higher-
risk patients (n ¼ 2539) but was still unable to confirm superiority
of the off-pump over the on-pump approach in this subset of
patients.35 Patient selection is critical, since the majority of patients
can safely and efficiently undergo on-pump CABG without the risk
of increased 30-day repeat revascularization rates associated with
off-pump procedures in the latest trials.29,30,35 It may therefore be
cumbersome for trainees to gain experience in a procedure with a
steep learning curve that is infrequently performed only in selected
patients.
It is worth noting that although evidence for a survival benefit of
off-pump CABG is inconsistent across the peer-reviewed literature,
a preponderance of evidence suggests that it is associated with
significant reductions in transfusion requirements, prolonged ven-
tilation, ICU and hospital length of stay, new renal failure, stroke/
neurocognitive decline and other clinical endpoints.36
Clampless/anaortic off-pump surgery
If off-pump CABG is performed, the degree of aortic manipulation
should be reduced to a minimum. The benefit of off-pump CABG
may be limited unless partial clamping of the aorta is avoided.
Aortic clamping produces a significantly higher number of solid
microemboli on transcranial Doppler than clampless surgery and
can therefore lead to procedural stroke.37 It is to note that in most
trials, including the major randomized trials, off-pump CABG was
not performed using an anaortic technique, the major driver for re-
ducing stroke.
Thenumberof studies that comparedclamplessCABGto ‘regular’
CABGwith clamping is limited (Table 1). In the absence of a large ran-
domized comparison, Bo¨rgermann et al.38 used propensity matching
to comparemortality and stroke rates between patients who under-
went clampless off-pump or conventional CABG. In the propensity-
matched cohort of 395 pairs, clampless off-pump CABG reduced
rates of death (OR ¼ 0.25, 95% CI: 0.05–1.18; P ¼ 0.080) and
stroke (OR ¼ 0.36, 95%CI: 0.13–0.99; P ¼ 0.048).More specifically,
one of the largest studies to date found significantly lower stroke
rates after off-pump than on-pump CABG, if an all-arterial ‘no
touch’ technique was applied or when the proximal vein-graft anas-
tomoses were performed clampless using the HeartString device
(Guidant, Indianapolis, USA).39 This evidence is complemented by
a meta-analysis including 11 398 patients that showed that the
absence of aortic manipulation was associated with a significant re-
duction of neurological complications (OR ¼ 0.46, 95% CI: 0.29–
0.72; P ¼ 0.0008).40
Minimally invasive coronary artery bypass
grafting/hybrid revascularization
One of the drawbacks of CABG remains its invasiveness, even
without the use of cardiopulmonary bypass. Quality of life scores
at 30 days and patient treatment satisfaction surveys throughout
the first 6 months are significantly higher after PCI than after
CABG.41 Moreover, CABG is sometimes referred to as a procedure
where ‘the chest is cracked open’, which from a patient’s perspective
presents a frightening prospect of postoperative pain and extended
rehabilitation. As a result, patients often prefer PCI to CABG
because of ‘temporal discounting’, i.e. disproportionally emphasize
short-term results even though CABG has been shown to be super-
ior to PCIwith respect to long-term survival and angina relief.10,41–44
S.J. Head et al.2874
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Optimizing outcomes of CABG
Less invasive surgical techniques may present an attractive alterna-
tive; minimally invasive direct coronary artery bypass (MIDCAB)
does not require sternotomy and is therefore more acceptable to
patients than conventional CABG.45 The left minithoracotomy inci-
sion is smaller, the risk of scarring is less, and risks of deep sternal
wound infection and problemswith sternum healing are omitted. Al-
thoughMIDCABmay be associatedwith slightly increased pain post-
operatively due to spreading of the ribs, the length of stay is markedly
reduced and there is an early postoperative quality of life benefit over
conventional CABG.46–48 MIDCAB was shown to be as safe and ef-
ficient as off-pump CABG, while reducing the recovery time.49
Holzhey et al.50recently reported long-term results from their single-
centre experience on 1768 patients. Five- and 10-year survival was
88.3 and 76.6%, respectively. The rates of freedom from major
adverse cardiac or cerebrovascular events and angina were of 85.3
and 70.9%, respectively.
ExposureduringMIDCAB is largely limited to the left anterior des-
cending (LAD) artery and eventually diagonal branches, and there-
fore almost exclusively performed in patients with isolated LAD
stenosis or occlusion. An open left internal mammary artery (IMA)
graft to the LAD is without doubt the single most important
conduit thatoffers aprognosticbenefitbasedon its proven long-term
patency and improved survival. Patients with multivessel disease—
especially at youngerage—alsoderive a survival benefit from total ar-
terial graftingwith bilateral IMA (BIMA) grafts.51 The added benefit of
a second arterial graft in older patients is less well documented;52
however, the rate of early vein-graft failure, especially to distal
targets and severely diseased small vessels, is high and ranges from
10 to 26% between 12 and 18 months after surgery.21,53 In some
patients, a hybrid procedure can combine the benefits of an
MIDCAB—providing a left IMA (LIMA) graft to the LAD—and stent-
ing of the circumflex and/or the right coronary artery. This type of
managementmay yield results similar to thoseof a fullCABGproced-
ure,54 but randomized trials are still lacking (Table 2). The hospitaliza-
tion costs of hybrid revascularization are similar to the costs of
off-pump CABG, but the time to return to work is shorter and
patient satisfaction higher.55 Halkos et al.56,57 showed that survival
after hybrid revascularization at 5-year follow-up was comparable
with off-pump CABG in patients with left main disease (88.6 vs.
83.4%, respectively; P ¼ 0.55) and in patients with multivessel
disease (86.8 vs. 84.3%, respectively; P ¼ 0.61) (Figure 1).
Complete revascularization in patients with multivessel disease by
minimally invasive CABG can also be achieved via a totally endos-
copic coronary artery bypass (TECAB) procedure,58 by combining
an endoscopic with an open approach,59 or by a hybrid endoscopic
and percutaneous procedure.60 Such procedures are only per-
formed in selected patients at specialized centres and require exten-
sive operating times. Earlier series reported unsatisfactory patency
results, but with the evolution of better endoscopic stabilizers the
results from these highly experienced centres are similar to conven-
tional CABG with a reported mortality rate of 1–2% 58–61 and a
5-year survival in the range of 85–95%.60–62
Adoption of minimally invasive CABG procedures has been slow.
For MIDCAB, this may be explained in part by the low incidence of
isolated proximal LAD stenosis63 and also by the high technical
demands of this procedure. Hybrid revascularization for multivessel
disease, theoretically, has a much larger target population. However,
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a systematic search of the literature shows that the accumulated evi-
dence is based on small non-randomized studies comprising just over
1000 patients in total (Table 3). Between October 2003 and April
2010, only 174 patients underwent hybrid revascularization in the
USA.56,57 Apart from technical issues, the low-adoption rate is
partly due to logistic reasons; the staging of two procedures in a
(hybrid) operating rooms, and/or catheterization laboratory, and
the administration or discontinuation of antiplatelet therapy. A
survey performed in 2002 indicated that 80% of US surgeons
perform less than five MIDCAB procedures annually.64 When
asked about hybrid procedures, only 10% of surgeons were in
favour. In contrast, 50% of 180 cardiologists were in favour of
hybrid revascularization. Yet, only two cardiologists (1.1%) had re-
ferred patients for MIDCAB (with or without PCI). Stronger
evidence to support a recommendation for hybrid revascularization
is expected from a number of currently on-going registries, the
largest of which is the Hybrid Revascularization Observational
Study (NCT01121263) that includes patients throughout the USA
and is sponsored by the National Heart, Lung, and Blood Institute
(NHLBI).
Arterial grafting
The useof one IMAgraft,most often the left IMAanastomosed to the
LAD combined with venous conduits represents the standard
therapy for patients undergoing CABG.65,66 However, venous
bypass grafts tend to fail: a recent study by Kim et al.67 found that
11.8% of saphenous vein grafts failed within 7 days, which is similar
to the failure rate reported by FitzGibbon et al.68 Therefore, BIMA
grafting should be strongly considered in patients with multivessel
coronary disease, because BIMA grafting is associated with reduced
mortality during the first year post-surgery and during the long-term
follow-up.69 A meta-analysis of seven pooled studies with 11 269
single and 4693 bilateral IMA grafts demonstrated that BIMA was
associated with a reduced risk for death: HR ¼ 0.81 (95% CI:
0.70–0.94).51
In the Arterial Revascularization Trial (ART), the only randomized
trial to date comparing BIMA and single IMA (SIMA), 3102 patients
were randomized in 28 centres in 7 countries.70 Mortality rates at
30 days were 1.2% in both groups, and 2.3 vs. 2.5% at 1-year for
SIMA and BIMA groups, respectively. Therewere also no differences
in the incidence of stroke,MI, and repeat revascularization.While the
use of a second IMA graft added 23 min to the operative procedure
which in itself took 3–4 h, the trial clearly demonstrated that BIMA
grafting was as safe as SIMA grafting, even though the risk of a need
for later sternal reconstruction was increased: relative risk 3.24
(95% CI: 1.54–6.83). An extended follow-up (for up to 10 years) is
expected for this study andwill hopefully determinewhether survival
with BIMA grafts is indeed superior. The trial, however, also
Table 2 Reasoning supporting hybrid
revascularization
Patients with double vessel disease and chronic total occlusion of the
LAD
Patients with multivessel disease and an indication for CABG requiring
complete revascularization in whom a full sternotomy is
contraindicated or not desired
Patients with multivessel disease with a dominant LAD or complex
proximal LAD lesion morphology and poor surgical targets in the
distal CX or RCA territory amenable for PCI
Patients with multivessel disease with an indication for PCI (SYNTAX
score ,22) or in clinical trials comparing hybrid revascularization
with PCI or CABG (SYNTAX score .23)
Patients with multivessel disease undergoing emergent PCI of a culprit
lesion of a CX or RCA lesion (in the setting of STEMI, non-STEMI, or
ACS) with a staged surgical revascularization of the LAD
Figure 1 Long-term survival of hybrid revascularization in comparison with off-pump coronary artery bypass grafting. A comparison between
treatment strategies shows no differences in 5-year survival in patients with multivessel disease (A), nor in patients with left main disease (B).
Adapted with permission from Halkos et al.56,57
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highlighted the difficulties with BIMA grafting; 16.4% of patients ran-
domized to BIMA did not receive the allocated treatment compared
with 3.3% patients not receiving SIMA grafting.71
The proportion of procedures that are performedwith IMA grafts
is increasing, but a large inter-hospital variance remains. The use of at
least one IMA can be as low as 45–65% in some centres, failing to
provide optimal care to patients.72 It is disconcerting that in the
USA the use of BIMA grafts was only 4.0% among 541 368 patients.72
The respective figures are 12% in Europe and 30% in Japan.73 Among
1541 procedures performed in the SYNTAX trial and registry,
97.1% included a single arterial conduit while 22.7% received a
second IMA graft. Owing to the technically more challenging and
time-consuming nature of BIMA grafting, the fear of highermorbidity
(i.e. sternal wound complications) and mortality, and the absence of
clear randomizeddata showing a survival benefit, some surgeonsmay
be reluctant to use BIMA grafts. Nevertheless, in order to improve
CABG outcomes, the use of both IMA grafts should be considered
more frequently.
Whenunilateral IMAgrafting isperformed, the saphenousvein is the
most frequently chosen conduit for additional graft(s). Because of high
failure rates of venous grafts, the radial artery has been investigated as
analternative.The long-termresults fromtheRSVPtrial (n ¼ 142) sug-
gested favourable radial artery graft patency rates.74 More recent
5-year results from the larger randomized RAPS trial (n ¼ 510)
showed that, compared with the saphenous vein grafts, the radial
artery had lower rates of functional graft occlusion (12.0 vs. 19.7%, re-
spectively; P ¼ 0.03) and complete occlusion (8.9 vs. 18.6%, respect-
ively; P ¼ 0.002), although the string sign was observed more
frequently in radial artery grafts (3.4 vs. 0%, P ¼ 0.01).75 Several large
observational studies have confirmed excellent graft patency and
haveevenreportedsuperior long-termsurvival rates,76,77alsoafterap-
plying propensity matching.78–80 However, widespread utilization of
the radial artery has been hampered by concerns regarding vessel
spasm, graft atherosclerosis, and unfavourable results from a number
of studies. The largest trial (n ¼ 733) to date found no differences in
graft patency at 1-year follow-up;81 similar results have been reported
from a number of observational studies.79,82 At least one study has
shown radial artery graft patency to be significantly worse than right
IMA graft patency.83 To ensure good graft patency, the radial artery
should be used preferably in high-grade lesions.84 Data from the STS
database suggest that only 9% of CABG procedures are performed
with the radial artery.85
A higher rate of disease progression to total occlusion in native
coronaries has been reported afterCABGthan afterPCI.86 Patent ar-
terial grafts, by virtue of their nitric oxide secreting properties, may
protect against future atherosclerotic lesions. Therefore, arterial
grafting can be viewed as a preventive measure that goes beyond
pure treatment.87,88
Endoscopic vein harvesting
Traditional open saphenous vein-graft harvesting requires a large in-
cision, resulting in a large scar and a riskof postoperativewound com-
plications. Endoscopic vein harvesting was introduced in the
mid-1990s as an alternative.89 This method has the advantages of
reduced scarring, less pain, decreased postoperative complications,
and shorter length of stay.90
Several randomized studies and meta-analyses have shown that
endoscopic harvesting significantly reduces rates of wound infection,
wound dehiscence, and overall complications.91 However, subgroup
analyses from the PREVENT IV and ROOBY randomized trials sug-
gested that endoscopic vein harvesting resulted in reduced graft
patency during the follow-up.92,93 In PREVENT IV, there even were
significantly higher rates of death. Although this is of potential
concern, long-term follow-up analyses from large observational
studies have not been able to confirm that clinical outcomes are
worse in patients that underwent endoscopic vein harvesting.94,95
A recent study that included 235 394 patients with 3-year follow-up
showed no increased risk of mortality [adjusted HR ¼ 1.00 (95% CI:
0.97–1.04) P, 0.99] or the composite of mortality, myocardial in-
farction, and repeat revascularization [adjusted HR ¼ 1.00 (95% CI:
0.98–1.05) P ¼ 0.34].95
Current data indicate a paradigm shift towards endoscopic harvest-
ing as opposed to open vein graft harvesting. Between 2003 and 2008,
52%of graftswere harvested endoscopically at 989 sites in theUSA; in
2008, the ratewas already 70%.95 Trainees in theUSA nowalmost ex-
clusively learn how toperformendoscopic harvesting.90 It is important
to start using this technique at an early stage, especially because inex-
perienced surgeons are known to cause significantly more vein
injury.96The InternationalSocietyofMinimally InvasiveCardiothoracic
SurgeryConsensusstatementhasgivenaClass IBrecommendationfor
endoscopic veinharvesting.97 Still, endoscopic harvesting is performed
in only a minority of cases in Europe. A recent single-centre study
showed that only 12.4% of veins were harvested endoscopically
between 2008 and 2010.98 Unfortunately, large-scale real-world
data from European centres are scarce.
Intra-operative assessments
Epiaortic scanning
Atherosclerosis of the ascending aorta is present in.50% of patients
undergoing CABG.99 Aortic atherosclerosis was found to be a signifi-
cant predictor of postoperative neurological events and renal failure,
both caused by atheroembolism.100,101 Palpation of the aorta is fre-
quently employed prior to cannulation and/or aortic manipulation,
but the sensitivity of this technique is very limited.102 Therefore,
imaging is advocated to detect atherosclerosis if an anaortic technique
cannot be applied.Depending on the findings, the operative technique
can be modified as needed.103 Both transoesophageal echocardio-
graphy and epiaortic ultrasonography were introduced as methods
for detecting severe atherosclerosis. While transoesophageal echo-
cardiography severely underestimates the degree of atherosclerosis,
epiaortic scanning is an easy, safe and efficient procedure and is pre-
ferred.104
Epiaortic scanning is not routinely used probably because of the
cost of the machine (.E100 000) and the fact that there have
been no direct randomized comparisons between CABG with and
without epiaortic scanning that demonstrate a benefit. Such a study
would be problematic because of the large sample size required.
However, although one small study indicated no reduction in tran-
scranial Doppler-detected cerebral emboli,105 several studies have
suggested that early postoperative stroke is significantly reduced
when the operative technique is modified in accordance with
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results of epiaortic scanning.106–109Wareing et al.110 reported that in
14% of elderly patients undergoing cardiac procedures (CABG in
89%), the site of aortic cannulation and/or clamping, the sites for
attaching vein grafts, and/or the sites for instillationof cardioplegic so-
lutionwere altered. The precise rates of suchmodifications provided
in the literature vary, between 4 and 31%.99 A recent study byDaniel
et al.111 showed that epiaortic scanning was increasingly performed
from 2002 to 2009 (45 and 90%, respectively) and coincided with
less frequent aortic clamping (98 and 73%, respectively).
Graft flowmeasurement
Data from the PREVENT IV trial showed a suboptimal rate of saphe-
nous vein-graft failure after on- and off-pump CABG at 1 year;112 a
meta-analysis reported a failure rate of 5 and 25% at 3 and 12
months, respectively.113 Several mechanisms of graft failure have
beendescribed. Early graft failure canoccur as a result of anastomotic
problems, limited outflow, graft kinking upon chest closure, and
thrombosis. Late failure is the result of thrombosis and processes
of intimal hyperplasia and atherosclerosis. Intra-operative graft as-
sessment has been introduced to evaluate grafts and identify anasto-
motic problems and limited outflow. Disturbingly, Balacumaraswami
et al.114 demonstrated that intra-operativegraft assessment identified
9%of graftswith inadequate flow in 25%ofCABGpatients, which led
to revision in 3% of grafts and 8% of patients. Multiple techniques for
intra-operative graft assessment have been proposed: coronary
angiography, transit time flowmeasurement (TTFM), high-frequency
epicardial echocardiography, thermal coronary angiography and
intra-operative fluorescence imaging (IFI).115 Although angiography
is thought to be the best and most reliable method for assessing
flow,116 the infrastructure required for coronary angiography is
rarely available in standard operating rooms. Wider implementation
of hybrid operating rooms could potentially facilitate the use of cor-
onary angiography. Currently, intra-operative graft assessment is
most frequently performed by TTFM or IFI.
Both TTFM and IFI have strengths and weaknesses and have been
criticized for their inability to identify graftswithminor abnormalities
that present a risk for failure. Furthermore, inconsistent and variable
measurementsmay lead to unnecessary graft revisions.114 Twopara-
meters, graft function and anatomy, are required for the complete as-
sessment of bypass grafts. Transit time flow measurement assesses
function and can very accurately detect truly poor and truly good
grafts (true positives, true negatives), but there is an issue with
respect to detecting poor grafts with a low pulsatility index (PI)
(false negatives). False positives (good graft, high PI) rarely occur.
Intra-operative fluorescence imaging evaluates anatomy but is asso-
ciated with more inter-observer error than standard angiography.
Comparisons between TTFM and IFI suggest that IFI is more
sensitive.113,114,117 Transit time flow measurement combined with
epicardial ultrasonic scanning is a recently introduced approach
that may provide both a functional as well as anatomic assessment.
Despite issues, the clinical value of TTFM has been demonstrated
in studies that found that TTFM predicted graft failure at 3, 6, and/or
12months post-CABG.118–120 Inadequate graft flowas defined by PI
.5 on TTFM was found to be an independent predictor of major
adverse cardiac events, operative death in particular.121 No studies
have yet explored the impact of IFI measurements on clinical out-
comes during the follow-up. In general, randomized comparisons
between CABG with and without graft flow measurement remain
absent. Such studies would be required to evaluate the true benefit
their routine intra-operative use would have on early and late rates
of reintervention, myocardial infarction and death. One issue that
remains, however, is that long-term graft failure would still occur
as caused by other mechanisms than those controlled by intra-
operative graft assessment. This could beoneof the reasonswhy sur-
geons doubt its clinical impact and consequently why routine use has
been limited.
Secondary prevention
Apart from technical and procedural considerations, further optimiza-
tion of long-term outcomes after CABG can be achieved through a
strict medical regimen. Progression of atherosclerosis in the native
coronary arteries continues after CABG and is associated with
deterioration of left ventricular function. However, this can be pre-
vented by the administration of antiplatelet agents,122 b-blockers,123
angiotensin-converting enzyme inhibitors (ACE-I),124 statins125,126
and fatty acids,127 all ofwhich have been identified as independent pre-
dictors of survival after CABG. The PREVENT IV trial found that sec-
ondary prevention medications were associated with significantly
reduced rates of death ormyocardial infarction after CABG.128More-
over, data suggest that graft patency may be better in patients taking
statins,129 fatty acids,130 aspirin,65 and possibly dual antiplatelet
therapy.131 Administration of secondary prevention medications has
increased remarkably,132,133 and differences between PCI and CABG
have shown to converge (Table 4). Nevertheless, some data have
shown that differences between PCI and CABG still remain and
again stressed the need for further progress (Figure 2).134–136
Furthermore, theeffect of lifestyle interventionsonoutcomesmay
be underestimated.A plethoraof data exists on the impact of lifestyle
intervention on outcomes after CABG. Van Domburg et al.,137 for
example, reported that patients who quit smoking had signifi-
cantly improved 30-year survival when compared with persistent
smokers after CABG [HR ¼ 0.60 (95% CI: 0.48–0.72)]. Education
and counselling on eliminating risk factors, healthy food choices,
stress relief and exercise provide substantial benefit for patients.138
A meta-analysis that combined 63 randomized clinical trials with
follow-up data on 21 295 patients found that implementation of sec-
ondary prevention programmes significantly reduced all-cause mor-
tality [risk ratio (RR) ¼ 0.85 (95% CI: 0.77–0.94)] and myocardial
infarction [RR ¼ 0.83 (95% CI: 0.74–0.94)].139 Notably, specific
patient subgroupsmay benefitmost from rigorous behaviouralmod-
ifications: young (age ,60 years) or old (age ≥75 years) patients,
patients with a sedentary lifestyle and/or a smoking habit, patients
with a low Mediterranean diet score and those who live alone.140
However, data from three EUROASPIRE surveys showed that
there was a clear need for more effective lifestyle management
among patients with previous coronary revascularization.141 The
authors rightfully stated that treatment of coronary artery disease
‘without addressing the underlying causes of the disease is futile;
we need to invest in prevention’.
Initiatives should be undertaken to increase the rate of prescribing
appropriate discharge medications and to emphasize the need for
long-termmedication compliance and lifestyle changes. In particular,
home-based programmes may be efficient and more acceptable to
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patients—with the additional benefit of lower costs.142 Such quality
improvement programmes canbe easily instated and couldpotential-
ly improve patient care significantly.
Decision-making
Despite the potential for further optimization of CABG outcomes,
PCI will remain an excellent alternative in specific patients. Evidence
suggests that there is overuse, underuse and inappropriate selection
of revascularization strategies.143 Inappropriate use and underuse
may partly explain the preferences expressed by patients,144 who
prefer less invasive techniques with minimized pain over the long-
term prospect of improved survival. In that respect, MIDCAB or
hybrid procedures may present an alternative, but often patients
are not even informed about the survival advantage with CABG.145
Naturally, if two treatments are considered to produce similar
results, patients will opt for the least invasive.
Reflecting on the current revascularization guidelines, recent trial
results and weighting risk–benefit ratios of (new) developments,
Figure 3 provides a proposal for a decision-tree for revascularization.
The myriad of treatment options emphasize the need for targeted
patient selection, and themix of surgical and interventional therapies
provides rationale for multidisciplinary Heart Team decision-making
to discuss all potential treatment options and obtain informed
consent. Clinical cardiologists, interventional cardiologists and
cardiovascular surgeons should convene on a regular basis to
recommend the most appropriate treatment strategy for individual
patients.143,146 The importance of a Heart Team was once more
stressed in the SYNTAX trial147 and was subsequently included in
the European andAmerican guidelines.3,148 Practicemay be different
across centres and countries, and a local protocol should be estab-
lished to define patient populations that are candidates for certain
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Table4 Trends in theuseof secondarypreventivemedicationand thedifferencebetweencoronaryarterybypassgrafting
and percutaneous coronary intervention
EUROASPIRE I
1995–96,
n 5 9 countries
EUROASPIRE II
1999–2000,
n 5 15 countries
EUROASPIRE III
2006–07,
n 5 22 countries
Antiplatelets (%)
CABG 87.9 86.8 92.9
PCI 89.4 90.0 94.9
D 21.5 23.2 22.0
Beta-blockers (%)
CABG 56.5 68.0 90.7
PCI 61.7 73.6 84.4
D 25.2 25.6 +6.3
Blood pressure-lowering drugs (%)
CABG 86.2 90.1 98.7
PCI 87.4 91.3 95.9
D 21.2 21.2 +2.8
Lipid-lowering drugs (%)
CABG 36.7 67.6 90.5
PCI 42.2 69.9 89.4
D 25.5 22.3 +1.1
Data from Kotseva et al.133
CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention.
Figure2 Difference in secondarypreventionmeasures afterper-
cutaneous coronary intervention and coronary artery bypass graft-
ing. Data from Hiratzka et al. 134 ACE-I, angiotensin-converting
enzyme inhibitor; CABG, coronary artery bypass grafting; PCI, per-
cutaneous coronary intervention.
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therapies. The various pros and cons of surgical revascularization
strategies should then be considered by the Heart Team (Table 5).
Future studies
Rigorous evaluation of potential advancements remains crucial
before they are introduced on a wide scale. Even an extensive body
of evidence supporting some interventions is not necessarily suffi-
cient to provide evidence-based recommendations. This is exempli-
fied by the .60 randomized trials comparing off-pump with
on-pump surgery:13,30,35 a benefit of off-pump CABG has been sug-
gested in many studies that included different patient populations.
Nevertheless, the two latest and largest randomized trials that
included low- and high-risk patients found no difference between
the two treatment options.30,35
In contrast, data on some new therapeutic strategies remain
scarce, but the existing datamay demonstrate excellent safety and ef-
ficacy. Such results often represent outcomes from highly selected
patients treated by experienced surgeons in high-volume centres.
This introduces a bias; the generalizability of such results is limited
and caution is advised. An example of this is the evaluation of
TECAB procedures.
Percutaneous coronary intervention vs.
coronary artery bypass grafting studies
Continuous evaluation of PCI vs. CABG calls for a specific focus on
new developments in both interventions. For PCI patients, new
stents will become available and the use of fractional flow reserve
to assess the need and completeness of revascularization is empha-
sized.149,150 Equivalent data on FFR-guided CABG are scarce.151
Future studies should explore the use and differences of FFR-guided
revascularization between PCI and CABG.152 The impact of the
degree of ischaemia and viability on the outcomes of both CABG
and PCI in patients with stable angina is still under debate.
Whether image-guided revascularization that is based on a combin-
ation of functional and anatomical imaging—for example, position
emission tomography computed tomography (Figure 4)—can
improve the outcomes as compared with the traditional occuloste-
notic approach warrants further trials.
Figure 3 Proposal for a decision-tree for revascularization. Some of these recommendations have not yet been validated and still require rando-
mized evaluation. CABG, coronary artery bypass grafting; LAD, left anterior descending; LM, left main; MIDCAB,minimally invasive coronary artery
bypass; PCI, percutaneous coronary intervention.
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Traditionally, trials are limited to their internal validity, i.e. the
results are only applicable to the included patient cohort; large ‘real-
world’ registries are required to demonstrate whether trial results
are also applicable to the general population.10 Alternatively, an ‘all-
comers’ trial design with none to limited patient exclusion criteria
increases external validation, and presents amore balanced trade-off
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 5 Pros and cons of different surgical revascularization techniques
Conventional
CABG
Off-pump CABG MIDCAB TECAB Hybrid
revascularization
Lesions Multivessel disease
(+)
Multivessel disease (+) Isolated LAD stenosis
(+/2)
Multivessel disease (+) Multivessel disease (+)
Technical difficulty None (+) Moderate (+/2) Moderate (+/2) Difficult (2) Moderate (+/2)
Incision Sternotomy (2) Sternotomy (2) J-incision (+/2) Endoscopic (+) J-incision (+/2)
Cardiopulmonary bypass Yes (2) No (+) No (+) No (+) No (+)
Procedure time Short (+) Prolonged (+/2) Long (2) Long (2) Long (2)
Blood products Many (2) Less (+/2) Few (+) Few (+) Few (+)
Completeness of
revascularization
Complete (+) Complete (+) or
incomplete (+/2)
Complete (+) or
incomplete (+/2)
Complete (+) or
incomplete (+/2)
Complete (+)
Postoperative length of
stay
Long (2) Prolonged (+/2) Short (+) Short (+) Short (+)
Postoperative pain Yes (2) Yes (2) Yes (2) Less (+/2) Yes (2)
Recovery time Long (2) Long (2) Short (+) Short (+) Short (+)
Rate of stroke High (2) Less (+/2) Less (+/2) Less (+/2) Less (+/2)
Rate of repeat
revascularization
Good (+) Moderate (+/2) Good (+) Moderate (+/2) Moderate (+/2)
The various features are scored as following: in favour of the technique (+), reasonable in favour (+/2), detrimental for the technique (2).
CABG, coronary artery bypass grafting; LAD, left anterior descending; MIDCAB, minimally invasive coronary artery bypass.
Figure 4 Functional and anatomical imaging using position emission tomography computed tomography. Case: 70-year-old male had atypical
symptoms of three-vessel coronary artery disease for which he underwent stenting of the right coronary artery in 2012. Scan is positive for infer-
olateral wall ischaemia (purple). LAD, left anterior descending artery; LCX, left circumflex artery; RCA, right coronary artery.
Optimizing outcomes of CABG 2883
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Chapter 4
60
between internal and external validation.153 Furthermore, reporting
the experience of centres and operators will also contribute to the
internal and external validity of trial results: superior outcomes in
experienced centres as opposed to inexperienced centres unveils
limited external validity and should restrict one from over-
extrapolating trial results to real-world clinical settings.
In the SYNTAX trial a new angiographic scorewas validated—the
SYNTAX score—for grading the complexity of coronary artery
disease.154This score appears tobe averypromising tool fordeciding
if PCI or CABG would be preferable. Use of the score is therefore
recommended for decision-making. Recently, the SYNTAX II score
was introduced and showed an improvement in guiding decision-
making.155 Yet, further validation of these hypothesis-generating
data is needed and future studies should provide a larger body of evi-
dence about the SYNTAX (II) score.
Pharmacological management of patients after PCI and CABG
differs significantly and has an impact on long-term results. It would
be interesting to see the results of PCI and CABG if the pharmaco-
logical management and treatment adherence after PCI and CABG
would be identical.
Discussion
Broadening indications for and increasing use of PCI calls for more
focus on the optimization of short- and long-term outcomes after
CABG. Expanding the use of lesser invasive techniques may per-
suade patients to accept surgery as the preferable treatment
option. Particularly studies comparing PCI with CABG require the
most optimal surgical revascularization strategy to show superiority
over PCI. Arterial revascularization with minimized aortic manipula-
tion and intra-operative graft flow measurement is a relatively easy
way to improve outcomes.
Adoption rates of new techniques have been low, despite all
advances. This may be due to: (i) the familiarity that surgeons have
with existing techniques, a reluctance to change and the willingness
to go through the learning curve typical for a new technique, (ii)
the more demanding nature of some technical advances, (iii) compli-
cations related to the use of a new technique and/or device, (iv) time-
consuming steps that may have to be carried out during the proced-
ure, and (v) logistic reasons with regard to the need for additional
equipment, planning and sterility. Particularly when the presumed
benefits with new techniques are not yet clearly proven, these
factors play a major role in maintaining existing protocols.
However, the benefit of advancements will often become evident
when overcoming the learning curve.On the other hand, some tech-
niques will always be time-consuming and reserved for highly specia-
lized centres.
Guidelines
One explanation for the underuse of new techniques and secondary
preventionmeasuresmay be the lackof data supporting their benefit.
This calls for large registries and randomized trials to provide add-
itional rigorous evaluation of, in particular, MIDCAB, hybrid revascu-
larization, epiaortic scanning and graft flow measurement. Another
reason for lack of widespread implementation and geographic varia-
tions may be the differing recommendations of the American and
European guidelines concerning their use (Table 6). This is illustrated
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by recommendations for epiaortic scanning and graft flow assess-
ment. The current European ESC/EACTS revascularization guide-
lines include a class 1C recommendation for intra-operative graft
flow assessment 3 and the American guidelines state that ‘epiaortic
ultrasound is reasonable to evaluate. . .’, which translates to a class
IIa B recommendation.148 However, the American guidelines do
not include a recommendation for graft flow assessment, while the
European guidelines lack a recommendation for epiaortic scanning.
Patient, cost, and market considerations
Adoption of minimally invasive techniques that result in lower post-
operative complications and reduced length of stay will significantly
improve patient satisfaction, and raise patients’ willingness to
undergo CABG as opposed to PCI. On the background of the issue
of rising healthcare expenditures, these improvements may also
help reduce overall costs.
Continued optimization of short- and long-term outcomes of
CABG will reduce costs for health insurance providers who may
therefore favour adoption of new techniques associated with
shorter initial in-hospital stays, reduced complication rates and
fewer repeat revascularizations. In addition, pay for performance is
increasingly instated.156 This system provides additional incentives
to innovate and improve outcomes.
Containing costs to both health insurance providers and societies
may in somehealthcare systems require a reductionof the numberof
centres performing CABG. Innovation and integrating technological
advances into everyday clinical practice may be rewarded by certifi-
cation as a centre of excellence, by continued issuance of a practice
licence and by more patient referrals. Implementation of the Heart
Teamdecision-making processmay furthermore strengthen the pos-
ition of a centre. This approach highlights the centre’s collaborative
environment between specialties, which is appreciated by
patients.143 Theremay also be major cost implications by eradicating
suboptimal treatment: healthcare costs will be contained as rates of
adverse events requiring rehospitalization and additional procedures
are reduced.
Conclusion
Outcomes after surgical revascularization have the potential to
improve beyond the level achieved during recent decades
(Figure 5). However, to facilitate these improvements, surgeons
need to be willing to adopt new techniques that increase procedural
safety, patient satisfaction, and long-term survival. To achieve these
goals, guidelines should be conclusive about recommending certain
techniques and provide guidance for their use. Future trials will
need to provide sufficient evidence for such recommendations by
focussing on specific areas where optimal therapy has yet to be
substantiated.
Conflict of interest: none declared.
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Letter to the Editor of JTCVS
TO THE EDITOR:
I greatly appreciated reading Dr Lylte’s insightful comments in his editorial on the radial 
artery (RA) versus the right internal thoracic artery (RITA) as a secondary arterial conduit 
for coronary surgery.1 All that he says is true: the RITA graft, when considering its histori-
cal older brother the left internal thoracic artery (LITA) graft, should have the same long-
term potential but technically poses a bigger challenge. Hence surgeons opt for a more 
user-friendly arterial conduit, the RA. I would like to suggest a dierent comparison/sub-
stitute: the RA for the vein graft. Dr Lylte’s comment in his editorial, “n my judgment, the 
RA graft is less predictable than the RITA graft in regard to patency,” intrigued me. Over 
the past 15 years as a practicing cardio- thoracic surgeon, I have become profoundly 
aware of the inadequacy of veins, and since my recent attendance at the enlightening 
and energy-invoking symposium “Arterial Conduits for Myocardial Revascularization” 
in Rome by Dr G. F. Possatti and Dr A. M. Calaore, I believe the thrust should be to 
continue to use double ITA grafts whenever possible (especially in the young) but to 
substitute the RA for the vein graft. Since my return from this symposium, I have tried 
to do this; perhaps I did not see (or did not want to see) before, but many patients have 
serious venous disease of their legs precluding use of the saphenous vein. I think one 
of the turning points for me was when I recently (July 24, 2003) had to reoperate on an 
83-year-old woman, on whom I had placed 2 grafts at age 81. Her LITA had gone down, 
I believe because I placed the graft inadvertently above a stenosis and her vein graft 
to a marginal artery occluded. If her vein graft had stayed open, she probably would 
not have needed reoperation at age 83. I used a sequential RA graft to the left anterior 
descending coronary artery and the marginal branch on- pump, and postoperatively 
she woke up stating that this was easier than her rst operation. (Obviously this time 
both grafts were working!)
A second reason to substitute the vein for the RA graft could be the anticipated 
longer-lasting results of the drug-eluting stents used by interventional cardiologists. 
I know we are all interested in the same end—stamping out coronary artery disease 
eects—but it can be a little dis- concerting for many surgeons currently in practice 
to see their favored coronary artery bypass grafts (LITA plus 2 veins) going the way of 
the dodo bird. I want to be so bold as to predict that the drug- eluting stents will rival 
our saphenous vein grafts (that is, by the time they gure out which drug, from which 
drug family, how much eluting, over what period of time, and so on, works; it might take 
20 years). Although we should never be competitive with our interventional colleagues 
because we have the same end point in common, we must as surgeons nd something 
ancillary to their work. I believe total arterial grafting (be it bilateral IT A, LIT A/RA, RIT 
A, bilateral ITA/ gastroepiploic artery) may well be the answer. As Dr Lytle most wisely 
stated at the 2003 meeting of The American Association for Thoracic Surgery in Boston 
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(and I quote him often in this): “Did you think you were going to be doing the same 
operation for 100 years!?” Dr Lytle continues to be a driving force leading all our quests 
for the best coronary artery bypass conduit.
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Bilateral internal mammary artery (BIMA) grafting has been the 
operation of the future for 25 years - it must now arrive! One can-
not talk about BIMA grafting without first discussing why venous 
bypass grafts are no longer best practice.
Why are vein grafts so bad?
Because veins were never meant to be arteries. It is true that some 
vein grafts last 30 years but the majority don’t. The blood pressure 
in veins is 25-30 mmHg; the pressure in arteries is 120/80 mmHg. 
So when a vein is expected to do the job of an artery, it all too 
often fails. In 1996, FitzGibbon1 studied 5,065 bypass grafts from 
1969 to 1994: early graft patency (<3 weeks) was 88%. In 2010, the 
results for early patency were still exactly the same: 88.2% patency 
in 322 venous grafts at ≤7 days in a study by Kim2 versus 98.9% 
(3,495/3,535) in arterial grafts. In a 2008 study meant to deter-
mine if edifoligide would prevent vein graft failure due to neoin-
timal hyperplasia, the one-year venous graft patency was 74.3%3. 
In FitzGibbon’s study, “A” vein graft patency at one year was 76%. 
Despite improvements in every area of medicine and surgery over 
decades, vein graft patency has remained the same: unacceptable. 
As time goes on, vein graft patency worsens: at 10 years, 48% are 
“A” grafts and at ≥15 years 40% are patent1.
Why are BIMA grafts so good?
Because God made them that way. The literature is replete with 
the benefits of BIMA grafting: decreased risk of death, reopera-
tion and angioplasty4, improved in-hospital mortality5, increased 
long-term survival6-9. BIMA is also better in certain subgroups of 
patients, e.g., those with reduced ejection fraction10 and patients 
with diabetes11,12. Use of BIMA has been shown to have better five-
year reintervention-free survival compared with drug-eluting stents 
in diabetic patients13. Most recently, Kurlansky14 demonstrated that 
use of BIMA reverses the influence of gender on CABG outcomes 
short and long-term, ameliorating both the increased perioperative 
mortality in female patients and the reduced long-term survival of 
male patients. The cut-off age for benefit of BIMA grafting ranges 
from 65 to 74 years of age8,15-17. The low incidence of BIMA graft-
ing is no longer justifiable with the evidence to date.
Why do surgeons use veins?
Because this is how they were taught, immediate results are good, 
it’s easier, inertia (it is hard to leave one’s “comfort zone” and per-
form more technically demanding procedures with the requisite 
learning curve). BIMA grafting devascularises the sternum more 
than single mammary harvest and predisposes to deep sternal 
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wound infection. In the United States, the centres for Medicare and 
Medicaid Services no longer reimburse for the extra care neces-
sary for treatment of deep sternal wound infection as this is deemed 
a “never event”18. W orld-famous chefs do not use “freezer-burned 
chicken” and “one-week-old lettuce” to create a culinary master-
piece; they use the very best ingredients. Then why do we as sur-
geons use a vein?  Fast-food mentality?
Why do surgeons not use BIMA?
Because BIMA harvest is more time-consuming, surgeons like to 
be “slick”. In some respects, we surgeons have not evolved much 
from the early days of barber-shop surgery. W e now have general 
anaesthesia, so we do not have to be so “quick”. It may take an 
extra 20 minutes in a three- to four-hour operation to use the sec-
ond mammary (principally the harvest time). W hat a payback for 
patients –  an extra 20 minutes for an extra 20 years… .
In a survey of 101 of 147 Canadian surgeons by Mastrobuoni 
et al19, the main factors influencing BIMA use by surgeons were: 
risk of sternal wound infection for 35% of surgeons, the reluctance 
to believe in the superiority of the right internal mammary artery 
(RIMA) over the saphenous vein for long-term outcome for 30% 
of surgeons, limited length of the RIMA for 28% of surgeons, and 
increased operative time or bleeding for 6% of surgeons.
One famous surgeon (I am not sure who) said “I think that maybe 
what we should be doing is just put two internal mammaries on the 
heart somewhere and leave it at that”. This is a worthy thought: two 
IMAs on the two biggest territories (/AD, CIRC, or RCA) would 
leave the patient with single-vessel disease which (if symptomatic) 
could (if amenable) be addressed with P CI; this would perhaps be 
a more meaningful “hybrid” procedure than just the L IMA-L AD 
and the other two territories with DE S stents.
The team effort
There is a common theme emerging from cardiologists all over the 
world – they “yearn for BIMA grafting”. W hy is this?  V enous graft 
disease is almost impossible to deal with for two reasons: 1) patients 
with serious venous graft disease often have a patent L IMA to L AD 
on which most surgeons will be reluctant to perform reoperation for 
fear of damage to the IMA upon chest re-entry; 2) P CI is fraught 
with the danger of embolisation causing serious myocardial dam-
age, and the atherosclerosis that develops in vein grafts is the biggest 
challenge for any type of stent. Drug-eluting stents are somewhat 
better20, but nothing fully corrects the problem of vein graft athero-
sclerosis, except not using veins to begin with. P lease do not mis-
understand – there is a place for using the vein. It has saved many 
a patient’s life, but its use should be the exception rather than the rule.
Cardiologists refer business to surgeons: as cardiac surgeons we 
are heartened when we see beautiful BIMA grafts studied years 
after CABG surgery. W e rise to the occasion when the following is 
proposed: “If you would do a left internal mammary artery (L IMA) 
to the /AD and a RIMA to the RCA (or CIRC), we can do 3CI for 
the third if the patient suffers angina”. And then there is tough love 
– what if cardiologists didn’t send surgeons CABG cases unless 
surgeons do BIMA(!)?  Detailed discussion of cases between sur-
geons and cardiologists are often enlightening for both. W e should 
learn to talk to each other - patients can only benefit…
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Background. Although bilateral internal thoracic artery
(BITA) grafting in coronary artery bypass grafting
(CABG) is associated with low morbidity and good
long-term results, controversy exists about the age after
which BITA grafting is no longer beneficial. We sought
to determine if such an age cutoff point exists.
Methods. The study cohort consisted of 5,601 consecu-
tive patients from a cardiac surgery registry who under-
went isolated CABG (1,038 [19%] BITA grafts, 4,029 [72%]
single internal thoracic artery [SITA] grafts, 534 [10%]
vein-only grafts) between 1995 and 2008. A Cox model
was used to compare survival by use of bilateral, single,
or no internal thoracic artery (ITA) grafts, adjusting for
baseline clinical and demographic characteristics.
Results.Mean follow-up was 7.1 years. Patients under-
going BITA grafting had the lowest 1-year mortality
(2.4% versus 4.3% SITA grafting and 8.2% vein-only
grafting; p < 0.0001). Relative to SITA grafting, a crude
survival benefit of 54% existed for BITA grafting (hazard
ratio [HR] 0.46; 95% confidence interval [CI], 0.37 to 0.57;
p < 0.0001) with worse survival for vein-only grafts (HR,
1.16; 95% CI, 0.99 to 1.37; p  0.07). After adjustment, the
benefit of BITA grafting was no longer statistically sig-
nificant (HR, 0.87; 95% CI, 0.69 to 1.08; p  0.2). However
age may be an effect modifier: a spline analysis plotting
HR (BITA grafting versus SITA grafting) against age
suggested a potential survival advantage associated with
BITA grafting in patients younger than 69.9 years.
Conclusions. Bilateral internal thoracic artery grafting
is a reasonable revascularization strategy in suitable
patients up to age 70 years. As benefits of arterial grafting
become more obvious over time, a longer period of
follow-up will be needed to confirm the advantage of a
BITA grafting strategy. In the meantime the BITA graft-
ing advantage for patients older than 70 years is not clear.
(Ann Thorac Surg 2011;92:1269–76)
© 2011 by The Society of Thoracic Surgeons
Approximately 1 million patients worldwide undergocoronary artery bypass grafting (CABG) every year
[1]; the current standard of care is to use 1 internal
thoracic artery (ITA) and saphenous vein for the remain-
ing bypasses, the full benefit of arterial conduits becom-
ing most obvious after 5 years or longer. Advantages of
bilateral internal thoracic artery (BITA) conduits have
been known since 1999 [2, 3]; however use of BITA
grafting has not been widely adopted. In North America
4% of patients who undergo CABG receive BITA grafting
[4] and in Europe the proportion is 12% [5]. Reasons for
these low rates include longer operation times, technical
demands, risk to the patients related to sternal healing,
and lower flow to the myocardium in the early hours
after surgery, especially if inotropic drugs are required.
Coronary artery bypass grafting with BITA grafting has
traditionally been reserved for the young patient. The
point at which “young” becomes “old” is in transition
and may continue to advance as improved public health
and lifestyle changes cause people to live longer. Cur-
rently there are no age guidelines for performance of
CABG with BITA grafting. The aim of this study was to
determine the role advancing age might play in the
decision to perform CABG with BITA grafting.
Patients and Methods
Data Sources and Study Cohort
A cohort of consecutive patients who underwent isolated
primary CABG between April 1, 1995 and March 31, 2008
was identified using a local cardiac surgery database.
This cohort was then linked to a second data source, the
Alberta Provincial Project for Outcomes Assessment in
Coronary Heart Disease (APPROACH) database, an on-
going prospective clinical data collection initiative that
captures detailed clinical information on all patients
Accepted for publication May 18, 2011.
Presented at the Forty-seventh Annual Meeting of The Society of Thoracic
Surgeons, San Diego, CA, Jan 31–Feb 2, 2011.
Address correspondence to Dr Kieser, Foothills Medical Centre, Rm C816
1403 29th St NW, Calgary, Alberta, Canada T2N 2T9; e-mail:
t.kieserprieur@ucalgary.ca.
© 2011 by The Society of Thoracic Surgeons 0003-4975/$36.00
Published by Elsevier Inc doi:10.1016/j.athoracsur.2011.05.083
A
D
U
LT
C
A
R
D
IA
C
   b y   T e r e s a   K i e s e r   o n   O c t o b e r   5 ,   2 0 1 1   a t s . c t s n e t j o u r n a l s . o r g D o w n l o a d e d   f r o m  
81
Age of benet for BITA grafting
undergoing cardiac catheterization and subsequent in-
terventions in the Province of Alberta, Canada since 1995
[6]. After data collection from the APPROACH database,
a data enhancement process verifies patient comorbidi-
ties and maximizes data completeness [7, 8]. Follow-up
mortality for all patients is ascertained through quarterly
linkage to the Alberta Bureau of Vital Statistics. Excluded
from this study were patients undergoing repeated
CABG or CABG with concomitant valve or other opera-
tions, non-Alberta residents, and patients with incom-
plete surgical or comorbidity data. This study was ap-
proved by the Health Research Ethics Boards of the
University of Calgary.
Clinical and Outcome Variables
APPROACH contains detailed clinical information, in-
cluding patient demographics, risk factors, comorbidi-
ties, diagnosis, and the Duke Jeopardy Score. The Duke
Jeopardy score, included as an index of severity of
coronary artery disease, encompasses both the percent-
age of stenosis in a coronary lesion and the volume of
myocardium subtended by the stenosis—ie, the myocar-
dium at risk. It has been validated in the APPROACH
population and has been shown to provide independent
prognostic information in patients with ischemic heart
disease [9, 10]. Information retrieved from the local
cardiac surgery database included the number and type
of grafts used. Patients were followed until March 31,
2009 for determination of all-cause mortality (including
operative mortality), the primary outcome. Secondary
outcomes included repeated cardiac catheterization, the
need for further revascularization by percutaneous cor-
onary intervention or repeated CABG, and death within
1 year of CABG.
Statistical Analysis
Coronary artery bypass graft patients were divided into 3
groups: those with saphenous vein-only grafts, those
with SITA grafts, and those with BITA grafts. Between-
group comparisons were conducted using 2 or analysis
of variance tests as appropriate. Kaplan-Meier survival
curves were produced by graft type. A Cox proportional
hazards analysis was used to compare survival by graft
type. Adjustment variables included demographic infor-
mation, comorbidities, the cardiac catheterization indica-
tion, left ventricular ejection fraction, and Duke Jeopardy
Score. A second analysis was performed using the
EuroSCORE as the sole adjustment variable [11]. These
different adjustment methods were undertaken as a sen-
sitivity analysis and account for differing dimensions of
risk (ie, anatomic versus comorbidity risk).
Time was calculated from the date of CABG to the date
on which the patient was censored (the end of follow-up
March 30, 2009) or the date that an outcome event
occurred. Risk-adjusted survival curves were plotted
from the proportional hazards model using the corrected
group prognosis method [12]. The proportional hazards
assumption was evaluated and satisfied for these multi-
variable survival analyses by examining plots of the
log-negative-log within-group survivorship functions
versus log-time and also by examining Schoenfeld resid-
uals. A spline analysis by age was conducted to deter-
mine whether there is evidence for an age cutoff for
benefit of BITA grafting relative to SITA grafting. Statis-
tical analyses were performed with SAS version 9.2 (SAS
Institute Inc, Cary, NC). Outcomes at 1 year were com-
pared using 2 tests; a multivariable-adjusted uncondi-
tional logistic regression model was used to calculate the
odds ratio for death at 1 year.
Results
Study Population
A total of 5,601 patients underwent primary isolated
CABG from April 1, 1995 through March 31, 2008. Among
this group, 10% of patients (n  534) had CABG using
saphenous vein-only grafts, 72% (4,029) had SITA grafts,
and 19% (1,038) had BITA grafts. A total of 105 patients
with BITA grafts (10.1%), 1,853 (46%) of patients with
SITA grafts, and 225 (42.1%) patients with vein-only
grafts were 70 years or older (p  0.0001).
Baseline Clinical Characteristics
Baseline clinical characteristics of the study patients are
shown in Table 1. Patients who received BITA grafts were
younger, more often men, and had less comorbidity
(except hyperlipidemia) than those receiving SITA or
vein grafts, factors reflected in the lower EuroSCOREs
seen in the BITA graft group. Patients with BITA grafts
had higher baseline left ventricular ejection fractions and
more often underwent cardiac catheterization for stable
angina. Although the Duke Jeopardy Score was similarly
distributed across the 3 groups, a greater proportion of
patients with BITA grafts were high risk. The mean
follow-up for all patients was 7.0 years (range, 0 to 13.9
years); the mean follow-up for patients with vein grafts
was 7.9 years, for patients with SITA grafts it was 7.1
years, and for patients with BITA grafts it was 6.4 years.
Survival and Postoperative Revascularization
A total of 1,233 deaths (22.0%) occurred by the end of the
follow-up period. A Kaplan-Meier curve showed that
crude mortality was significantly lower in patients with
BITA grafts than in patients with SITA grafts and this
survival difference continued to increase over prolonged
follow-up (Fig 1A): (HR, 0.46; 95% CI, 0.37 to 0.57) (Table
2). After multivariable adjustment controlling for age,
sex, diagnosis, comorbidities, extent of coronary disease,
and left ventricular ejection fraction, the BITA advantage
was no longer statistically significant (Fig 1B) (adjusted
HR for mortality, 0.87; 95% CI, 0.69 to 1.09; p  0.22) in a
survival analysis extending to 13.9 years of follow-up.
Patients with vein-only grafts fared worse than those
with SITA grafts in both crude (HR, 1.16; 95% CI, 0.99 to
1.37; p 0.07) and adjusted (HR, 1.14; 95% CI, 0.94 to 1.38;
p  0.18) analyses, but again the relationships were not
statistically significant. An additional sensitivity analysis
adjusting for EuroSCORE rather than APPROACH co-
morbidity variables yielded similar results (Table 2). To
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Table 1. Characteristics of the Study Population
Variable
Vein Graft
N  534
SITA Graft
N  4,029
BITA Graft
N  1,038 p Value
Mean EuroSCORE (SD) 5.3 (3.1) 4.9 (2.8) 3.0 (2.3) 0.0001
Demographics
Mean age (SD) 66.9 (10.2) 67.6 (9.5) 58.0 (9.1) 0.0001
Age  70 225 (42.1) 1,853 (46.0) 105 (10.1) 0.0001
Mean follow-up (years) 7.9 (4.1) 7.1 (3.4) 6.4 (3.2) 0.0001
Comorbidities
Cerebrovascular disease 52 (9.7) 366 (9.1) 47 (4.5) 0.0001
Pulmonary disease 81 (15.2) 578 (14.4) 122 (11.8) 0.07
Congestive heart failure 91 (17.0) 594 (14.7) 97 (9.3) 0.0001
Liver/gastrointestinal disease 31 (5.8) 291 (7.2) 74 (7.1) 0.48
Peripheral artery disease 81 (15.2) 441 (11.0) 77 (7.4) 0.0001
Renal disease (Creatinine level  200 mol/L) 33 (6.2) 137 (3.4) 32 (3.1) 0.003
Malignancy 38 (7.1) 219 (5.4) 36 (3.5) 0.005
Hypertension 335 (62.7) 2,629 (65.3) 678 (65.3) 0.51
Hyperlipidemia 339 (63.5) 2,652 (65.8) 828 (79.8) 0.0001
Dialysis 10 (1.9) 48 (1.2) 16 (1.5) 0.34
Diabetes 146 (27.3) 1,057 (26.2) 289 (27.8) 0.54
Former smoker 208 (39.0) 1,847 (45.8) 433 (41.7) 0.002
Thrombolysis 36 (6.7) 235 (5.8) 68 (6.6) 0.54
Cardiac history
Previous myocardial infarction 306 (57.3) 2,097 (52.1) 435 (41.9) 0.0001
Previous coronary artery bypass grafting 6 (1.1) 48 (1.2) 12 (1.2) 0.98
Previous percutaneous coronary intervention 63 (11.8) 429 (10.7) 79 (7.6) 0.007
Indication for catheterization 0.0001
Stable angina 147 (27.5) 1,369 (34.0) 390 (37.6)
Myocardial infarction 161 (30.2) 1,265 (31.4) 340 (32.8)
Unstable angina 207 (38.8) 1,228 (30.5) 279 (26.9)
Other 19 (3.6) 167 (4.1) 29 (2.8)
Left ventricular ejection fraction 0.0004
 50% 338 (63.3) 2,681 (66.5) 737 (71.0)
35%–50% 108 (20.2) 896 (22.2) 213 (20.5)
20%–34% 37 (6.9) 216 (5.4) 35 (3.4)
20% 1 (0.2) 14 (0.4) 4 (0.4)
Not done 37 (6.9) 165 (4.1) 41 (4.0)
Unknown 13 (2.4) 57 (1.4) 8 (0.8)
Jeopardy score
0/12 5 (0.9) 22 (0.6) 6 (0.6) 0.98
2/12 23 (4.3) 133 (3.3) 33 (3.2)
4/12 51 (9.6) 368 (9.1) 100 (9.6)
6/12 97 (18.2) 764 (19.0) 189 (18.2)
8/12 101 (18.9) 767 (19.0) 200 (19.3)
10/12 103 (19.3) 795 (19.7) 220 (21.2)
12/12 154 (28.8) 1,180 (29.3) 290 (27.9)
Duke index 0.02
Low riska 73 (13.4) 548 (13.6) 105 (10.1)
High riskb 297 (55.6) 2,335 (58.0) 654 (63.0)
Left mainc 164 (30.7) 1,141 (28.3) 278 (26.8)
Missing/not entered 0 5 (0.1) 1 (0.1)
a Duke index 1–6 (1 VD 50-75%, 1 VD 95%, 2 VD, 2 VD both 95%, 1 VD 95% PLAD, 2 VD 95% PLAD). b Duke index 7–11 (2 VD 95%, PLAD, 3 VD,
3 VD 1 95%, 3VD PLAD, 3VD 95% PLAD). c Duke index 12 or 13 (Left main, severe left main).
BITA  bilateral internal thoracic artery; EuroSCORE  European System for Cardiac Operative Risk Evaluation; PLAD  proximal left anterior
descending artery; SITA  single internal thoracic artery; VD  vessel disease.
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specifically assess the impact of age on outcome with
BITA grafts, we performed a spline analysis, which sug-
gested that age might be an important effect modifier (Fig
2). BITA grafting appeared to be associated with im-
proved outcomes for patients up to the age of 70 years
and possibly reduced survival after age 70 years.
For the secondary outcomes, within the first year after
surgery only crude mortality at 1 year was significantly
lower in patients with BITA grafts (2.4%) than in patients
with SITA grafts (4.3%) or in patients with vein grafts
(8.2%) (p  0.0001) (Table 3). A logistic regression model
for mortality at 1 year gave an odds ratio (relative to SITA
grafting) of 2.4 (95% CI, 1.58 to 3.66; p  0.001) for vein
grafts and 1.04 (95% CI, 0.64 to 1.70; p  0.9) for BITA
grafts.
Comment
In this population of consecutive isolated patients who
underwent CABG, our work suggests that the use of
BITA grafting was associated with a survival advantage
in patients up to the age of 70 years that continued to
increase with time, although this advantage lost statisti-
cal significance after clinical feature adjustment. These
findings align with studies that suggest better outcomes
with BITA grafting relative to SITA grafting.
Long-term patient outcome is directly related to coro-
nary artery bypass durability [13]. Additionally, athero-
sclerosis of the ITA is quite rare [14] and patency rates of
more than 90% have been demonstrated at 10 to 12 years
[15–18]. As a result, the full effect of BITA grafting would
be expected to continue to accumulate well beyond the
relatively short 7-year follow-up period used in this
analysis.
There is some support in the literature for an improved
survival with BITA grafting [19, 20]. Most recently Kur-
lansky and colleagues [19] reported that BITA grafting
offers a long-term survival at a mean follow-up of 11.5
years with an advantage over SITA grafting in propensity-
matched groups. However this advantage appears to
decline in the elderly, and the age at which this advan-
tage is lost has been debated (cutoff ages of 60 to 69 have
been suggested) [20, 21]. In contrast, a study of 716
patients with BITA grafts and 662 patients with SITA
grafts with a mean age of 69.2 and 71.0, respectively,
found mortality rates at 5.3 years of 5.2% for BITA grafts
and 9.1% for SITA grafts [22]. In a large cohort study,
Mohammadi and colleagues [20] found an advantage of
BITA grafting over SITA grafting up to age 60 years, with
a favorable trend extending to the age of 67 years (HR,
0.74; p  0.05). Our results are qualitatively in agreement
with those of Mohammadi and colleagues, with a signal
Fig 1. (A) Kaplan-Meier survival curve by conduit used (vein only, single or bilateral internal thoracic artery). (B) Multivariable Cox-adjusted
survival by conduit used (vein only, single or bilateral internal thoracic artery).
Table 2. Unadjusted and Adjusted Hazard Ratios by Vessel
Vessel Used
Crude Hazard Ratio
(95% Confidence Interval)
Adjusteda Hazard Ratio
(95% Confidence Interval)
EuroSCORE Adjustedb Hazard
Ratio (95% Confidence Interval)
Vein 1.16 (0.99–1.37) 1.14 (0.94–1.38) 1.08 (0.91–1.27)
SITA 1.00 1.00 1.00
BITA 0.46 (0.37–0.57) 0.87 (0.69–1.09) 0.76 (0.61–0.94)
a Adjusted for age, sex, comorbidities, diagnosis, Duke Jeopardy Score and ejection fraction. b Adjusted for EuroSCORE only.
BITA  bilateral internal thoracic artery; EuroSCORE  European System for Cardiac Operative Risk Evaluation; SITA  single internal thoracic
artery.
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of diminished relative benefit of BITA grafting becoming
evident beyond the age of 70 years, suggesting extra
caution when considering BITA grafting for patients
older than this.
There are limitations to this study. It is observational,
and we acknowledge that revascularization strategies
occurred in a nonrandom fashion. We used a dataset rich
in clinical detail, and although we had the ability to
control for important potential confounding variables, it
is possible that other factors (eg, patient fitness) are
associated with both selection of BITA grafting and
outcome not accounted for in our analysis. This is a
single-center study; important differences may be seen
across regions. In addition, BITA grafting was performed
by surgeons most comfortable with the procedure and
not uniformly performed by all. Weighing against these
limitations are the notable study strengths of robust
outcome data from an unselected regional CABG pop-
ulation and the rich clinical risk adjustment that we
were able to undertake using various risk measure-
ment methods that capture differing dimensions of risk
(EuroSCORE, Duke Jeopardy Score, and Duke Index).
Mortality was the principal end point used in this
analysis, but this is not the only or even the most
important outcome of relevance to the elderly. Improve-
ment in quality of life was previously demonstrated by
our group in elderly patients receiving CABG [23]. Ber-
reklouw and colleagues [24] reported that 47.5% of pa-
tients with BITA grafts versus 35.4% of patients with
SITA grafts had an ischemic event–free existence after 13
years (p  0.001). Muneretto and colleagues [25] also
found better ischemia-free survival at 1 year in a pro-
spective randomized group of 188 patients older than 70
years randomized to either total arterial grafting or SITA
grafting. Recurrent angina occurred in 11.1% of the left
ITA/vein group versus 2.1% of the total arterial group.
Follow-up symptom status was not available for our
study cohort.
Reasons why BITA grafting may be problematic in
older patients include increased tissue fragility, espe-
cially in women, technical challenges with attaching
the right ITA to its target arteries, and operator inex-
perience in performing BITA grafting in this age group.
Also, BITA CABG is most likely performed in elderly
patients when no adequate venous conduits exist. In
addition some think that the ITA, being smaller than
the saphenous vein, is not capable of supplying ade-
quate flow to the myocardium, creating a “conduit-
coronary mismatch.” Finally, concern has been ex-
pressed that BITA grafting adversely affects sternal
blood flow, predisposing the patient to infection, espe-
cially in patients with diabetes [26], even though there
is evidence to the contrary in patients with a broad
range of comorbidities [27–36]. To date Taggart and
colleagues [36] are responsible for the only study
randomizing to BITA grafting or SITA grafting—a
study design that reliably addresses the potential im-
proved survival with BITA grafting. One-year results
showed that BITA grafting is feasible on a routine
basis; the 10-year results will determine if BITA graft-
ing confers better survival and decreased repeated
intervention.
In conclusion, 7-year observation of 5,601 patients
Fig 2. Relationship of hazard ratio for bilateral internal thoracic
artery (BITA) relative to single internal thoracic artery (SITA) across
age. The solid line is the hazard ratio and the dotted lines are the
95% confidence interval around the hazard ratio. A hazard ratio less
than 1 suggests decreased mortality with BITA grafting relative to
SITA grafting, as seen in this figure up to age 70 years.
Table 3. Reintervention and Death Within 1 Year of Coronary Artery Bypass Grafting
Intervention
N  5,601
p Value
Vein
N  534 (%)
SITA
N  4,029 (%)
BITA
N  1,038 (%)
Catheterization 31 (5.8) 258 (6.4) 66 (6.4) 0.87
Percutaneous coronary intervention 12 (2.3) 67 (1.7) 24 (2.3) 0.29
Repeated CABG 3 (0.6) 18 (0.5) 8 (0.8) 0.43
Revascularization (percutaneous coronary
intervention or CABG)
15 (2.8) 82 (2.0) 31 (3.0) 0.13
Death 44 (8.2) 174 (4.3) 25 (2.4) 0.0001
BITA  bilateral internal thoracic artery; CABG  coronary artery bypass grafting; SITA  single internal thoracic artery.
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undergoing isolated primary CABG suggests that there
is no basis for undue caution with respect to liberal and
routine use of BITA grafting, at least up to age 70 years.
However a trend to greater adverse outcomes after
BITA grafting in patients older than age 70 years
demands that caution be exercised when using this
technique in older patients until further studies can
clarify the nature of an adverse outcome versus age
relationship in BITA grafting.
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DISCUSSION
DR JENNIFER L. ELLIS (Washington, DC): A great talk. Thank
you very much. Can you talk about where you put that second
arterial graft and whether or not you think that is important to
put it on the right side versus the left side?
DR KIESER: Thank you for your question Dr Ellis. I can’t speak
for all of my colleagues, but I believe most of the time we tend
to put it on the circumflex system through the transverse sinus,
although Dr Sabik has a paper out in Circulation that said there
wasn’t much difference whether you put it on the right or the
left. I can speak for my own practice: two thirds went to the
circumflex system and about one third most often to the PDA,
because the right is often not negotiable for bypass.
DR JOSEPH F. SABIK (Cleveland, OH): From this morning’s
discussion there was a lot of talk about who we should use, and
I think everyone kind of agrees about the age cutoff. At one time
it used to be 60; now we are seeing it is probably closer to 70. Do
you have any insight into other things that might be important?
People talked about size, in particular, BMI greater than 40, or
diabetes.
DR KIESER: Thank you Dr Sabik. I think certainly one of the
biggest risks that deter people from doing a bilateral internal
thoracic artery procedure is the risk for infection. I just know
from a bit of work that I have done on my own that the one
subgroup of diabetics that I do not do double mammaries in are
obese women. They do, in my experience, have a higher risk of
infection. I think with the elderly, you can have trouble with
fragility of tissues and that is why we are putting a note of
caution in this paper. If you look at the number of patients who
are under the age of 70, if you think our average age is 65 to 66
years, maybe 66% to 70% of patients are under the age of 70. So
if we just did 50% of patients under the age of 70, we would be
doing 34% mammaries, and if we did 80%, you can’t do bilateral
mammaries on everybody, but if you did 80%, you would be
doing double mammaries in 55%, which is a far cry from 4% and
12%.
One part of me didn’t want to talk about the downside, but if
you look at the upside, it really increased the number. For the
spline diagram, I just want to say one thing; it is analogous to
something I believe we see in our everyday life, the milk cartons.
What is written on our milk cartons is “it is ‘best before’”; it does
not say ”bad after.”
DR SUDHIR P. SRIVASTAVA (Atlanta, GA): I think I agree
exactly. One comment and a question. The comment is that I
think this age cutoff obviously is being discussed in light of the
sternotomy cases where there are certain concerns, but I think
we have seen that in less invasive approaches or nonsternotomy
approaches we have used bilateral IMAs without any concern,
elderly patients in their 80s and all that, and we would love not
to give them leg incisions, because those are the patients that
often will get into healing issues and so on. So could you
comment on that?
DR KIESER: Thank you. I couldn’t agree more. I think the same,
though, you could say for off pump versus on pump. I think the
ideal operation for an 82-year-old is a double mammary off
pump; they do very, very well, And just because they’re 82, if I
can do a no-touch aorta off pump, I think that’s the best. I don’t
have any experience in minimally invasive, not yet. I’m not sure
I will, to be quite honest. But thank you for your comments. I
agree.
DR WALTER E. MCGREGOR (Pittsburgh, PA): A significant
limitation of the right internal mammary artery is that it is just
not as versatile as a vein graft. Can you please comment on what
techniques you use in the operating room to increase this
conduit’s utility, ie, gaining length, proximal anastomosis, just
overall grafting strategy?
DR KIESER: Thank you. That is very, very good. Honestly, I
think to do 2 internal thoracic—well, the left, you’re okay, but
the right, skeletonization is a big, big plus. By the time you go to
use the right mammary, if you have wrapped it in a papaverine
sponge, it has grown longer. If I am putting the RITA to the RCA
system, I can get 80% of my RITAs to the PDA. Sometimes there
are a few little tricks. When I bring the RITA to the right, if I
bring it to the main right, I bring it through an incision in the
pericardium just above the superior vena cava, and if I am
bringing it to the PDA, I bring it outside the pericardium
through an incision just opposite, just above the inferior vena
cava, so it comes directly as the crow flies, and it always, almost
always, reaches. Less than 5% of double mammaries in my
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hands are attached to the aorta. Skeletonization I think is the
biggest, biggest plus.
DR JAMES TATOULIS (Parkville, Victoria, Australia): I enjoyed
your talk and obviously I am a believer. To follow on from the
previous question, do you have much experience in and can you
comment about the use of free internal thoracic artery grafts,
particularly the free RITA, and techniques to handle it and make
it more versatile and more comfortable to use?
DR KIESER: Thank you very much Dr Tatoulis. Certainly it is
excellent to do an ITA where you can, but an in situ ITA has only
1 man-made anastomosis, and the fewer man-made, the more
God-made anastomoses, the longer your conduit will last. This is
just a personal bias that I have. I certainly have used what I call
creative arterial grafting where you take bits of radial artery to
make it reach an ITA and RITA to a huge heart. It is all within the
spectrum of arterial grafting, because you can’t just go and get
more ITA, you can’t just go and get more radial artery like you
can vein, so it is difficult sometimes.
DR RAVISHANKAR RAMAN (Philadelphia, PA): I enjoyed
your presentation, and I am glad this generated a good discus-
sion about bilateral internal mammary arteries. In our center, we
harvest bilateral internal mammary arteries in 75% of cases,
including valvular heart surgery. I entirely agree with your
comment, the older the patient, the better it is to use bilateral
internal mammary arteries, as stroke incidence is significantly
lower with a no-touch technique.
Thank you.
DR KIESER: Thank you very much.
Notice From the American Board of Thoracic Surgery
Regarding Trainees and Candidates for Certification Who
Are Called to Military Service Related to the War on
Terrorism
The Board appreciates the concern of those who have
received emergency calls to military service. They may be
assured that the Board will exercise the same sympathetic
consideration as was given to candidates in recognition of
their special contributions to their country during the
Vietnam conflict and the Persian Gulf conflict with regard
to applications, examinations, and interruption of training.
If you have any questions about how this might affect
you, please call the Board office at (312) 202-5900.
Valerie W. Rusch, MD
Chair
The American Board of Thoracic Surgery
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Abstract
Objective: This study was undertaken to evaluate transit-time flow (TTF) as a tool to detect technical errors in arterial bypass grafts intra-
operatively and predict outcomes. Methods: TTF’s three parameters, pulsatility index (PI, index of resistance), flow (cc min1) and diastolic
filling (DF, proportion of diastole with coronary flow), were measured in 990/1000 (99%) of arterial grafts in 336 consecutive patients,
prospectively enrolled in a database. Grafts were revised when TTF findings supported the otherwise suspected graft malfunction. If no other
signs/suspicion of graft malfunction existed (normal electrocardiogram (EKG), stable haemodynamics and unchanged ventricular function on
trans-oesophageal echocardiography (TEE)), and the PI was>5, grafts were not revised. Major adverse cardiac events (MACEs: recurrent angina,
perioperative myocardial infarction, postoperative angioplasty, re-operation and/or perioperative death) were related to TTF measurements.
Results: The average number of grafts per patient was 3.02, of which 99% were arterial. Satisfactory grafts were achieved in 916/990 (93%) of the
grafts, with flows from 34 to 61 cc min1, PI 5 and DF of 62—85%. Fourteen conduits, 20 grafts (2%) suspected to be problematic, were revised.
Patients were divided into two groups: 277 (82%) with at least one graft with PI5 and 59 (18%)with a PI>5. MACE occurred in 25 (7.4%) patients —
15/277 patients with a PI 5 (5.4%) and 10/59 with a PI>5 (17%, p = 0.005). Mortality following non-emergent surgery was significantly higher in
patients with a PI>5 (5/54, 9%) than in patients with a PI 5 (5/250, 2%, p = 0.02). Flow and DF were not predictive of outcomes. Conclusion: A
high PI predicts technically inadequate arterial grafts during surgery — even if all other intra-operative assessments indicate good grafts; it also
predicts outcomes, particularly mortality.
# 2010 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
Keywords: Transit-time flow; Coronary artery bypass surgery; Arterial grafts; Outcomes
1. Introduction
Early postoperative graft failure following coronary artery
bypass graft (CABG) surgery is associated with high morbidity
and mortality [1—4]. Surgeons generally rely on finger
palpation assessment of the pulse in the bypass graft; recent
data suggest that only 20% of cardiac surgeons in North
America use transit-time flow (TTF) measurement to assess
grafts.1 It is well established that arterial grafting with
internal thoracic arteries confers long-term benefit [5—7]; a
reliable method to assess graft function before completing
the operation could potentially improve outcomes. There are
no published studies of this size evaluating TTF in a pure
series of arterial grafts.
In the present study, we used TTF in 336 consecutive
patients to assess the value of this method in predicting
postoperative major adverse cardiac events (MACEs). Our
findings suggest that the pulsatility index (PI), one of three
TTF measurements, is highly predictive of outcomes.
2. Materials and methods
This study is a retrospective analysis of data from
consecutive patients of a single surgeon in whom TTF was
first used in our institution for bypass graft assessment intra-
operatively. Beginning April 2004, TTF was used in all but
three patients (with 10 grafts for whom the equipment was
either in use or not functioning) until the number of 1000
consecutive arterial grafts were reached (April 2007). This
study was submitted to our institutional Research Ethics
Board and individual patient consent was waived.
2.1. Surgical details
Intermittent antegrade warm blood for myocardial
protection and systemic hypothermia at 32 8C were used.
Internal thoracic conduits were harvested in a skeletonised
www.elsevier.com/locate/ejcts
European Journal of Cardio-thoracic Surgery 38 (2010) 155—162
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manner using a harmonic scalpel. Radial artery conduits were
harvested in a non-skeletonised manner, also with a harmonic
scalpel. High spinal anaesthesia (local anaesthetic and
opioid) supplemented by light general anaesthesia was used;
intra-operative trans-oesophageal echocardiography (TEE)
was also used except where contraindicated. Patients with
radial artery conduits received long-acting nitrates for 6
weeks to prevent arterial spasm.
2.2. TTF assessment
TTF measurement provides three parameters: PI, mean
flow and diastolic filling (DF). Abnormal values for bypass
grafts for these three parameters used in this study were as
follows: PI >5, flow<15 cc min1 and DF <25. A PI value 5,
as recommended by the manufacturer (MediStim Oslo,
Norway),2 was chosen as the principal measure of graft
adequacy. The cut-off value for flow has not yet been defined
in the literature and was defined as <15 cc min1 to be
consistent with that used in several previous studies [9—12].
Similarly for DF, an optimal cut-point has not been clarified
and, therefore, after consultation with MediStim personnel,
it was defined as<25,3 a value well below the accepted range
of 45—80 recommended by the manufacturer.4
The measurements were performed three times for each
graft — after removal of the cross-clamp with a beating
heart, off-pump before protamine and then off-pump after
protamine administration. Only the post-protamine value
was used for the present analysis. Probe sizes were selected
to match the largest arterial conduit, skeletonising a small
portion of the radial artery when necessary. Grafts were
revised if a poorly functioning graft was suspected employing
usual clinical criteria (electrocardiogram (EKG) changes,
haemodynamic instability and new regional wall motion
abnormalities on TEE). For the most part, if the TTF values
alone indicated a poor graft, the grafts were not revised.
Occasionally, a graft was revised if the TTF value was
surprisingly abnormal or corroborated the suspicion of a poor
graft. Individual graft measurement for sequential grafts was
donewhenever possible bymeasuring the whole graft and the
‘in-between segment’. This was usually only possible for
grafts on the anterior surface of the heart (left anterior
descending coronary artery (LAD) region) because the
necessary displacement of the heart (causing blood pressure
(BP) drop) precluded measurement of this segment in
sequential grafts to the posterior and inferior regions of
the left ventricle. Perioperative mortality was defined as
death within 30 days of surgery or during the same
hospitalisation if it was longer.
2.3. Data collection
All patients were entered at the time of initial cardiac
catheterisation into a provincial database (APPROACH:
Alberta Provincial Program for Outcome Assessment in
Coronary Heart disease) [8]. APPROACH is an ongoing
prospective data collection initiative in the province of
Alberta in which patients are followed up long term to assess
outcomes. Patients were seen 6—8 weeks postoperatively by
the operating surgeon and the mean follow-up was 3 years.
2.4. Statistical analysis
Continuous variables are expressed using the median and
interquartile range since the distributions were highly
skewed. Exact binomial 95% confidence intervals (CIs) were
calculated for proportions. The data of two independent
groups were compared by Fisher’s exact test (FET). Initially, a
univariate logistic regression analysis was done for each of
the potential predictor variables of MACE. Variables that
were significant at p < 0.10 were also included in a
multivariate regression model. Statistical analyses were
performed using Stata.8.0 (StataCorp, College Station, TX,
USA). A p value of <0.05 was considered to be statistically
significant.
3. Results
3.1. TTF measurements
Demographics of the patient population are shown in
Table 1. A total of 336 consecutive patients had 1015 grafts,
of which 1000 were arterial. TTF was used to measure flow in
990 (99%) of the grafts, which included single (grafts with
only one distal anastomoses), sequential (grafts with one or
more side-to side and one end-to-side anastomoses) and
composite (grafts with two separate conduits joined to make
‘Y’ or ‘T’ graft) left internal thoracic arteries (LITAs), single
and sequential right internal thoracic arteries (RITAs), single
and sequential radial arteries and single inferior epigastric
arteries (Table 2). Fifteen primary vein grafts were used and
five arterial grafts were replaced with saphenous veins at a
second emergent operation in four patients (one of the five
arterial grafts had a PI>5). Sequential grafts comprised 111/
323 (34%) of LITA conduits and 66/239 (28%) of radials. Of the
1000 arterial grafts, 693 (69%) were internal thoracic
arteries, and 234/336 patients (70%) of the patients had
bilateral internal thoracic artery (BITA) grafts. Almost all the
operations were on-pump (95%); off-pump was done either
T.M. Kieser et al. / European Journal of Cardio-thoracic Surgery 38 (2010) 155—162156
Table 1
Patient demographics.
Average age (range) 64 years (36—86 years)
Male 79%
Out-patient 42%
In-patient a 49%
Emergent 10%
Diabetes 35%
Hypertension 65%
Hyperlipidemia 68%
Active smoker 24%
Past smoker 58%
Never smoked 18%
Ejection fraction <30% 7.4%
a In-patient — patient considered too unstable to be discharged home
before undergoing surgery.
2 Karamanoukian HL, Donias HW. Seeing is Believing Intraoperative Graft
Assessment During on- and Off-Pump Coronary Bypass Surgery; Product Mono-
graph MediStim.
3 Personal communication with MediStim representative Andreas Koop.
4 Personal communication with Medi-Stim representative Clemens Kuhn-
Neureuther.
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for single grafts or in patients with a calcified ascending
aorta.
Satisfactory grafts were those grafts with a PI 5.
Suboptimal grafts were those grafts with a PI of >5. As
many as 916 of the 990 grafts assessed (93%) were deemed
satisfactory (a PI value5). The remaining 74 grafts (7%) with
a PI value>5 occurred in 59 of the 336 patients (18%). None of
the patients in the latter group showed any other signs of
graft malfunction, such as EKG changes, regional wall motion
abnormalities on TEE or haemodynamic compromise. Table 3
shows the TTF values for the grafts deemed satisfactory and
Table 4 shows the values for the grafts deemed suboptimal.
As seen in Table 3 (satisfactory grafts), the mean PI values
for the individual conduits ranged from 1.7 to 3.1 and the DF
values from 62% to 73%. Median flow in the major single
conduits (LITA, RITA and radial) was 39, 32 and 34 cc min1,
respectively (average 35 cc min1). In the sequential grafts
(LITA, RITA and radial), the median flow was 43, 45.5 and
42 cc min1, respectively (average 43.5 cc min1), and the
composite grafts had the highest median flow (54 cc min1).
We found that sequential grafts had greater flow than single
conduits and when these ‘in-between segments’ were in a
technically easy accessible location to measure, the
individual components could be evaluated. Flow in the
sequential grafts was 1.24 times higher, and flow in the
composite grafts was 1.5 times higher than flow in single
conduits. For the measured sequential LITA grafts, one
coronary artery territory was served by the majority of the
sequential conduits (107/110, 97%), whereas two coronary
artery territories were served by composite grafts in the
majority of cases (21/23 grafts, 91%).
Table 4 shows the TTF parameters for the suboptimal
grafts: for all types of grafts, the median PI was higher
ranging from 5.8 for the sequential radial grafts to 8.8 for the
single radial grafts. The single RITA group had the highest
number of grafts with a PI >5. (14.2% compared with 3.7%
single LITAs, 5.5% sequential LITAs, 4.3% composite LITAs, 0%
sequential RITAs, 7.7% single radial grafts, 4.6% sequential
radial grafts and one of two IEAs (Inferior Epigastric
Arteries)). Fig. 1(a) and (b) shows examples of TTF values
of a good and suboptimal graft, respectively.
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Table 2
Conduit type and number of grafts for each type of conduit.
Conduit type Number of conduits Number of grafts
Single LITA 189 189
Sequential LITA 111 222
Composite LITA 23 29a
Single RITA 236 236
Sequential RITA 8 17b
Radial 173 173
Sequential radial 66 132
IEA 2 2
Vein 13 15
Total 821 1015
IEA, inferior epigastic artery; LITA, left internal thoracic artery; RITA, right
internal thoracic artery.
a Includes six composite LITA’s made with only LITA.
b Includes one triple sequential RITA.
Table 3
TTF values of satisfactory grafts.
Conduit n (%) PI Flow DF
LITA-single 180/187 (96) 2.3 (1.8—2.8) 39 (26—55) 72 (64—77)
LITA-Seq 104/110 (95) 2.3 (1.9—2.9) 43 (29—62) 73 (67—80)
LITA-Comp 22/23 (96) (27grafts) 1.7 (1.3—2.7) 54 (29—95.5) 69 (66.5—73)
RITA-single 199/232 (86) 2.5 (1.9—3.3) 32 (22—47) 68 (60—74)
RITA-Seq 8/8 (100) (17 grafts) 3.0 (2.0—3.4) 45.5 (32.3—71.3) 64.5 (53—71)
Radial-single 155/168 (92) 1.9 (1.4—2.7) 34 (19—53) 62 (56—68)
Radial-Seq 62/65 (95) 1.9 (1.6—2.7) 42 (23.3—60) 67 (62.3—73)
IEA 1/2 (50) 3.1 4 71
Vein 15/15 (100) 2.4 (1.1—3.6) 38.5 (28—80) 64 (63—66)
Total 926
Values aremedian and interquartile ranges. LITA, left internal thoracic artery; RITA, right internal thoracic artery; IEA, inferior epigastric artery; PI, pulsatility index;
DF, diastolic filling; Seq, sequential; Comp, composite.
Table 4
TTF values of suboptimal grafts.
Conduit n (%) PI Flow DF
LITA-single 7/187 (3.7) 7.8 (7.2—12.3) 16 (6—24) 62.5 (46.5—92)
LITA-Seq 6/110 (5.5) 6.0 (5.2—6.1) 21 (9—25) 87 (46—98)
LITA-Comp 1/23 (4.3) (2 grafts) 6.1 21 44
RITA-single 33/232 (14.2) 7.5 (6.2—9.7) 11 (7—17) 49 (36—66.5)
RITA-Seq 0
Radial-single 13/168 (7.7) 8.8 (6.3—10.5) 10 (5—12) 54 (41.5—60)
Radial-Seq 3/65 (4.6%) 5.8 (5.6—8.2) 9 (5.5—13) 81 (72.5—89.5)
IEA 1/2 (50%) 6.2 5 100
Vein 0
Total 74 (7.4%)
Values are median and interquartile ranges. DF, diastolic filling; IEA, inferior epigastric artery; LITA, left internal thoracic artery; PI, pulsatility index; RITA, right
internal thoracic artery; Seq, sequential; Comp, composite.
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3.2. Intra-operative revisions
Fifteen conduits in 14 patients, responsible for 20 grafts
(2%), were revised. Simple corrections were required in five
grafts (four conduits) by preventing twisting of the graft or
tendency to flip, by incision of an obstructing pericardial
edge or by correcting spasm. Ten conduits responsible for 15
grafts required major revisions: redo distal anastomosis (four
conduits, five grafts), direct attachment of conduit to aorta
or another conduit (seven conduits, nine grafts), endarter-
ectomy (one conduit, one graft) or replace with a vein (one
conduit, two grafts). (Some patients required more than one
type of revision.) Most of the revisions (19/20) were
performed before protamine administration: five grafts after
the first TTF measurements (on-pump, cross-clamp off), 14
grafts when a problemwas noticed off-pump and one revision
was required after protamine administration. The decision
was made to revise when other signs of graft malfunction
occurred (abnormal wall motion on TEE in two patients and
ventricular fibrillation in one patient), when all three TTF
parameters suggested an unanticipated poorly functioning
graft (eight patients) or when there was a high index of
suspicion that the graft was not good and was associated with
poor TTF parameters (three patients). After revision, PI
improved in 17 of the 20 grafts and 16 of the 17 grafts had an
improved PI to a value<5. The TTF values listed were for the
revised grafts.
3.3. Major adverse cardiac events
Twenty-five (7.4%) patients suffered 41 (95% CI 4.9—1.8%)
MACEs postoperatively — recurrent angina: 6/336 (1.8%),
perioperative myocardial infarction: 9/336 (2.7%), percuta-
neous coronary intervention (PCI): 6/336 (1.8%), early re-
operation (no late re-operations): 4/336 (1.2%) and/or
perioperative death: 16/336 (4.8%). Excluding emergency
operations (patients requiring surgery within 24 h of known
requirement for surgery), operative mortality was 3.3%.
MACE occurred in 10/59 (17%) of those patients with at least
one bypass graft with a PI value >5, and in 15/277 (5.4%) of
those with a PI 5 for all bypasses ( p = 0.005). Excluding 32
emergency operations from these two groups (two deaths out
of the five with a high PI, and four deaths out of the 27 with a
low PI), there were still significantly more deaths in the high
PI group: 5/54 (11%; 95% CI 4.4—23.4) compared to 5/250
(2%; 95% CI 0.4—4.0 patients in the low PI group ( p = 0.02).
A flow value <15 cc min1 and a DF value of <45 did not
predict MACE, including cardiac death, with the possible
exception of a mortality difference using DF to assess graft
function only after emergency cases were excluded (Table 5).
The variables PI >5, age (per 10 years) and admission
status were all significant predictor variables of MACE at
p < 0.05. No other variable was significant at p < 0.10 and,
therefore, no other variables were included in the multi-
variate regression analysis. All three variables were inde-
pendent significant predictors of MACE in the multivariate
regression model. Note that although the variables were
significant, the CIs are wide due to the small number of MACE.
The multivariate logistic regression model showed that PI >5
was a significant predictor of MACE (odds ratio (OR) = 4.23,
95% CI 1.7—10.6, p = 0.002) after controlling for admission
status, that is, for a given admission status and age, the risk
of MACE was 4.2 times higher when the PI >5 (Table 6).
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Fig. 1. (a) Example of TTF flow curve and TTF parameters in patent bypass. (b)
Example of TTF trace of suboptimal graft.
Table 5
Relations between TTF and MACE.
MACE Mortality Deaths excluding 32
emergency patients
Patients
(N)
% p
value
Patients
(N)
% p
value
Patients
(N)
% p value
PI
>5 10/59 17% 0.005 7/59 12% 0.011 5/54 9% 0.020
5 15/277 5% 9/277 3% 5/250 2%
Flow
<15 8/73 11% 0.209 4/73 5% 0.757 3/69 4% 0.700
15 17/263 6% 12/263 5% 7/235 3%
DFa
<45 6/43 6% 0.124 4/43 9% 0.256 4/40 10% 0.043
45 18/263 14% 12/263 5% 6/234 3%
Flow (cc min1). PI, pulsatility index; DF, diastolic filling.
a DF recorded in 306/336 patients (91%) (DF is dependent on the EKG trace,
which was not always acceptable).
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We examined in detail the 10 patients with high PI values
in at least one graft that also suffered MACEs and related the
territory of the high PI graft to the territory causing angina,
PCI and myocardial infarction. In seven of these 10 patients,
there was a direct correlation: three with angina (one went
on to have PCI) had verification to the same territory with
regular angiography (1), computed tomography (CT) angio (1)
and thallium (1). In four patients with perioperative
myocardial infarction, one of whom needed emergency re-
operation (all four died), the infarct was in the territory
supplied by the artery with the high PI, verified by the EKG
changes (2), echo changes (1) and re-operative findings (1). In
the three remaining patients, although the PI was high (5.2,
6.3 and 6.9) the flows were reasonable or good (17, 42 and
64 cc min1), and the cause of death was non-cardiac (sepsis
and cerebrovascular accident (CVA) (1), autopsy-documen-
ted CVA with patent bypasses (1) and intra-abdominal
catastrophe (1)).
4. Discussion
In this study of 336 consecutive patients who had CABG
surgery with almost exclusively arterial grafts, we have
shown that the PI obtained by TTF measurement is a strong
predictor of clinical outcomes, whereas flow and DF
measurements were not. Thus, those patients with at least
one graft with a PI value >5 were more than four times more
likely to suffer an MACE postoperatively. In addition, if the
operation was non-emergent, the mortality was four times
higher if the PI >5. Thus, our study directly links MACEs,
including operative mortality with grafts predicted, to be
malfunctioning by TTF.
Several authors have also correlated adverse events with
abnormal intra-operative TTF measurements. Herman et al.
[13], in a study of 985 cardiac surgery patients with both
arterial and venous conduits, found abnormal grafts (PI > 5)
in 19% of patients; this group suffered significantly more
events compared with the normal PI group (31% vs 17%,
p < 0.0001). However, in-hospital mortality did not correlate
with abnormal grafts. Becit et al. [14] compared 100 patients
with 40% arterial and 60% venous grafts, before starting to
use TTF with a subsequent 100 patients in whom TTF was first
used; there were more adverse events in the pre-TTF patient
group. Poorly functioning bypass grafts are known to be
associated with postoperative morbidity and mortality.
Weman et al. [4] reported that 54.7% of 223 patients who
died early after CABG surgery had gross technical problems in
the bypasses (unrecognised twisted conduits, stenotic
anastomoses and dissections).
Using the PI to assess intra-operative graft function is
simple and takes little time. This is especially important in
on-pump surgery where at least three measurements are
optimal; with serial measurements, a surgeon can be alerted
to the presence of a poorly functioning graft before the more
complex-to-reverse steps in an operation, such as coming off-
pump or administering protamine.
The cut-off value of 5 for an optimal graft is suggested by
the manufacturer; some authors have chosen a PI <3 as an
indicator of a good graft [9,10]. Grafts with a PI value
between 3 and 5 may not necessarily indicate poor graft
function because parameters such as competitive flow or
diffuse disease of the grafted artery can also increase
resistance. Competitive flow can be assessed by snaring the
native coronary proximal to the anastomosis. If neither
significant competitive flow nor diffuse disease exists and the
PI is suboptimal (3—5), the graft may require revision. In this
study, 93% of grafts had a PI 5; 78% (775/990) had a PI of
<3.0. The authors devised an algorithm for decision making
based on our experience and that of others (Fig. 2). However,
we do not suggest that every graft with a PI of 5 must be
revised. Rather, a high PI should serve as an indicator that the
graft should be re-assessed and that revision may be
appropriate. Sometimes a minor twist or an obstructing
pericardial edge is easily reparable and improvement can be
confirmed with a quick second TTF measurement. Compe-
titive flow, for example, may cause an elevated PI value of 6—
7; however, in this case, usually the flow is good
(>15 cc min1). This could possibly be the case in the three
patients with high PI and non-cardiac cause of death
discussed in the previous paragraph.
A PI value may be elevated in very long arterial conduits
because resistance to blood flow is determined by, among
other factors, vessel length. This may not indicate poor graft
function. In this study, the in situ RITA group, mostly going
through the transverse sinus to a marginal artery (67% of the
RITAs went to circumflex system), had the highest number of
grafts with a high PI (14.2% vs 5.5% average for the single,
sequential, composite LITA, single and sequential radial) —
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Table 6
Logistic regression analysis predicting MACE.
Univariate
Variable Odds ratio 95% CI p value
Significant at p < 0.05
PI >5 3.56 1.51, 8.39 0.004
Age (per 10 years) 1.57 1.04, 2.37 0.033
Admission
Out-patient 1
In-patient 4.6 1.3, 16.23 0.018
Emergent 12.79 3.1, 52.8 <0.001
Non-significant at p < 0.10
Male 0.54 0.22, 1.31 0.172
Diabetes 0.7 0.28, 1.73 0.440
Hypertension 1.15 0.48, 2.74 0.758
Hyperlipidemia 1.55 0.6, 3.99 0.368
Smoking status
None 1
Current 1.01 0.22, 4.71 0.987
past 1.16 0.29, 4.64 0.837
Ejection fraction 0.5 0.06, 3.83 0.502
On-pump 0.35 0.09, 1.29 0.115
Multivariate
Variable Odds ratio 95% CI p value
PI >5 4.23 1.69, 10.59 0.002
Age (per 10 years) 1.67 1.08, 2.57 0.022
Admission
Out-patient 1.00
In-patient 4.61 1.28, 16.58 0.019
Emergent 15.29 3.52, 66.37 <0.001
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we suspect that the necessarily greater length of conduits
may explain higher PI values in this group.
Several authors have commented on the difficulty in
assessing TTF in sequential grafts and have not included them
in their studies [10,11]. However, sequential grafting is an
important feature of total arterial grafting — in this study 37%
(371/1000 grafts) were sequential. We found that if one
could measure the ‘in-between-segment’, the flow is almost
always less and the PI higher when compared with total graft
flow. In this manner, the individual components of a
sequential graft can be assessed.
Flow did not prove to be a good indicator of graft function.
It is dependent on many factors, including size, length and
quality of conduit and native artery, run-off quality of
coronary bed, mean arterial pressure, heart rate, competi-
tive flow, viscosity of the blood and quality of distal  prox-
proximal anastomoses. Some authors have controlled one
factor, such as mean BP, with inotropic agents when
measuring flow [10—12]. As flow is affected by so many
variables, we chose not to standardise mean BP, which in our
patients ranged from 60 to 70 mmHg. Several authors [9—12]
have suggested that a flow of <15 cc min1 may signal a poor
graft. In this study, a flow of <15 cc min1 did not correlate
with either postoperative death or MACE. Moreover, in those
patients who underwent angiography, many with clinical
indications, initial low flow values recorded at the time of
surgery, did not appear to predict patent (n = 7, mean flow of
10.6 cc min1) or occluded or compromised grafts (n = 5,
mean flow of 9 cc min1). Others have had similar findings:
Shin et al. [15] observed that in LITA grafts, decreased graft
flowwith an acceptable PI correlated with vasospasm and not
anastomotic problems. Hirotani et al. [16] found that mean
flow in ITA grafts was greater than that in saphenous vein
grafts and correlated significantly with the size of the
territory being supplied by the graft.
As can be seen in Table 5, DF appears to be a significant
predictor of MACE in the non-emergency group of patients.
Although it is possible that this finding is significant, we are
concerned that, for several reasons, this may be just
incidental — there weremultiple comparisons; the significant
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Fig. 2. Transit-time flow algorithm.
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p value was achieved only when emergency patients were
excluded and this is the least well-defined cut-point of all
three TTF parameters. (This value was recommended by the
manufacturers; there is no research data to support this cut-
point). Furthermore, the DF data are incomplete (9%missing)
because the EKG trace (on which the DF depends) was not
always satisfactory. This remains an open question, and
should be addressed in further studies.
5. Conclusions
The PI, obtained by TTF measurement, is a valuable tool
to assess adequacy of arterial grafts and predict outcomes.
Postoperative adverse events, especially operative mor-
tality, are significantly higher in patients with grafts with a
high PI. Such grafts should be carefully assessed even when
there is no other indicator of a suboptimal graft function
clinically, by either EKG or echocardiography. The authors
suggest that intra-operative use of TTF measurement of
arterial aortocoronary bypass grafts should become the
standard of care.
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Appendix A. Conference discussion
Dr G. D’ancona (Palermo, Italy): Although I am a great promoter of intra-
operative graft patency verification, I think that this paper doesn’t answer
the question of which are the bad grafts and which are the good grafts,
because there is no angiographic control. But the issues are very important.
Now, my question is, it is difficult on the basis of a sole univariate analysis to
state that a PI more than 5 is a determinant of mortality and MACE. Did the
author consider building a more structured, multivariate analysis model and
maybe in this model to see which are the real determinants for MACE and
mortality, including also morbidity data and data concerning the coronary
anatomy and the coronary quality? If in such a model the PI result is a
determinant of MACE and mortality, then it is possible with C analysis to see
which is the real cut-off for a PI. This I think would be a great message. Have
you considered doing that?
The second question is, on the basis of your experience, and if I followed
your presentation and your paper correctly, you are now suggesting revision of
any grafts that have a PI more than 5, but you just showed us an inferior
epigastric artery with a normal angiogram, with a PI that was around 6. I have
been using this technology for more than 10 years, and I can tell you it is very
difficult to say a PI should be precisely 5, especially because coronary rheology
differs. The right coronaries, for example, have flows both in systole and
diastole and they have a higher PI; it is higher than 5. So, again, we don’t have a
real cut-off. So would you feel very confident in suggesting revision of any graft
that has a PI more than 5? This is the second question.
The third question is for the floor. Actually allow me to ask this question:
How many in the audience routinely use any means of intra-operative graft
patency verification?
Dr Kieser: First of all, themultivariate analysis, no, we have not thought to
do that. I will look at this, though. I am not sure if there are enough patients
involved to do this with, but I did look at the two groups and there was no
difference between the characteristics of the two groups. There were a few
more diabetics in the high PI group, but it did not reach statistical significance.
But that is a good point.
Dr D’ancona: What about the coronary artery, because I am afraid that the
PI is a surrogate that tells you, well, there may be also something wrong with
the peripheral condition of the coronaries, you know what I mean? Did you look
at the type of lesions, did you look at the coronary anatomy, did you try
analysing those variables as well?
Dr Kieser: Well, I do have all the data. I haven’t actually looked at that
specifically. I do have angiographic follow-up, but it is sporadic and it is only
about 13% of the patients, anywhere from zero to three years, so it isn’t going
to correlate with what happened in the time of the operating room,
unfortunately.
Your second question was, would I feel comfortable in revising a graft if the
PI was high? No, that is not what I would recommend. I would recommend
looking at that graft, addressing the high PI. Just a quick glance — if it is 6, 7,
you look at the graft. If you know you just did a graft to a terribly diseased
vessel, and you did the best you could, or you see maybe there is a kink in it. A
high PI needs addressing, looking at it just to see, not necessarily to revise.
Dr D’ancona: So the 5 cut-off you agree is not realistic?
Dr Kieser: No, no, it is not, but it is the first level. If it is over 5, you really
have to look at it, but if it is between 3 and 5, there are other reasons:
competitive flow, a diffusely diseased vessel, poor run-off. But as long as you, I
guess, address it, look to see if there is a problem, instead of just saying the
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machine is wrong, I know I did a good graft. It is just one way to check before
you leave the operating room.
Dr D’ancona: I agree with you.
And so the last question. Howmany in this room routinely use any means of
intra-operative graft patency verification?
Dr F. Beyersdorf (Freiburg, Germany): Nobody? No. So raise your arms,
who is using this flow measurement?
(Show of hands).
Dr Beyersdorf: Thank you very much, and I just remind you that coronary
artery bypass surgery is one of the only surgeries on vessels which is not
controlled in the OR by angiography, for reasons we all know. So at least the
flow measurement is one of the quality assurance measurements we can do,
and therefore I am also a great proponent for using that even though there
are, of course, many problems with the distal flow, the distal vascular bed
and so on, but, still, it is something that we can check when we are doing the
graft.
T.M. Kieser et al. / European Journal of Cardio-thoracic Surgery 38 (2010) 155—162162
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Adhesive-Enhanced Sternal Closure to Improve
Postoperative Functional Recovery: A Pilot,
Randomized Controlled Trial
Paul W. M. Fedak, MD, PhD, Teresa M. Kieser, MD, Andrew M. Maitland, MD,
Margaret Holland, RN, Aleksey Kasatkin, MD, Pamela LeBlanc, Jae K. Kim, MD, PhD,
and Kathryn M. King, RN, PhD
Division of Cardiac Surgery, Department of Cardiac Sciences, University of Calgary, Libin Cardiovascular Institute of Alberta;
Faculty of Nursing, University of Calgary; and Department of Community Health Sciences, University of Calgary, Calgary,
Alberta; and Thunder Bay Regional Research Institute, Thunder Bay, Ontario, Canada
Background. We previously established a proof-of-
concept in a human cadaveric model where conventional
wire cerclage was augmented with a novel biocompatible
bone adhesive that increased mechanical strength and
early bone stability. We report the results of a single-
center, pilot, randomized clinical trial of the effects of
adhesive-enhanced closure of the sternum on functional
postoperative recovery.
Methods. In 55 patients undergoing primary sternot-
omy, 26 patients underwent conventional wire closure
and were compared with 29 patients who underwent
adhesive-enhanced closure, which consisted of Kryp-
tonite biocompatible adhesive (Doctors Research
Group Inc, Southbury, CT) applied to each sternal
edge in addition to conventional 7-wire cerclage. Pa-
tients were monitored postoperatively at 72 hours,
weekly for 12 weeks, and then after 12 months for
incisional pain, analgesic use, and maximal inspiratory
capacity measured by spirometry. Standardized assess-
ment tools measured postoperative physical disability
and health-related quality of life.
Results.No adverse events or sternal complications from
the adhesive were observed early or after 12 months.
Incisional pain and narcotic analgesic use were reduced in
adhesive-enhanced closure patients. Inspiratory capacity
was significantly improved, postoperative health-related
quality of life scores normalizedmore rapidly, and physical
disability scores were reduced. Computed tomography im-
aging was suggestive of sternal healing.
Conclusions. Adhesive-enhanced closure is a safe and
simple addition to conventional wire closure, with
demonstrated benefits on functional recovery, respira-
tory capacity, incisional pain, and analgesic require-
ments. A large, multicenter, randomized controlled
trial to examine the potential of the adhesive to pre-
vent major sternal complications in higher risk pa-
tients is warranted.
(Ann Thorac Surg 2011;92:1444–50)
© 2011 by The Society of Thoracic Surgeons
Postoperative recovery after cardiac operations is in-fluenced by early sternal bone stability. Small de-
grees of sternal motion can result in decreased patient
mobility, compromised respiration, excessive incisional
pain, and major complications, such as infection and
sternal dehiscence. Wire cerclage closure of the sternot-
omy is the current standard of care but can result in
pathologic sternal displacement (2 mm) during physi-
ologic distracting forces such as coughing [1, 2]. Tradi-
tional sternal closure techniques may not always provide
optimal fixation [3]. Even in the absence of gross insta-
bility, imaging can discern sternal gaps and delayed
healing after a routine uncomplicated sternotomy [4].
Sternal complications, including sternal malunion, infec-
tion, and dehiscence, are a growing concern due to the
increasing risk profile of patients undergoing cardiac
operations. Innovations in closure techniques, such as
modified external fixation devices, may provide incre-
mental benefit; however, no single technique has been
widely adopted and a practical solution is needed [5–11].
Kryptonite bone adhesive (Doctors Research Group Inc,
Southbury, CT) is a biocompatible polymer that can accom-
plish rigid bone fixation within 24 hours of application. The
porous network within the product allows healing by os-
teointegration with the host bone over time, without fibro-
sis or inflammation [12]. We previously demonstrated in a
human cadaveric model that Kryptonite bone adhesive,
combined with a standard wire cerclage, enhanced me-
chanical strength and prevented pathologic sternal dis-
placement [13]. Augmenting sternal closure with tech-
Accepted for publication May 3, 2011.
Address correspondence to Dr Fedak, C880, Foothills Medical Center,
1403-29 St NW, Calgary, AB T2N 2T9, Canada; e-mail: paul.fedak@
gmail.com.
Dr Fedak discloses that he has a financial relationship
with Doctors Research Group Inc.
© 2011 by The Society of Thoracic Surgeons 0003-4975/$36.00
Published by Elsevier Inc doi:10.1016/j.athoracsur.2011.05.014
A
D
U
LT
C
A
R
D
IA
C
   b y   T e r e s a   K i e s e r   o n   O c t o b e r   5 ,   2 0 1 1   a t s . c t s n e t j o u r n a l s . o r g D o w n l o a d e d   f r o m  
103
Adhesive-enhance sternal closure
niques to enhance early bone stability may accelerate
functional recovery from cardiac operations and prevent
major sternal complications. In this report we present the
results of a single-center, single-blinded, pilot, randomized
controlled trial of adhesive-enhanced sternal closure com-
pared with conventional wire cerclage in patients undergo-
ing routine cardiac operations.
Patients and Methods
Participants and Study Design
Eligible patients undergoing first-time cardiac operations
through a median sternotomy between April 2009 and
February 2010 at Foothills Medical Center, Calgary, Al-
berta were approached to participate in this study. Inclu-
sion criteria mandated that adult patients underwent
elective or semielective operations, resided within 1-hour
driving distance from Calgary to enable close follow-up,
as necessary, and were capable of informed consent.
Exclusion criteria included patients who:
● were at high-risk of early postoperative bleeding
requiring reopening of the chest; for example,
taking clopidogrel within 5 days of the operation
or intravenous antiplatelet medication within 24
hours of the operation;
● had received previous chest radiotherapy;
● did not speak and read the English language;
● presented in a clinical preoperative state that sug-
gested a prolonged recovery; for example, other
concurrent illness such as significant respiratory
disease or renal failure requiring dialysis, residence
in a long-term care facility, preoperative hospital-
ization exceeding 3 weeks in which physical decom-
pensation occurred, or current substance abuse;
● were identified by physiotherapist in a preopera-
tive assessment as requiring assistance with ster-
nal precautions; or
● did not have telephone access.
Demographic data were collected, and all eligible pa-
tients were assessed for baseline parameters by specially
trained research assistants. Study participants were ran-
domized to conventional wire sternal closure (control) or
adhesive-enhanced closure using Kryptonite bone adhe-
sive with wire cerclage. All patients were treated with the
same postoperative protocols; caregivers were blinded to
the intervention. All patients were placed in routine “ster-
nal precautions” according to the protocol at our institution.
All data were collected by blinded research assistants and
were maintained at a secure site at the University of
Calgary. The protocol received institutional ethics approval.
Written informed consent was obtained from each
participant.
Surgical Technique
All patients underwent sternal closure using 7-wire inter-
rupted cerclage with 12-gauge stainless steel. Use of bone
wax or other hemostatic agents was prohibited. In adhe-
sive-enhanced closure patients, trabecular bone was
cleaned with a sterile brush and irrigated with saline
solution. The Kryptonite bone adhesive was mixed for 4
minutes, and then 3 to 6 mL was applied as a thin layer to
each hemisternum at the trabecular interface. Bone and
soft-tissue approximation was identical in each patient.
Data Collection
Data were collected by site research assistants while
patients were still in the hospital. Pain and discomfort
scores, analgesic use, wound healing scores, incentive
spirometry values (a measure of lung capacity using
Voldyne incentive spirometry [Hudson RCI, Research
Triangle Park, NC]), and standardized assessments of
physical disability, as assessed by the Health Assessment
Questionnaire and by the EQ-5D health-related quality
of life instrument (EuroQol, Rotterdam, The Nether-
lands), were obtained. Data were collected for each
patient preoperatively (baseline) and postoperatively at
days 1, 3, 5, and 7, and at weeks 2, 4, 6, 8, and 12.
Pain and discomfort were measured using Likert-type
11-point numeric rating scales that were anchored with
descriptors (0  none, 10  worst), as previously described
[14]. Analgesic use data (generic name, dose, number of
doses) for the preceding 24 hours were collected at each
interval. Narcotic analgesics included codeine, morphine,
hydromorphone, and fentanyl. Nonnarcotic medications
included acetaminophen, ibuprofen, and ketorolac.
Sternal wound-healing data were collected using The
Society of Thoracic Surgeons–based descriptors on ordi-
nal scales for wound drainage (5-point scale: 0  none,
5  large amount requiring dressing changes  2 per
day), stability (3-point scale: 0  stable, 3  palpable
movement without cough), and incision approximation
(5-point scale: 0  closed, 5  gaping). Participants were
successfully taught how to score their sternal wounds in
this study, as previously described [14].
Clinical data were collected through a health record
audit at the time of discharge. Once the patient was
discharged, data were collected by telephone contact.
Pain, discomfort, analgesic use, sternal wound-healing
data, incentive spirometry values, physical disability, and
health-related quality of life were collected at each con-
tact. A final follow-up assessment was performed at a
minimum of 12 months for all patients.
Statistical Analysis
All analyses were based on intention-to-treat principles.
Wilcoxon tests, Student t tests, two-way analysis of vari-
ance, and 2 tests were used, as appropriate, to compare
the demographic and clinical characteristics of partici-
pants assigned to the intervention and control groups. All
data are expressed as mean standard deviation. Values
of p  0.05 were considered statistically significant.
Results
The study comprised 55 patients: 26 were randomized to
conventional wire closure and 29 to adhesive-enhanced
closure. Despite the small sample size, baseline demo-
graphics and other relevant clinical variables were not
1445Ann Thorac Surg FEDAK ET AL
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significantly different between groups (Table 1). Analysis of
baseline demographics indicates that most of the popula-
tion comprised low-risk patients who were free of multiple
risk factors for sternal complications. Completeness of fol-
low-up at 12 weeks was 98% (54 of 55 patients). One patient
refused further follow-up after 1 week despite an uncom-
plicated recovery. Bleeding unrelated to the closure tech-
nique required 2 adhesive-enhanced closure patients to
undergo reopening. The patients were closed secondarily
without adhesive but were included in the intervention
group according to the intention-to-treat protocol.
Early Outcomes
There were no differences between groups in conven-
tional postoperative complications (Table 1). No major
complications and no deaths were documented after 12
months of follow-up. No patients required hospital read-
mission for sternal malunion, infection, or dehiscence.
Minor sternal instability was identified in 2 control pa-
tients and treated conservatively with regular follow-up
and prolonged sternal precautions. Superficial sternal
wound infection occurred in 2 control patients. Wound-
healing scores were not significantly different between
groups (Table 2).
Postoperative Pain
Pain was assessed at baseline and with trigger activities
such as walking, deep breathing, changes in position
while attempting to sleep, and with coughing. On the
11-point Likert scale, scores below 3 were considered
minor discomfort [14, 15]. Incisional pain after sternot-
omy, as expected, was most severe early after sternotomy
and declined significantly after 2 weeks in most patients
(Table 3). The adhesive-enhanced closure patients had
significantly less incisional pain after sternotomy (p 
0.0001), with mean scores below 3 of 10 at all time points
(maximal mean incisional pain was 2.46  1.71 at 72
hours postoperatively, Table 3). Pain scores between
groups were not significantly different with triggers such
as deep breathing, sleeping, or walking (data not shown).
However, coughing, a well-known pain trigger for
patients after sternotomy, stimulated the most severe
pain and incisional discomforts. The adhesive-enhanced
closure patients reported significantly less pain with
coughing than controls during the 12-week study period
(p  0.0001, Table 3). At 72 hours postoperatively, inci-
sional pain during coughing was substantially dimin-
ished in the adhesive-enhanced closure patients (3.9 
2.4 vs 5.8  2.3, p  0.004). No patients in the control
group reported scores of less than 2, and many scores
exceeded 6 (Fig 1) compared with the adhesive-enhanced
closure patients, where coughing pain was greatly re-
duced in a significant proportion.
Analgesic Usage
We used assessments of electronic nursing records to
compare postoperative analgesic use between groups.
Use of any analgesic medicine (yes/no) postoperatively
was not significantly different between groups (data
not shown). However, at days 3 and 5—when pain
scores are highest—use of narcotic analgesics was
significantly lower in the adhesive-enhanced closure
Table 1. Demographics and Outcomes of Study Participants
Variablea
CWC AEC
p Value(n  26) (n  29)
Age 62.5  9.8 62.0  9.1 0.87
Body mass index, kg/m2 30.8  8.9 27.8  4.4 0.11
Type of operation
CABG 23 (88) 21 (72) 0.57
Aortic valve regurgitation 2 (8) 5 (18)
Mitral valve regurgitation 1 (4) 2 (7)
Myxoma 0 (0) 1 (3)
History
Diabetes 7 (27) 8 (28) 0.99
COPD 3 (12) 2 (7) 0.66
Arthritis 4 (16) 4 (14) 0.99
Stroke 1 (4) 2 (7) 0.99
Postprocedural events
Neurologic 0 (0) 0 (0) 0.99
Pneumonia 0 (0) 0 (0) 0.99
Atrial fibrillation 10 (38) 10 (34) 0.79
Return to ICU 2 (8) 4 (14) 0.67
Superficial sternal infection 2 (8) 0 (0) 0.22
Deep sternal infection 0 (0) 0 (0) 0.99
a Continuous data are presented as mean  standard deviation; categoric
data as number (%).
AEC  adhesive-enhanced closure; CABG  coronary artery bypass
grafting; COPD  chronic obstructive pulmonary disease; CWC 
conventional wire closure; ICU  intensive care unit.
Table 2. Wound Scores by Type of Sternal Closure
Postop
Time
Wound
Score
CWC AEC
p Value
(n  26) (n  29)
N (%) N (%)
Day 3 0 25 (96) 25 (89) 0.38
1 2 (7)
2 1 (4) 1 (4)
Day 7 0 20 (87) 29 (100) 0.13
1 2 (9)
2 1 (4)
Week 2 0 23 (89) 27 (96) 0.45
1 1 (4)
2 2 (8) 1 (4)
Week 4 0 23 (89) 27 (93) 0.34
1 3 (11) 1 (3)
3 1 (3)
Week 8 0 24 (100) 27 (93) 0.42
4 1 (3)
5 1 (3)
Week 12 0 25 (96) 28 (97) 1.00
1 1 (4) 1 (3)
AEC  adhesive-enhanced closure; CWC  conventional wire clo-
sure; Postop  postoperative.
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patients (Fig 2). Pain scores were also significantly
lower. The proportion of narcotic pain medicine use
was not significantly different between groups after 1
week (data not shown).
Inspiratory Capacity
The ability to deep breathe is compromised after sternot-
omy due to pain and altered chest mechanics. We as-
sessed inspiratory capacity in all patients throughout the
postoperative period. The adhesive-enhanced closure
patients were observed to have a marked improvement
in inspiratory capacity at all time points (Table III).
Inspiratory capacity was significantly improved in the
adhesive-enhanced closure patients after controlling for
preoperative incentive spirometry values (p 0.05), body
mass index (p  0.01), and patient age (p  0.005). The
adhesive-enhanced closure patients showed an earlier
recovery to baseline preoperative values compared with
controls. At postoperative day 3, when pain and deep
breathing are most compromised, the adhesive-
enhanced closure patients showed a similar distribution
of scores but with a marked improvement in maximal
inspiratory capacity compared with controls (Fig 3).
Physical Disability and Health-Related Quality of Life
We used the Health Assessment Questionnaire to eval-
uate physical disability postoperatively compared with
baseline. All patients showed a similar and expected
pattern of negligible baseline disability scores, with a
steep rise in disability early after the operation and a
steady recovery to baseline over 12 weeks (Table 3). The
disability scores were significantly lower in the adhesive-
enhanced closure patients, suggesting that the degree of
physical disability was blunted in this group compared
with controls.
In addition, we assessed health-related quality of life
during the same intervals using the EQ-5D standardized
tool. We compared 14 conventional wire closure patients
and 15 adhesive-enhanced closure patients with equiva-
lent baseline (preoperative) health-related quality of life
scores. The adhesive-enhanced closure patients returned
to baseline health-related quality of life more rapidly
than the conventional wire closure patients, suggesting
an accelerated postoperative recovery (46.7% vs 14.3% at
3 weeks, p  0.06, Table 3).
Table 3. Effect on Treatment and Time on Outcome Scores
by Sternal Closurea
Outcome Variable
CWC AEC
p ValueMean  SD Mean  SD
Incisional pain at rest
Treatment effect 0.001
Time effect 0.001
72 hours 4.00  1.52 2.46  1.71 0.001
1 week 2.23  1.80 1.45  1.62 0.097
2 weeks 1.46  1.27 1.21  1.57 0.472
4 weeks 1.19  1.88 0.98  1.39 0.643
8 weeks 0.56  0.96 0.62  0.82 0.83
12 weeks 0.69  1.67 0.28  0.59 0.245
Incisional pain with
cough
Treatment effect 0.001
Time effect 0.001
72 hours 5.81  2.33 3.89  2.36 0.004
1 week 4.27  2.34 3.10  2.18 0.062
2 weeks 4.54  2.40 2.75  2.22 0.007
4 weeks 3.00  2.37 2.72  1.89 0.637
8 weeks 1.32  1.91 2.00  2.10 0.258
12 weeks 1.00  1.74 1.21  1.71 0.713
Inspiratory capacity, mL
Treatment effect 0.001
Time effect 0.001
72 hours 1109  399 1405  318 0.004
1 week 1604  536 1995  451 0.006
2 weeks 1990  665 2330  451 0.034
4 weeks 2228  669 2601  442 0.02
8 weeks 2546  778 2928  612 0.051
12 weeks 2625  928 3059  629 0.051
Physical disability, HAQ
score
Treatment effect 0.048
Time effect 0.001
Baseline (pre-op) 0.16  0.27 0.15  0.31 0.424
1 week 2.03  0.51 1.76  0.59 0.053
2 weeks 1.39  0.70 1.09  0.73 0.129
4 weeks 0.82  0.67 0.57  0.44 0.115
8 weeks 0.40  0.40 0.30  0.30 0.297
12 weeks 0.25  0.32 0.15  0.19 0.202
Recovery of HRQL Patients, % Patients, %
2 weeks 7.1 26.7 0.12
4 weeks 21.4 46.7 0.34
8 weeks 71.4 73.3 0.83
12 weeks 85.7 100 0.89
a Data are not shown for 5 days, 3 weeks, 5 weeks, 6 weeks, 8 weeks, and
10 weeks.
AEC  adhesive-enhanced closure; CWC  conventional wire clo-
sure; HAQHealth Assessment Questionnaire; HRQLHealth-
Related Quality of Life; SD  standard deviation.
Fig 1. The distributions of individual pain scores with cough at
postoperative day 3 are compared by adhesive-enhanced closure
(AEC, black circles) and conventional wire closure (CWC, white cir-
cles). The horizontal bars indicate the group means. Scores of less
than 3 are considered minor discomfort (dashed line).
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Follow-Up at 1 Year
Follow-up after 12 months was complete for 54 of 55
patients (98%; 1 control patient was lost to follow-up).
Mean follow-up was 16.4  2.3 months. No major sternal
complications were documented. No patients in the con-
trol group (n  26) reported persistent incisional chest
pain or discomfort. One patient in the adhesive-
enhanced closure group (n  29) reported significant
residual incisional chest pain. An examination showed he
had a stable and well-healed sternal incision. The patient
localized pain over the internal mammary artery harvest
site and was treated for neuropathic pain. A computed
tomography (CT) scan ruled out nonunion or infection.
Two patients from each group were randomly selected
for late CT imaging. All 4 patients showed evidence
consistent with varying stages of sternal healing and
bony union compared with postoperative CT scans 11
months earlier. A gradual interval increase in radioden-
sity between the sternal edges was observed, suggestive
of new bone formation within the adhesive core (Fig 4).
Comment
More than 1 million sternotomies are performed every
year worldwide. Patient recovery and return to normal
activities after cardiac operations is often delayed by the
6 to 8 weeks required for osteosynthesis (solid bony
union), necessitating use of sternal precautions for 6 to 8
weeks in most centers. These measures are designed to
limit the distracting forces on the sternum until osteo-
synthesis is achieved. Sternal wires are placed under
significant load during upper limb movement, deep
breathing, and coughing before osteosynthesis occurs
[16]. Bone instability can result in substantial patient
discomfort and sometimes prevent healing.
Many novel techniques to improve the stability of
sternal closure have been proposed, but no single
method has gained widespread adoption [8]. Surgeons
have developed minimal access approaches that are
sometimes cumbersome, expensive, and risky. Although
appropriate in selected cases, minimal access cardiac
techniques have not had a significant impact in reducing
the worldwide frequency of sternotomy. Accordingly,
most patients receive sternal closure with techniques that
have not changed substantially since the dawn of cardiac
surgery more than 60 years earlier. Although sternotomy
provides optimal exposure for most cardiac operations,
efforts to accelerate postoperative wound healing and
physical recovery are welcome.
Pain after sternotomy correlates with the stability and
alignment of the sternal closure [17]. We observed sig-
nificant reductions in postoperative pain and analgesic
requirements with use of adhesive-enhanced closure.
These benefits were observed within the first 2 postop-
erative weeks and have maximal benefit within the first
week. Early pain after operations can result in poor
mobility and shallow breathing (splinting) that may lead
to complications, including deep vein thrombosis, pul-
monary embolus, and pneumonia. The use of strong
narcotic medication was significantly reduced; in elderly
patients, these medications can have serious side effects
such as hallucinations, confusion, and disabling falls [18].
Most patients with adhesive-enhanced closure did not
reach significant levels of pain (pain score  3), whereas
the concomitant finding of reduced pain in the setting of
reduced analgesic requirements also supports a signifi-
cant effect of the therapy on pain and discomfort. Re-
Fig 2. Analgesic use during a 24-hour period and its profile are
compared between adhesive-enhanced closure (AEC, black bars) and
conventional wire closure (CWC, white bars). Results are shown for
(A) postoperative day 3 and (B) postoperative day 5.
Fig 3. The distributions of individual inspiratory volumes at postop-
erative day 3 are compared by adhesive-enhanced closure (AEC,
black circles) and conventional wire closure (CWC, white circles).
The horizontal bars indicate the group means.
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duced postoperative pain can potentially result in de-
creased hospital length of stay and improved functional
recovery [19].
Among the most frequent causes of postoperative
morbidity and death after cardiac operations are respi-
ratory dysfunction and pulmonary complications [20].
Sternotomy results in significant postoperative atelecta-
sis and reduced pulmonary function for more than 8
weeks after the operation [21]. Pain may be partly re-
sponsible for this reduced pulmonary function because
patients with adhesive-enhanced closure showed much
earlier improvement to baseline in inspiratory capacity.
Promoting deep breathing in the postoperative period is
an important clinical target that is believed to reduce
complications and accelerate recovery.
From the perspective of the contemporary cardiac
surgical patient, an accelerated return to normal activ-
ities after the operation and rapid functional recovery
are of great interest and importance [22]. Patients with
adhesive-enhanced closure showed an accelerated re-
covery of heath-related quality of life and a reduction
in overall physical disability in the postoperative pe-
riod compared with control patients. Providing these
patient-centered benefits while allowing for maximal
surgical exposure for the operator through conven-
tional full sternotomy may facilitate excellent clinical
outcomes without the need for patient discomfort and
prolonged recovery. Sternal precautions and other
protocols that restrict patient activities until the ster-
notomy has fully healed may not be necessary after
adhesive augmentation in low-risk patients. Further
research will be required to assess the safety of this
strategy. In addition, although not specifically ad-
dressed in this study, these benefits could result in a
substantial cost-benefit to patients as well as to health
care providers. Further economic analysis will be re-
quired to support these opinions.
We believe that improving conventional sternal clo-
sure can enhance and accelerate postoperative recovery.
Improved early sternal stability may reduce postopera-
tive pain, decrease the need for narcotic analgesics,
improve breathing and chest wall mechanics, and stim-
ulate early mobility with rapid hospital discharge. Kryp-
tonite bone adhesive can rapidly provide internal bone
fixation. We previously demonstrated in a cadaveric
model that early sternal bone fixation is substantially
improved with the addition of this bone adhesive. Wire
cerclage is still needed for the first few hours postoper-
atively until the adhesive “bonds” with the sternal bone
[13]. In addition, the adhesive has osteoconductive prop-
erties. Host osteoblasts can synthesize new bone within
the porous network of the material without loss of struc-
tural support, fibrosis, or inflammation [12]. We show
suggestive evidence of new bone formation and healing
in the adhesive core after 12 months by CT scan.
Adhesive-enhanced closure improved early functional
recovery after cardiac operations. No safety concerns or
side effects were identified after 12 months of follow-up.
No infections occurred. Given that deep sternal wound
infection and dehiscence are rare complications, a much
larger study will be required to confirm that infection is
not increased in patients with adhesive-enhanced clo-
sure. However, the early stability provided by the adhe-
sive could potentially reduce the incidence of deep ster-
nal wound infection and dehiscence, which can only be
assessed in a much larger patient population.
In summary, adhesive-enhanced closure is a safe and
simple addition to conventional wire closure, with dem-
onstrated benefits on functional recovery, respiratory
function, incisional pain, and analgesic requirements. A
large, multicenter, randomized controlled trial to exam-
ine the potential of the adhesive to prevent major sternal
complications in higher risk patients is warranted.
Dr Fedak and Dr King are supported by Alberta Innovates
Health Solutions, and Dr Fedak is supported by the Heart and
Stroke Foundation of Alberta, NWT, and Nunavut. This pilot
study was partly funded by Doctors Research Group Inc. Kryp-
tonite adhesive was donated for the study. The authors had full
control of the design of the study, methods used, outcome
variables, analysis of data, and production of the written report.
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Toward zero: Deep sternal wound infection after 1001 consecutive
coronary artery bypass procedures using arterial grafts: Implications
for diabetic patients
Teresa M. Kieser, MD,a M. Sarah Rose, PhD,b Uthman Aluthman, MD,a Marlene Montgomery, RN,c
Thomas Louie, MD,d and Israel Belenkie, MDe
Objective: Coronary artery bypass graft (CABG) surgery with arterial conduits is considered optimal. A deter-
rent to bilateral internal thoracic artery (BITA) grafting is the risk of deep sternal wound infection (DSWI). We
introduced infection prevention measures sequentially, attempting to reduce DSWIs. The aim was to determine
(1) if the absence of DSWIs in the last 469 of 1001 consecutive operations was significant; (2) which measures
explained the change; and (3) the impact of diabetes.
Methods: The measures included internal thoracic artery (ITA) skeletonization, no bone wax, wound irrigation,
1 observer per case, harmonic scalpel harvest of ITAs, vancomycin paste on sternal marrow, iodine-impregnated
skin drapes, chlorhexidine-alcohol skin preparation, no BITA grafts in obese, diabetic women, more off-pump
procedures, aseptic wound care, and marrow irrigation before sternal approximation.
Results:Mean age was 65 10.4 years, 78%were male, 34% had diabetes, and 34%were obese. The first 532
patients had 16 DSWIs (3%) and the subsequent 469 had none (P<.001). Analysis of the data suggested that the
first 11measures likely contributed to the absence of DSWI and less likely, the twelfth. Keymeasures were likely
chlorhexidine-alcohol use and avoidance of BITAs in obese diabetic womenwho had a 10-fold higher DSWI rate
than the other patients (21.4% vs 2.0%). Other diabetics, including obese men, had no increased risk of DSWI.
Conclusions: The measures applied caused a substantial reduction in DSWIs. Key measures included the use of
chlorhexidine-alcohol and avoidance of BITA grafting in obese diabetic females. These measures reduced
DSWIs after BITA grafting in most diabetics. (J Thorac Cardiovasc Surg 2014;148:1887-95)
For more than 25 years, the standard of care for coronary ar-
tery bypass graft (CABG) conduits has been the use of 1 in-
ternal thoracic artery (ITA) and saphenous veins. However,
the shorter life span of venous grafts limits the long-term
benefits of the procedure. Use of bilateral ITAs (BITA),
although known to improve results in all patient groups, is
not common (4% in North America, 12% in Europe, and
30% in Japan).1 Reasons for limited use of BITAs include
longer operating times, technical challenges, perceived
conduitcoronary perfusion mismatch, and risk of deep
sternal wound infection (DSWI). The latter is considered
a major deterrent to using BITA grafts.2,3 If this risk
could be reduced to that associated with single ITA grafts,
BITA grafting might be considered more often.4 Although
mediastinitis is infrequent after CABG surgery (0.4%-
4%), the associated mortality ranges from 10% to 47%.5
After sequential implementation of numerous changes
designed to reduce infection rates associated with CABG,
we analyzed our data to (1) verify that the perception of a
reduced DSWI rate was indeed significant, (2) determine
which prevention measures were responsible for the
reduced rate, (3) assess the relative risk in diabetics, and
(4) compare DSWI rates with those of our other surgeons
who did not systematically use the same measures.
MATERIALS AND METHODS
From July 2003 to October 2012, total arterial grafting was performed
where possible in all patients operated on by 1 surgeon, regardless of
age, level of urgency, and comorbidities. There was continuous effort to
mitigate infections by implementing sequential preventative measures.
This retrospective analysis of prospectively collected data from consecu-
tive patients was undertaken when it was noted that there were no DSWIs
over 4 years, 7 months. For the first 532 patients, the DSWI rate was 3%.
This study was approved by our institutional Research Ethics Board.
Surgical Details
All operations were performed with standard cardiopulmonary bypass
or off-pump using high spinal and light general anesthesia. Intermittent
See related commentary on pages 1896-8.
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antegrade blood cardioplegia and systemic hypothermia (32C) were used
for on-pump procedures; off-pumpCABGwas performedwith the Octopus
stabilizing device (Medtronic, Inc, Minneapolis, Minn). ITA conduits were
harvested and skeletonized, most with an ultrasonic scalpel (Harmonic
Scalpel; Ethicon Endo-Surgery, CVD, Cincinnati, Ohio). ITAs were used
mostly as in situ grafts and wrapped in papaverine-soaked gauze. Negative
air pressure was used in operating rooms. Antibiotic coverage (cephazolin
2 g 30 minutes before knife to skin, every 4 hours intraoperatively, and
every 8 hours for 3 doses) was routine as was intraoperative glycemic con-
trol (4-9 mmol/L) by insulin infusion. Seven single horizontal sternal wires
were used for a single ITA and 8 for BITA or when body surface area was
greater than 2.0 m2.
Deep Sternal Wound Infection
DSWIwas defined as infection involving the sternum, pericardium, and/
or mediastinum requiring 6 weeks of antibiotics with or without surgical
debridement, rewiring, or muscle flap reconstruction.6 In the infectious dis-
ease literature for all types of surgery, 3 categories of surgical site infection
are defined: type 1, superficial incisional; type 2, deep incisional (muscle
and fascia); type 3, deep organ space, bone, and/or mediastinum.6 The
DSWI definition used in this study is the same as type 3. Patients were fol-
lowed for a minimum of 2 months at their postoperative clinic assessment;
all DSWIs appeared before 4 weeks.
Infection Prevention Measures
Before 2003, 4 measures were in place: bone wax was not used on ster-
nal edges and subcutaneous tissues were irrigated with a solution of baci-
tracin/saline before skin closure. From 1994, we limited observers to 1.
Skeletonization of the ITAs began in 2000. From July 2003 onwards, 8
measures were added sequentially and continued subsequently. (1) Starting
in November 2003, an ultrasonic scalpel was used to skeletonize ITAs
(Harmonic Scalpel; Ethicon Endo-Surgery). Because a bloodless surgical
field is required, less clot or charred tissue in the mammary bed reduces
substrate for infection. (2) Starting in July 2005, vancomycin paste (2 g
of vancomycin powder in 2 to 3 mL of saline) was applied to the sternal
marrow before approximation.7 (3) Beginning in January 2006, iodine-
impregnated surgical adhesive drapes (Ioban 3M, St Paul, Minn) were
applied on the chest area before incision and removed at skin closure. (4)
DSWIs occurred in 15 of the first 500 patients in this study; 5 were in obese
(body mass index [BMI] 30 kg/m2) diabetic women. Thereafter
(November 2007), only 1 ITA and radial arteries were used in this group
with diabetes, either the left ITA as a Y with itself, or the radial divided
into two-thirds/one-third with the one-third used as a Y graft with the
left ITA and the two-thirds used as a separate graft. (5) Beginning in
November 2007, operative skin preparation was changed to 2% chlorhex-
idine gluconate/70% isopropyl alcohol (Soluprep 2% to 70% tinted;
Laval, Quebec) (instead of 10% povidone-iodine) which was applied for
at least 30 seconds over potential incision sites. Also, the night before, pa-
tients underwent skin preparation with a 6-wipe package of chlorhexidine
(Sage Products LLC, Cary, Ill). (6) Beginning in April 2008, off-pump
CABG was performed in 75% of cases versus 6% before then. (7) In
June 2008, wound care was changed to an aseptic technique (Figure 1).
(8) Irrigating and manual cleansing of the sternal marrow before applying
vancomycin paste began in September 2009, which was part of a protocol
for a trial of Kryptonite bone cement8 for approximation of the sternum
(15 patients). Marrow cleansing was necessary before applying the cement;
this was done in all subsequent patients.
Data Collection
Systematically collected data from consecutive patients were entered
prospectively into a surgical database. DSWIs were recorded prospectively
by the Infectious Disease Department of the hospital. For comparison with
rates from other surgeons at the same hospital, data were retrieved from
our APPROACH database9 (prospectively collected data from patients
enrolled at the time of cardiac catheterization and followed to assess
outcomes).
Statistical Analysis
Objective 1. To determine whether there was a significant change in
DSWI rate and, if so, when the change occurred. Because the surgeries
were unevenly distributed over time, we used groups of 20 consecutive sur-
geries to model the infection rate, ensuring sufficient numbers in the de-
nominator for adequate precision. To avoid the use of zero (for statistical
reasons), the rate of successful surgeries (ie, those without a DSWI) was
modeled instead of infection rates. In this case, time was considered as
the sequential number representing each consecutive group of 20 surgeries.
To determine our objective, a nonlinear 4-parameter logistic model was
fitted to the successful surgery rate. One equation for this model is10
rate ¼ b0þb1=f1þexp½b23ðtimeb3Þg
This describes a sigmoidal function that allows for an initial infection
rate b0 and a final infection rate b1 and a gradual change over a period of
time (midpoint b3).
Objective 2. To determinewhichmeasurewas key in reducingDSWIs,
we considered that a change in the rate was most likely due to the measure
implemented just before when the infection rate attains the right-hand
asymptote (the new infection rate). This key intervention was considered
necessary (but not necessarily sufficient) to reduce the rate, provided that
the probability of observing a DSWI (after the last observed infection if
the rate remained the same) was nonzero. Any of the measures imple-
mented before this key intervention may also have contributed, but we
were unable to determine this in this study. Similarly, it is possible that
any measure implemented after this key intervention also contributed to
a decreased rate, if the probability of a DSWI at this point after the last
change point was nonzero.
To estimate the probability of a DSWI after the last observed infection
as a function of the number of surgeries completed, we assumed that the
DSWIs formed a stationary Poisson point process with mean l. This
required examination of the number of surgeries between each infection.
To be considered a stationary point process, there should be no autocorre-
lation between the interevent intervals (IEI) and the cumulative distribution
function should be exponential with rate 1/lwhere l is the mean of the IEI.
After this assumption was checked, we calculated the probability of a
DSWI for a given number of surgeries after the last infection using an expo-
nential distribution with rate 1/l. To examine the assumptions, we calcu-
lated the autocorrelation function of the IEIs and used a survival-type
analysis to determine the distribution function of the IEI.
Objective 3. We examined whether the proportion of patients in the
subgroup of obese diabetic women significantly decreased after the change
point and then examined the difference in DSWI rates between this sub-
group and the remainder of the patients before the change point. In both
cases, we used the Fisher exact test to compare the proportions.
Abbreviations and Acronyms
BITA ¼ bilateral internal thoracic artery
BMI ¼ body mass index
CABG ¼ coronary artery bypass graft
CI ¼ confidence interval
COPD ¼ chronic obstructive pulmonary disease
DSWI ¼ deep sternal wound infection
IEI ¼ interevent intervals
ITA ¼ internal thoracic artery
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Objective 4. To examine the change in DSWI rates in 2 other (overlap-
ping) cohorts at our institution before and after the institution-wide change
in operative skin preparation change to chlorhexidine-alcohol in November
2007 (several of the other measures were used by other surgeons, but not
consistently) for: (1) all cardiac procedures performed by all surgeons
for 3 years 4 months before the implementation of chlorhexidine-alcohol
and for 8 months after, using a comparison of proportions; (2) isolated
CABG surgeries performed by 8 other surgeons at this institution, over
the same period as the study cohort. A Poisson regression model was
used to estimate the incidence of DSWI for each surgeon and before and
after the implementation of chlorhexidine-alcohol. The model included a
categorical variable indicating surgeon and a binary variable indicating
before/after chlorhexidine-alcohol implementation. The interaction
between these 2 variables was examined to investigate whether the change
in rates differed by surgeon. In the absence of a statistically significant
interaction, and the absence of a statistically significant difference across
surgeons, overall rates (with 95% confidence intervals [CI]) were esti-
mated from the model from each time period.
FIGURE 1. Cardiac surgery wound care algorithm. BID, Twice daily; D/C, discontinue; Pt, patient; CT, chest tubes; d/c’d, discontinued; OD, once a day;
PRN, pro re nata [as needed]; ASAP, as soon as possible; CV-ICU, cardiovascular intensive care unit.
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RESULTS
Study Population
From July 18, 2003 to October 16, 2012, 1001 consecutive
CABG operations (1 patient had a second procedure 8 years
later for new disease) were performed with 98% (2928 of
2987) arterial grafts. Fifty-nine operations were for single-
vessel disease; 73% (689 of 942) of the remaining operations
were with BITA grafts. Graft conduits consisted of 70%
ITAs, 28% radial arteries, 2% venous, and 4 inferior
epigastric arteries (0.13%). The demographics of the patients
are listed in Table 1. There was less chronic obstructive pul-
monary disease (COPD) (P ¼ .022), fewer active smokers
(P ¼ .029), and less insulin-dependent diabetics (P ¼ .003).
In 4 patients, 6 of 8 harvested ITAs could not be used
because of damage and/or fragility. They were included in
the analysis because they shared the presumed associated
risk for infection. Twenty-six (2.7%) patients required reex-
ploration for bleeding, none of whom developed DSWI.
FIGURE 1. (Continued).
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Operative mortality was 3.9% overall, 16% for emer-
gency procedures, 4% for urgent operations, and 0.7%
for elective procedures. Among the 16 patients with
DSWIs, 6 (38%) died, 4 during the first admission and 2
after early readmission.
Deep Sternal Wound Infection
There were 16 DSWIs overall (1.6%; 95% CI,
0.9%-2.6%). Two occurred after single ITA grafting. Four-
teen DSWIs occurred after BITA grafting, all in the first 316
of 686 patients with BITA grafts (14 of 316, 4.4%; 95% CI,
2.4%-7.3%). Of the 14 with BITA grafts, 9 were diabetic; 9
were male, 8 were obese including 4 with morbid obesity
(BMI40 kg/m2) and 5 (36%) were obese diabetic women.
Treatment included debridement  rewiring in 6 (1 patient
left open), sternal reconstruction with muscle flap in 2, peri-
cardial window in 1, vacuum-assisted closure in 1, local
wounddressing in 2, antibiotics only for 6weeks in 3without
wound breakdown (purulent drainage, severe sternal pain,
positive white blood cell scans), and no treatment in 1 of
the 2 patients with a single ITA artery graft who died quickly
with purulent pleuritis/mediastinitis; the other single ITA
graft patient (the last) needed only dressing changes.
Detection of a Statistically Significant Change Point
The last DSWI was in patient number 532 on April 7,
2008. The estimated 4-parameter logistic model is shown
in Figure 2, A. There was a statistically significant
(P ¼ .001) change in the DSWI rate from 3.1% to 0%.
The midpoint of the inflection was the 513th operation on
November 16, 2007, and for practical purposes, we consider
surgery 532, when the last infection was observed, to be the
change point of infection rates.
Which Infection PreventionMeasures Contributed to
the Decrease?
Measures implemented just before the decrease in infec-
tion rates (April 2008) were avoidance of BITA grafts in
obese diabetic women on October 12, 2007 and change to
chlorhexidine-alcohol on October 30, 2007. However 1
more infection occurred after this just at the sixth measure
(change to off-pump and this patient had surgery performed
off-pump). Overall, the mean number of surgeries between
infections was 33.25 and the number of surgeries between
infections fitted an exponential distribution (Figure 2, B).
The probability of observing 17 surgeries without an infec-
tion at this incidence was high (P ¼ .60) indicating that the
wound care protocol may also have contributed to the
decreased infection rates. The final measure listed (irriga-
tion of bone marrow) was implemented on September 28,
2009, 155 surgeries after the last DSWI (P< .001) indi-
cating that it is less likely to have contributed substantially
to the decreased infection rate, but not impossible.
To decide whether the DSWIs had been eradicated
(ie, P < .000001 [1E-06] of observing no DSWIs after
TABLE 1. Patient characteristics: before and after the change point
All patients (n ¼ 1001) Before change point (n ¼ 532) After change point (n ¼ 469) P value
Off-pump, n (%) 388 (39) 37 (7) 351 (75) <.001
BITA rate excluding single-vessel disease 689/942 (73) 358/504 (71) 331/438 (76) .122
Demographics
Mean age, y (SD) 64.9 (10.4) 64.8 (10.6) 65.1 (10.2) .671
Male, n (%) 780 (78) 409 (77) 371 (79) .402
Outpatient, n (%) 435 (44) 227 (43) 208 (44) .151
Inpatient, n (%) 455 (45) 254 (48) 201 (43)
Emergency, n (%) 111 (11) 51 (10) 60 (13)
Comorbidities
Total diabetics, n (%) 345 (34) 180 (34) 165 (35) .755
Type 1 diabetes, n (%) 58 (6) 42 (8) 16 (3) .003
Type 2 diabetes, n (%) 287 (29) 138 (26) 149 (32) .130
Hypertension, n (%) 691 (69) 361 (68) 330 (70) .411
Hypercholesterolemia, n (%) 697 (70) 371 (70) 326 (70) .973
Active smoker, n (%) 208 (21) 125 (24) 83 (18) .029
Ejection fraction 30%-50%, n (%) 228 (23) 122 (23) 106 (23) .739
Ejection fraction<30%, n (%) 66 (7) 32 (6) 34 (7)
Obesity: BMI 35 kg/m2, n (%) 113 (11) 61 (11) 52 (11) .920
BMI 30 kg/m2, n (%) 339 (34) 185 (35) 154 (33) .547
COPD, n (%) 114 (11) 73 (14) 41 (9) .016
Cerebrovascular disease, n (%) 101 (10) 59 (11) 42 (9) .293
Peripheral vascular disease, n (%) 106 (11) 63 (12) 43 (9) .182
Renal disease, creatinine>200 mmol/L, n (%) 36 (4) 19 (4) 19 (4) 1.0
EuroSCORE, median (IQR) 2.9 (1.5, 6.2) 3.0 (1.6, 6.2) 2.8 (1.5, 6.2) .618
BITA, Bilateral internal thoracic artery; SD, standard deviation; BMI, body mass index; COPD, chronic obstructive pulmonary disease; IQR, interquartile range.
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the last 1 observed); we would have to follow an addi-
tional 460 patients after the last observed infection
without another occurrence. A total of 469 surgeries
were observed without infection (P ¼ 7.48e-07 if the
infection rate had not changed) indicating that the
rate of DSWI in BITA patients had decreased (and
potentially been eradicated) by the combination of
measures.
FIGURE 2. A, Infection rates per 20 consecutive surgeries (dots). The dashed red arrow indicates when the last deep sternal wound infection was observed.
The black arrows indicate when each infection prevention measure (see later discussion) was implemented. *Indicates an institution-wide measure. Infec-
tion prevention measures: (1) Skeletonization of internal thoracic arteries with ultrasonic scalpel; (2) vancomycin paste applied to sternal halves; (3) use of
iodine-impregnated surgical adhesive drapes; (4) avoidance of use of bilateral internal thoracic arteries in obese diabetic women; (5) preoperative skin prep-
aration with chlorhexidine-alcohol; (6) off-pump coronary artery bypass graft was performed where feasible; (7) wound care was changed to an aseptic
technique; (8) cleansing the sternal marrow before applying vancomycin paste. B, Distribution of the interinfection intervals for the first 523 surgeries:
the Kaplan-Meier estimate (green line) is the estimated probability of remaining infection-free given the number of surgeries since the last infection.
The red line indicates the fitted exponential distribution; ie, the probability of observing 50 surgeries or more between infections is high (about 25%).
The probability of observing 100 surgeries or more is about 5% and the probability of observing 200 surgeries or more without infection is low at
0.2%. DSWI, Deep sternal wound infection.
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DSWI Risk in Obese Diabetic Women
In Figure 3 shows the DSWI rate in the subgroups iden-
tified by sex, obesity, and diabetes. After October 2007,
BITA grafting was avoided in obese diabetic women and
therefore the proportion of such patients relative to the total
population of BITA patients (N ¼ 689) decreased from
5.3% (95% CI, 3.2%-8.2%) to 1.8% (95% CI, 0.7%-
3.9%), P ¼ .015. The DSWI rate in 28 obese diabetic
women before April 2008 was 21.4% (95% CI,
8.3%-40.9%), which was 10-fold greater than that in all
other patients in this first group of 532 patients combined
(N ¼ 504; DSWI rate ¼ 2.0% [8 of 504]; 95% CI,
1.0%-3.6%). Reasons for performing BITA in 6 diabetic
obese women after the changed strategy included ideal cir-
cumstances for just BITA, a BMI just more than 30 kg/m2,
ability to perform off-pump CABG and unawareness of a
BMI of 35.5 kg/m2 in 1 woman.
ComparisonWith All Other CABGProcedures in the
Same Institution
Before the operative skin preparation was changed to
chlorhexidine-alcohol (November 2007), the DSWI rate
was 3.1% (139 of 4420) for all cardiac procedures for all
surgeons over 3 years 4 months. Subsequently, the rate
over 8 months decreased to 0.8% (6 of 818 procedures)
(P ¼ .001). There was no evidence of an interaction be-
tween surgeon and the before/after November 2007 variable
(P ¼ .415) or of a significant difference in rates across
surgeons (P ¼ .127). The overall after/before November
2007 incidence rate ratio was 0.46 (95% CI, 0.24-0.86)
indicating that the overall rate of DSWI in isolated CABG
was halved after the introduction of chlorhexidine-alcohol
in November 2007, from 2.65% (95% CI, 1.74%-4.02%)
to 1.21% (95% CI, 0.67%-2.17%) but not eliminated.
DISCUSSION
In this study of 1001 consecutive CABG operations by a
single surgeon with near total arterial and 74% BITA graft-
ing, we were able to achieve a significant reduction in the
incidence ofDSWIs after sequential introduction ofmultiple
infection prevention measures. There were no DSWIs asso-
ciated with the last 469 procedures, whereas the DSWI rate
was 3.01% in the preceding 532 operations. To date, this is
the lowest reported DSWI rate after bypass surgery. This is
particularly important because of the substantial number of
patients with BITA grafts. Also important is that among
diabetic patients, only obese women seem to have a high
risk of DSWI and that the risk in other diabetics, including
obese men, is similar to the nondiabetic population.
Risk Associated With BITA Grafting
In 1990, Kouchoukos and colleagues11 first documented
the relationship between BITA grafting and DSWI (which
occurred in 6.9% of patients with BITA conduits, 1.9% of
patients with single ITA grafts, and 1.3% of patients with
FIGURE 3. Comparison of deep sternal wound infection (DSWI) rates in men, women, diabetic and nondiabetic, obese and nonobese patients.Diamonds,
DSWI rate in each subgroup before the change point. Lines indicate the confidence intervals (CI). CIs are one-sided (97.5%) when the estimates are zero and
95% when nonzero. There is no significant effect of obesity and diabetes in men (P ¼ .696); the overall rate was 2.4% (1.2-4.4). However, obese diabetic
women have a significantly higher risk of DSWI than other women (P<.001). Notably, the only DSWIs in womenwere observed in obese diabetics. The last
2 columns indicate the number of patients in each subgroup before and after the change point. There was no significant difference within women (P¼ .547)
or men (P ¼ .512).
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vein-only grafts). They suggested that BITA graftingwas not
justified (unless other conduits were not available) until they
were proven superior to single ITA grafts. Subsequently, in
1999 Lytle and colleagues12 documented the long-term ben-
efits of BITA grafting. However, there is still reluctance to
use BITA grafts in diabetics even though many have verified
the safety of BITA in such patients, especially if ITAs are
skeletonized.13-17 Our observations add credence to the
safety of BITA grafting (with respect to DSWI) and
demonstrate how the DSWI rate can be lowered even
further. This is particularly important in the United States;
the Centers for Medicare and Medicaid Services have
deemed mediastinitis after cardiac surgery a ‘‘never event’’
and no longer reimburse for extra care if a DSWI occurs.18
Risk Associated With Diabetes
As previously reported by Matsa and colleagues13 and
stated by Lev-Ran and colleagues,14 we found only 1 sub-
group of patients with an increased risk of DSWI: obese dia-
betic women; they had a 10-fold greater incidence of DSWI
than obese diabetic men. They represented 13% of the dia-
betics, but had 38% of the DSWIs (5 with BITA and 1 with
single ITA). Thus, our results suggest that there is no
increased risk of DSWI with BITA grafting in most dia-
betics in whom the DSWI rate was only 1.3% and that
only obese diabetic women should not undergo BITA graft-
ing. Because 2 measures (not using BITAs in obese diabetic
women and the switch to chlorhexidine-alcohol) were im-
plemented at approximately the same time; it remains
possible that just the antiseptic change was sufficient.
Although this raises the possibility that the current risk
may be lower in obese diabetic women than our data sug-
gest, the continued (but low) incidence in DSWIs in patients
operated on by other surgeons who also use chlorhexidine-
alcohol does not support that.
Key Infection Prevention Measures
The use of chlorhexidine-alcohol and avoidance of BITA
grafting in obese diabetic women seem to be the key effec-
tive measures responsible for eliminating DSWIs in a sub-
stantial number of subsequent procedures. Certainly, all
implemented measures may have contributed, but it was
only after these 2 that the DSWI rate decreased dramati-
cally. Even though the DSWI rate for our other surgeons
was halved after the introduction of chlorhexidine-
alcohol, it was not eliminated, which suggests that the intro-
duction of chlorhexidine-alcohol in November 2007 was
not solely responsible for the reduction in DSWIs in the
authors’ patients.
Chlorhexidine-alcohol is an effective infection preven-
tion agent. The 2011 Guidelines for the Prevention of Intra-
vascular Catheter-Related Infections, as a Category IA level
of evidence, recommends skin preparation with greater
than 0.5% chlorhexidine-alcohol for intravenous or arterial
line insertions.19 Several controlled trials20-22 compare
chlorhexidine-alcohol with povidone-iodine in surgical
patients. For general surgical patients undergoing clean-
contaminated surgery, chlorhexidine-alcohol was more
FIGURE 4. Comparison of the estimated deep sternal wound infection (DSWI) rate in this study (Kieser 2013) before and after the change point with other
previously reported studies. The diamonds represent the infection rates and the lines indicate the 95% confidence intervals (CI) of the estimate. Because the
number of infections for Kieser 2013 (after) was zero, a one-sided 95% confidence interval is presented.
Acquired Cardiovascular Disease Kieser et al
1894 The Journal of Thoracic and Cardiovascular Surgery c November 2014
A
C
D
Chapter 10
120
protective against superficial and deep infections but inex-
plicably not against organ-space infections.22
BITA Grafting and DSWI
The incidence of DSWI using skeletonized BITA grafts
varied from 1.1% to 3.3% in previous studies
(Figure 4)13,15,17,23,24 and was greater when ITAs were
harvested in a pedicled fashion16,23 in BITA
grafting,13,15-17,23-25 and lower after single ITA grafting.11,23
In our series, although the DSWI rate after BITA grafting
was 1.6% for the whole group, it was 3.0% for the first
532 patients and 0% in the last 469 patients (76% with
BITA grafts).
Limitations
As is common in retrospective studies, it was not possible
to control for all factors that may have changed outcomes in
the 2 groups of patients. The non-DSWI group had slightly
fewer active smokers, insulin-dependent diabetics, and pa-
tients with COPD; the small number of patients with these
characteristics should not have affected the results. Also,
general improvements over time in surgery, anesthesia,
and knowledge of infection may also have helped to reduce
infections. The strategy of not using BITA grafts in obese
diabetic women, and the switch to chlorhexidine-alcohol
were key measures. The strength of this study is that it is
a consecutive all-comer population of patients in which
most had BITA grafting, including most diabetics.
CONCLUSIONS
We have shown in a series of 1001 CABG procedures
with near total arterial grafting, three-quarters BITA grafts
and one-third diabetics, that the risk of DSWIs can be
reduced to close to zero through multiple infection preven-
tion measures. We cannot predict a zero rate; the risk will
certainly not disappear. We suggest that just as DSWI
may be caused by the transgression of several barriers to
infection, the incidence of DSWI may be reduced by the
addition of layers of prevention. We cannot point to a single
measure as being critical and speculate that multiple barrier
techniques are likely necessary to optimize outcomes.
DSWIs still occur in our unit at a low rate, but not in patients
in whom all the measures have been implemented. It is
important to emphasize that the risk was reduced in all sub-
groups except for obese diabetic women. Our data support
the avoidance of BITA grafting in obese diabetic women;
however, most diabetics may benefit from BITA grafting
without increased risk of DSWI.
The authors greatly appreciate the support of the APPROACH
cardiac and catheterization personnel.
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Arterial grafts balance survival between incomplete and complete
revascularization: A series of 1000 consecutive coronary artery
bypass graft patients with 98% arterial grafts
Teresa M. Kieser, MD,a Helen J. Curran, MD,b M. Sarah Rose, PhD,a Colleen M. Norris, PhD,c and
Michelle M. Graham, MDc
Objective: Coronary artery bypass grafting (CABG) with incomplete revascularization (ICR) is thought to
decrease survival. We studied the survival of patients with ICR undergoing total arterial grafting.
Methods: In a consecutive series of all-comer 1000 patients with isolated CABG, operative and midterm sur-
vival were assessed for patients undergoing complete versus ICR, with odds ratios and hazard ratios, adjusted for
European System for Cardiac Operative Risk Evaluation category, CABG urgency, age, and comorbidities.
Results: In this series of 1000 patients with 98% arterial grafts (2922 arterial, 59 vein grafts), 73% of patients
with multivessel disease received bilateral internal mammary artery grafts. ICR occurred in 140 patients (14%).
Operative mortality was 3.8% overall, 8.6% for patients with ICR, and 3.2% for patients with complete revas-
cularization (P ¼ .008). For operative mortality using multivariable logistic regression, after controlling for
European System for Cardiac Operative Risk Evaluation category (P<.001) and CABG urgency (P¼ .03), there
was no evidence of a statistically significant increased risk of death due to ICR (odds ratio, 1.73; 95% confidence
interval, 0.80-3.77). For midterm follow-up (median, 54 months [interquartile range, 27-85 months]), after con-
trolling for European System for Cardiac Operative Risk Evaluation category (P< .001) and comorbidities
(P¼ .017) there was a significant interaction between age 80 years and ICR (P¼ .017) in predicting mortality.
The adjusted hazard ratio associated with ICR for patients older than age 80 years was 5.7 (95% confidence
interval, 1.8-18.0) versus 1.2 (95% confidence interval, 0.7-2.1) for younger patients.
Conclusions: This is the first study to suggest that ICR in patients with mostly arterial grafts is not associated
with decreased survival perioperatively and at midterm in patients younger than age 80 years. Arterial grafting,
because of longevity, may balance survival between complete revascularization and ICR. (J Thorac Cardiovasc
Surg 2014;147:75-84)
The concept of complete revascularization (CR) in coronary
artery bypass graft (CABG) surgery portending to improved
patient outcomes was first espoused by McNeer and col-
leagues in 1974.1 This gold standard may not be applicable
today because data suggesting the benefits of CR included
young, stable patients, first-time procedures, and predomi-
nantly vein grafting.1 Newer studies are needed to evaluate
contemporary CABG surgery, including use of total ar-
terial grafting; off-pump CABG; and revascularization
procedures in older, sicker patients. The goal of our study
was to determine if there was a survival advantage of
completely revascularized patients compared with ICR in
a patient cohort with predominantly (98%) arterial grafting.
We hypothesized that the long-term advantage of arterial
grafts would potentially counteract the reduced survival of
ICR in an all-comer group of CABG patients.
METHODS
From July 2003, to October 2012, total arterial grafting was performed
where possible in all patients by 1 surgeon at a high volume academic ter-
tiary care center. Patients were divided into 2 groups: Those in whom revas-
cularization was complete and those in whom it was not.
All patients were entered into the Alberta Provincial Program for
Outcome Assessment in Coronary Heart Disease study,2 a prospective
data collection initiative in the province of Alberta, Canada, since 1995. Pa-
tients are enrolled at initial cardiac catheterization and are followed to
assess long-term survival and repeat revascularization with percutaneous
coronary intervention (PCI) or CABG. Mortality is verified by linkage to
Alberta Vital Statistics. All study patients were also entered into a prospec-
tive surgical database, recording patient demographics and relevant surgi-
cal data. This study was approved by our institution’s research ethics board.
Angiogram and operative reports, and office charts of each patient were
independently reviewed by both an interventional cardiologist and a car-
diac surgeon to determine completeness of the revascularization. Revascu-
larization was considered complete when all diseased arterial territories in
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Incomplete revascularization with arterial grafts
left anterior descending (LAD) artery, circumflex artery (CIRC), and right
coronary artery (RCA) regions, with70% stenosis—or50% in the left
main artery—received at least 1 bypass graft for coronary arteries
measuring>1 mm in diameter. Left main revascularization was considered
complete if grafts were placed to the LAD and CIRC.
Five categories of reasons for incomplete revascularization (ICR) were
obtained from operative reports: small vessel (<1 mm diameter), diffuse
disease precluding healthy anastomosis, coronary artery inaccessible for
grafting (location in the atrioventricular groove), infarcted territory (aki-
netic wall, thinned segment, or nonviable myocardium), technical prob-
lems (adhesions in reoperative surgery, high-risk or porcelain aorta
needing off-pump procedure).
Surgery Details
All operations were performed off- or on-pump. For on-pump proce-
dures, we used intermittent antegrade blood cardioplegia and systemic
hypothermia to 32C. Off-pump CABG was performed with the
Octopus stabilizing device (Medtronic, Inc, Minneapolis, Minn). Inter-
nal mammary artery (IMA) conduits were harvested in a skeletonized
manner, with the left IMA anastomosed to the LAD and the right
IMA to either the CIRC or RCA. IMAs were used mostly as in-situ
grafts and were wrapped in papaverine-soaked gauze after harvesting.
High spinal anesthesia (local anesthetic and opioid) supplemented by
light general anesthesia was used. Intraoperative transesophageal echo-
cardiography was used except where contraindicated. Long-acting ni-
trates were used postoperatively for 6 weeks in only patients with
radial artery grafts.
Statistical Analysis Methods
Descriptive analysis. Descriptive statistics (Table 1) for categorical
variables and the means  standard deviation for normally distributed
continuous variables and the median and interquartile range (IQR) for
non-normally distributed variables were provided for all patients. Compar-
isons of baseline variables were made between patients who experienced
ICR and those who did not, only in patients with multivessel disease
(single-vessel disease patients by virtue of their inability to be incompletely
revascularized were excluded) (Table 2). Comparisons were made using
the Fisher exact test for categorical variables and the t test (for normally
distributed) or Wilcoxon signed rank tests (for non-normally distributed)
continuous variables.
Regression modeling strategy for both logistic and pro-
portional hazards regression. Initially we used individual
regression models for each variable in Table 1 to examine if they were sig-
nificant predictors of outcome. The functional form for continuous vari-
ables was examined using residuals analysis and if nonlinearity was
detected, suitable transformations were used or the variable was
categorized using appropriate cut-points to aid interpretation of the model.
Next we entered each variable in Table 1 into a regression model, including
the ICR variable to assess for confounding. In the event of evidence of con-
founding we examined the possibility of an interaction between ICR and
that variable. All variables significant at P<.2 in the individual regression,
interactions significant at P<.20 and variables that appeared to be con-
founding were entered into a multivariable logistic regression model.
The possibility of collinearity was examined between predictor variables;
the inclusion of highly correlated predictor variables that might cause insta-
bility of the model was avoided. To avoid overfitting, we reduced the model
by excluding nonsignificant variables (starting with the largest P value),
provided that this did not change the estimate of the primary predictor var-
iable, ICR (ie, the excluded variable did not contribute to confounding).
This process continued until the appropriate number of degrees of freedom
in the model was retained (n/10) where n is the number deaths in each
model.
Logistic regression was used to assess operative mortality, with the ef-
fect of univariate predictors presented as odds ratios (ORs) with 95% con-
fidence intervals (CIs) and estimates of 30-day mortality for each level of
the variable. The multivariable model was presented as ORs and adjusted
30-day morality rates were estimated using predictive margins.
Midterm survival was estimated in the operative-survivor patient popu-
lation, using proportional hazards regression. Out-of-province patients not
available for follow-up were excluded. The assumption for proportional
hazards was examined using Schoenfeld residuals.3
RESULTS
Study Population
From July 18, 2003, to February 2, 2013, 1000 consecu-
tive patients underwent CABG surgery with 98% (2922 out
of 2981) arterial grafts. Excluding 59 patients (6%) with
single vessel coronary artery disease, 73% (686 out of
941) of patients had bilateral IMA grafts. The majority of
patients had triple vessel disease (60%; 600 out of 1000)
and 34% had double vessel disease (341 out of 1000). Graft
conduits consisted of 70% IMAs, 28% radial arteries, 2%
venous grafts, and 4 grafts were inferior-epigastric arteries.
Eighty-six percent of the ICR group (120 out of 140
patients) had triple vessel disease. Demographics of the
patient groups are shown in Table 1. Patients with ICR
were older, had higher European System for Cardiac Oper-
ative Risk Evaluation (EuroSCORE) category, experienced
more reoperative CABG, underwent off-pump procedures,
and were less likely to have normal ejection fraction.
ICR Versus CR
CR was achieved in 801 out of 941 patients (85%) with
multivessel disease and ICR occurred in 140 patients
(15%). Significant predictors of ICR are presented in
Table 2. The ICR group had less bilateral IMA grafting,
more off-pump procedures, higher logistic EuroSCORE
category, was more likely to have collaterals, was older,
more patients with ejection fraction<30%, fewer outpa-
tients, and more likely to undergo reoperative surgery.
The numbers for very low ejection fraction and reoperation
were small in both groups. No other cardiac risk factors or
comorbidities were associated with ICR.
Abbreviations and Acronyms
CABG ¼ coronary artery bypass graft
CIRC ¼ circumflex artery
CR ¼ complete revascularization
EuroSCORE ¼ European System for Cardiac
Operative Risk Evaluation
FFR ¼ fractional-flow reserve
ICR ¼ incomplete revascularization
IMA ¼ internal mammary artery
LAD ¼ left anterior descending
PCI ¼ percutaneous coronary intervention
RCA ¼ right coronary artery
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Operative Mortality
Overall operative mortality was 3.8%. In ICR patients,
30-day mortality was 8.6% compared with 3.2% in patients
with complete revascularization (P ¼ .008).
Examination of the continuous variables age and logis-
tic EuroSCORE categories revealed substantial nonline-
arity in the prediction of mortality. Although log
transformation of the logistic EuroSCORE category and
a quadratic form for age described this nonlinearity
well, we decided to categorize the variables to ease inter-
pretation. Age categories were<65 years, 65 to 80 years,
and 80 years. For EuroSCORE, there was substantial
heterogeneity in the highest risk category (EuroSCORE
>6); therefore we subdivided this category into 6 to
9.99, 10 to 19.99, and 20.
Baseline factors associated with 30-day mortality are
shown in Table 3. Most were also confounders of the rela-
tionship between ICR and operative mortality and were
considered eligible for entry into the multivariate logistic
regression model. Off-pump procedure history and sex
were potential confounding variables and were therefore
entered into the multivariable model.
In this full model, the effect of ICR was not significant
(OR, 1.82; 95% CI, 0.78-4.22; P ¼ .168). In the reduced
model (Table 3), containing only ICR, EuroSCORE cate-
gory, and urgency, the estimated OR was 1.73 (95% CI,
0.80-3.77; P ¼ .166). Adjusted operative mortality was
5.6% (95% CI, 2.7-8.5) for ICR patients and 3.6% (95%
CI, 2.3-4.6; P ¼ .166) for CR patients, indicating that after
controlling for EuroSCORE category and urgency the effect
of ICR on 30-day mortality, although higher than that for
CR patients, was not significantly different. For the 65 oc-
togenarians (1 patient aged 96 years), there was no differ-
ence in operative mortality due to ICR (for ICR: 9.5%;
95% CI, 1.2-30.3 and for CR: 6.8%; 95% CI, 1.4-18.6;
P ¼ .655), even though the 37 octogenarians with off-
pump CABG history had a significantly higher rate of
ICR compared with the non-octogenarians. (48.7% for
age 80 years; 95% CI, 31.9-65.6 compared with 10.7%
for age<80 years; 95% CI, 2.3-28.2; P<.001).
Midterm Follow-up
Thirty-eight patients who died during the 30-day postop-
erative period and 62 patients who were out-of-province
were excluded from the midterm follow-up, leaving a total
of 841 patients for follow-up (723 with CR and 118 with
ICR). The median follow-up time was 56 months. ICR
was a significant predictor of midterm mortality (hazard
TABLE 1. Baseline characteristics of the study population of 1000 patients; 801 with complete revascularization 140 with incomplete
revascularization and 59 with single vessel disease
All patients (N ¼ 1000)* CR (n ¼ 801) ICR (n ¼ 140) P valuey
Bilateral internal mammary artery grafts 686 (68.6) 626 (78.2) 60 (42.9) <.001
Off-pump coronary artery bypass graft 387 (38.7) 283 (35.3) 64 (45.7) .023
EuroSCORE (median [IQR]) 2.9 (1.5-6.2) 2.7 (1.5-5.9) 5.0 (2.7-10.2) <.001
Collaterals 628 (62.9) 489 (61.2) 116 (82.9) <.001
Demographics
Age, mean  standard deviationz 64.9  10.4 64.4  10.3 68.9  9.4 <.001
Male 779 (77.9) 624 (77.9) 112 (80.0) .657
Outpatient 435 (43.5) 370 (46.2) 44 (31.4) .004
Inpatient 454 (45.4) 345 (43.1) 76 (54.3) .138
Emergent 111 (11.1) 86 (10.7) 20 (14.3) .279
Comorbidities
Hypertension 690 (69.0) 549 (68.5) 102 (72.9) .323
Hypercholesterolemia 697 (69.7) 555 (69.3) 102 (72.9) .426
Diabetes 344 (34.4) 279 (34.8) 53 (37.9) .503
Ever smoked 587 (58.7) 470 (58.7) 87 (62.1) .457
Active smoker 208 (20.8) 171 (21.3) 31 (22.1) .824
Ejection fraction>50% 66 (6.6) 45 (5.6) 21 (15.0) <.001
Ejection fraction 30%-50% 228 (22.8) 182 (22.7) 37 (26.4) .455
Ejection fraction<30% 706 (70.6) 574 (71.7) 82 (58.6) .177
Body mass index 30 338 (33.8) 275 (34.3) 45 (32.1) .630
Chronic obstructive pulmonary disorder 131 (13.1) 103 (12.9) 24 (17.1) .180
Cerebrovascular disease 101 (10.1) 79 (9.9) 18 (12.9) .292
Peripheral vascular disease 105 (10.5) 87 (10.9) 17 (12.1) .661
Renal diseasex 35 (3.5) 27 (3.4) 7 (5.0) .328
Reoperative coronary artery bypass graft 37 (3.7) 23 (2.9) 10 (7.1) .021
Data are presented as n (%) unless otherwise indicated. CR, Complete revascularization; EuroSCORE, European System for Cardiac Operative Risk Evaluation; IQR, interquar-
tile range; ICR, incomplete revascularization. *Includes 59 single vessel disease patients. yComparing ICR patients (n ¼ 140) to CR patients (n ¼ 801). zRange (29-96 years).
xCreatinine>200 mg/dL.
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ratio [HR], 2.0; 95% CI, 1.3-3.3). Unadjusted overall sur-
vival curves are presented in Figure 1, A. Examination of
the linearity continuous variables revealed that different
cut-points were more appropriate when predicting midterm
mortality. Thus age had 2 categories (<80 and 80 years)
and EuroSCORE had 3 categories (0-2.99, 3-5.99, and
6). (see Table 4.) There was evidence against the propor-
tional hazards assumption for urgency; therefore, this vari-
able was not included in the model, but used for
stratification. Only 2 variables were confounding factors:
age>80 years and EuroSCORE. Interactions between these
2 variables and ICR were examined and the interaction with
EuroSCORE was not significant (P ¼ .240), whereas the
interaction with age was significant (P ¼ .072). The unad-
justed HR was 4.7 (95% CI, 1.5-14.4) for patients older
than age 80 years and 1.5 (95% CI, 0.9-2.7) for patients
younger than age 80 years in a model that contained only
the interaction between age and ICR. Therefore the
age 3 ICR interaction along with the predictors significant
at P<.2 were entered into the multivariable proportional
hazards model, stratified by urgency due to the
nonproportional hazards for this variable. Chronic obstruc-
tive pulmonary disease, renal disease, cerebrovascular dis-
ease, peripheral vascular disease, and diabetes were all
combined into a single variable of a comorbid condition.
The final model (Table 5) included the age 3 ICR interac-
tion (P¼ .017), comorbid conditions (P¼ .017), the 3 cate-
gory EuroSCORE (P<.001), and sex (P¼ .25) because this
was a confounding factor. The adjusted HR associated with
ICR for patients aged80 years was 5.7 (95%CI, 1.8-17.7)
indicating a higher risk of mortality due to ICR in older
patients. The estimated adjusted HR for patients younger
than age 80 years was 1.2 (95% CI, 0.7-2.1). The unad-
justed 5-year survival rate for patients younger than age
80 years was 90.9% for CR patients and 86.0% and for
ICR patients. For patients aged 80 years the 5-year sur-
vival rate was 77.7% for CR patients and 56.4% for ICR
patients. (Figure 1, B). Three factors significantly predicted
decreased long-term survival in the octogenarians and older
patients: ICR (P ¼ .006), higher logistic EuroSCORE cate-
gory (P¼ .006), and male sex (P¼ .029). When included in
the same regression model all 3 variables were simulta-
neously significant (P ¼ .029 for EuroSCORE, P ¼ .032
for ICR, and P ¼ .021 for men.) This indicates that even
controlling for fragility using EuroSCORE category, the
HR for ICR was 2.9 (95% CI, 1.1-7.7) and HR for male
sex was 4.4 (95% CI, 1.2-15.4).
Examination of these unadjusted survivor functions indi-
cates that midterm survival in ICR patients younger than
age 80 years was not statistically significantly different
from CR patients, either before (P¼ .141) or after adjusting
for other predictive factors (P ¼ .544).
Other Outcomes
Therewas no difference between ICR and CR patients for
recurrence of angina (6.4%; P ¼ .99), myocardial infarc-
tion (1.8%; P ¼ 1.0), and postoperative angiography either
for any reason (15.5%; P ¼ .787) or symptom-directed
(13.3%; P ¼ 1.00). Repeat revascularization procedures
with either PCI or CABG were also similar (0.7%;
P ¼ .267).
Reasons for ICR
Reasons for ICR in 140 patients included small vessel
<1 mm in 64% (n ¼ 92), diffuse disease in 17%
(n¼ 24), inaccessible location in 14% (n¼ 20), infarct ter-
ritory in 22% (n ¼ 31), technical reasons in 9% (n ¼ 13),
and multiple reasons in 25% (n ¼ 36). The RCA was the
most common artery not bypassed (52%), with 48% for
the CIRC. A diseased LAD territory was bypassed in all pa-
tients at this or at a previous surgery. The most common rea-
sons for not bypassing the CIRC was small vessel and
location, whereas reasons for not grafting the RCA were
small vessel and diffuse disease. For 138 of 140 patients
(99%) 1 territory of 3 was not bypassed; in 2 patients
TABLE 2. Significant predictors (P < .15) of incomplete
revascularization
Variable % ICR (95% CI) P value
Overall 14.9 (12.7-17.3)
Off-pump .023
Yes 18.4 (14.5-22.9)
No 12.8 (10.2-15.8)
Bilateral internal mammary artery grafts <.001
Yes 8.8 (6.7-11.1)
No 31.4 (25.7-37.5)
EuroSCORE <.001
0-2.99 8.7 (6.3-11.6)
3-5.99 18.6 (13.6-24.5)
6 23.4 (18.3-29.1)
Age <.001
<65 10.6 (7.8-14.0)
65-79 16.5 (13.1-20.3)
80 32.3 (21.1-45.1)
Urgency .004
Elective 10.6 (7.8-14.0)
Urgent in 18.1 (14.5-22.1)
Emergency 18.9 (11.9-27.6)
Ejection fraction <.001
<30 31.8 (20.9-44.4)
30-50 16.9 (12.2-22.5)
>50 12.5 (10.1-15.3)
Collaterals <.001
Yes 19.2 (16.1-22.5)
No 7.2 (4.7-10.6)
Reoperative CABG .021
Yes 30.3 (15.6-48.7)
No 14.3 (12.2-16.8)
CI, Confidence interval; EuroSCORE, European System for Cardiac Operative Risk
Evaluation; CABG, coronary artery bypass graft; ICR, incomplete revascularization.
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both RCA and CIRC territory were not grafted because cor-
onary arteries were too small in 1 patient and both diffusely
diseased and small in the second.
DISCUSSION
In this large contemporary series of 1000 CABG patients
with 98% arterial grafts, we have shown that after adjusting
for factors affecting operative mortality and midterm sur-
vival, there is no evidence that ICR decreases survival peri-
operatively in all patients and at midterm in patients
younger than age 80 years. Ours is the first study to evaluate
outcomes from ICR in a cohort of patients with extensive
(98%) arterial grafting. Midterm follow-up analysis yielded
a dichotomous result: for patients younger than age 80 years
ICR did not affect survival before or after adjusting for 11
significant predictors, even though 1 of these (EuroSCORE)
was a confounding variable. There was, however, a signifi-
cant effect of lCR on reduced midterm survival in patients
aged 80 years (7% of the overall cohort). Other studies
have shown age conundrums: Girerd and colleagues4 found
that patients aged<60 years had increased mortality with
ICR but not in patients aged >60 years. Three articles
TABLE 3. Predictors of operative mortality
Variable
Single predictor variable analysis Multivariable model
% Operative mortality (95% CI) OR (95% CI) P value OR (95% CI) P value*
Constant 0.002 (0.00-0.01) <.001
Incomplete revascularization .008 1.73 (0.80-3.77) .166
Yes 3.2 (2.0-4.5) 2.8 (1.4-5.7)
No 8.6 (3.9-13.2) 1
EuroSCOREy <.001 1 <.001
<3 0.4 (0.05-1.5) 1
3-5.99 3.3 (0.9-5.6) 7.9 (1.6-38.6) 5.4 (1.1-27.1)
6-9.99 6.8 (2.3-11.4) 17.3 (3.6-82.7) 10.2 (2.0-50.6)
10-19.99 7.8 (3.1-15.4) 19.9 (4.1-97.5) 8.9 (1.7-47.8)
20 31.1 (17.6-44.6) 106 (23.2-490) 42.2 (8.0-223.5)
Urgencyy <.001 1 .03
Elective 0.7 (0.0-1.5) 1
Urgent in 4.0 (2.2-5.9) 5.8 (1.7-19.8) 3.2 (0.88-11.4)
Emergency 17.0 (9.8-24.1) 28.0 (8.1-97.2) 5.6 (1.4-21.9)
Bilateral internal mammary artery graftsy .017
Yes 6.7 (3.6-9.7) 0.44 (0.23-0.85)
No 3.1 (1.8-4.4) 1
Agey, y .061
<65 2.5 (1.1-4.0) 1
65-80 5.0 (2.9-7.0) 2.0 (1.0-4.2)
>80 7.7 (1.2-14.2) 3.2 (1.1-9.5)
Hypertension .03
Yes 4.9 (3.3-6.6) 2.4 (1.0-5.9)
No 2.1 (0.1-3.7)
Ejection fractiony .021
<30 10.6 (3.2-18.0) 1
<30-50 4.6 (1.8-7.3) 0.4 (0.2-1.1)
>50 3.2 (1.9-4.5) 0.3 (0.1-0.7)
Cerebrovascular disease .013
Yes 8.2 (2.7-13.7) 2.4 (1.1-5.5)
No 3.6 (2.3-4.8)
Peripheral vascular disease .145
Yes 6.7 (1.9-11.5) 1.9 (0.8-4.4)
No 3.7 (2.4-5.0)
Renal disease
Yes 14.6 (2.8-26.6) 4.6 (1.7-12.6) .003
No 3.6 (2.4-4.9)
Reoperative CABGy
Yes 15.2 (2.9-27.4) 4.7 (1.7-13.0) .003
No 3.6 (2.4-4.9)
CI, Confidence interval; OR, odds ratio; EuroSCORE, European System for Cardiac Operative Risk Evaluation; CABG, coronary artery bypass graft. *Likelihood ratio statistic.
ySignificant predictors of incomplete revascularization.
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studying octogenarians have opposing views: Mohammadi
and colleagues5 found no difference in survival in octoge-
narians with ICR whereas Aziz and colleagues6 found
18% decline and Kozower and colleagues7 found 10%
reduced 8-year survival in octogenarians with ICR. For
the 53 patients aged 80 years in this series who survived
the operation, ICR carries an almost 6-fold risk of dying
but this may be sample-specific. This finding of reduced
survival in octogenarians with ICR is not explainable
within the data/scope of our study but deserves careful
consideration regarding its validity and/or meaningfulness.
Given that operative survival was not affected by ICR in this
age group, surgeons may wisely opt for early survival rather
than subject frail elderly patients to a CR operation of
greater risk; for example a difficult-to-graft lateral wall
target performed off-pump. Although well-selected elderly
patients undergoing CABG have good outcomes, an objec-
tive assessment of frailty has been found to be associated
with increased risk for morbidity and mortality after cardiac
surgery.8,9
FIGURE 1. A, Unadjusted overall survival rates by complete and incomplete revasculariztion. B, Unadjusted Kaplan-Meier survival curves stratified by
age<80 years (n ¼ 788) and age 80 years (n ¼ 53).
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Previous studies suggesting superiority of CR over ICR
have included patients in which the majority of grafts
were venous. Poorer outcomes with ICR in such popula-
tions may not be due to the ICR in and of itself but rather
due to relatively early occlusion of venous conduits. Early
postoperative vein graft occlusion has not changed in 4 de-
cades: at<3 weeks postoperatively in the study by FitzGib-
bon and colleagues10 of 5065 venous grafts performed from
1969 to 1994, vein graft occlusion was 12%, similar to the
more contemporary study from Kim and colleagues11
wherein 7-day vein graft occlusion was 11.8%. One-year
graft occlusion rates have also stayed the same since the
study by FitzGibbons and colleagues10: 24% compared
with the 1-year vein graft occlusion in the Prevent IV trial12
of 25.7%. This rapid attrition of vein grafts would convert a
patient with single vessel disease (1 territory not bypassed)
at the time of CABG to double vessel disease in 12% of pa-
tients at early postoperation and in 24% to 26% of patients
at 1 year and could well explain the poorer survival of pa-
tients with ICR. The use of more arterial conduit known
to last longer could therefore mitigate the effect of ICR.
Other Studies of CR and Arterial Grafting
The literature on ICR is difficult to interpret due to lack of
a universal definition; varying lengths of follow-up;
differing amounts of arterial and venous grafting; studies
including just PCI, just patients undergoing CABG, or a
combination of both; and studies including only specific
subgroups such as patients with diabetes and octogenarians.
Hence there is no consistent negative correlation between
ICR and survival; studies showing reduced survival with
ICR include the 10-year follow-up of the Medicine, Angio-
plasty, or Surgery Study for Patients Undergoing PCI
(MASS II),13 the Bypass Angioplasty Revascularization
Investigation 2 Diabetes trial in persons with diabetes,14
the 4-year SYNTAX trial results (including both random-
ized and registry patients),15 patients younger than age 60
years by Girerd and colleagues,4 studies in octogenarians,6,7
a study by Synnergren and colleagues16 in patients with 2 of
3 territories missed, and a 5-year follow-up study by Kleisli
and colleagues.17 Studies showing the opposing view—no
difference in survival between ICR and CR groups—
include as many studies and some even in similar patient
subgroups: the 10-year follow-up of the MASS II trial for
patients undergoing CABG11; a study of octogenarians by
Mohammadi and colleagues5; a study with left internal
thoracic artery to LAD in only 75% to 77% of patients
by Kim and colleagues11; McNeer and colleagues’ 1974
study1 of patients with all vein grafts; a study of patients
older than age 60 years by Girerd and colleagues4; a study
by Sarno and colleagues,18 including patients undergoing
PCI with less complex disease; a study by Rastan and col-
leagues19 with no difference at 1 and 5 years follow-up;
the SYNTAX trial (randomized patients) at 1 year20; a study
by Synnergren and colleagues16 for no difference if 1 of 3
territories missed; and the Bypass Angioplasty Revascular-
ization Investigation trial, which also noticed that multiple
grafting resulted in worse survival.21
Other investigators have assessed the effects of ICR in
patients with multiple arterial grafts, and similar to our
own findings, found no difference in survival between
CR and ICR: MASS II with 1 IMA in 92%, 1 IMA with
radial artery grafts in 36% and epigastric artery grafts in
10%.13 Rastan and colleagues’ study19 with 21.9% total
arterial grafting in the CR group and 32.2% in the ICR
group found that arterial revascularization was protective
for decreased mortality, and Kleisli and colleagues’ study17
showed that use of the right IMA (22.6%) and radial artery
(58.7%) correlated with improved survival at a mean of
5 years (HR, 0.51 for right IMA use and 0.49 for radial ar-
tery use). Hayward and colleagues22 showed that use of
arterial grafts for lesions (largely severe) in the right
TABLE 4. Individual predictors of midterm mortality, single
predictor variable analysis
Variable Hazard ratio P value 95% CI
Incomplete revascularization 2.0 .003 1.3-3.3
Off-pump 1.4 .151 0.9-2.4
Male 0.5 .004 0.4-0.8
Chronic obstructive pulmonary
disease
2.0 .006 1.2-3.2
Renal disease 3.8 <.001 1.9-7.6
Peripheral vascular disease 2.5 <.001 1.6-4.2
Re-do coronary artery bypass graft 2.0 .090 0.9-4.2
Cardiovascular disease 2.2 .002 1.3-3.7
Diabetes mellitus 1.5 .049 1.0-2.3
Bilateral internal mammary artery
grafts
0.8 .176 0.5-1.1
Age>80 y* 2.8 .001 1.6-5.0
EuroSCORE*
3-5.99 1.9 <.001 1.1-3.3
6 4.0 2.5-6.4
CI, Confidence interval; EuroSCORE, European System for Cardiac Operative Risk
Evaluation. *Variable was also a confounding factor. Estimates for urgency were not
included because there was evidence against the proportional hazards assumption for
urgency.
TABLE 5. Multivariable proportional hazards regression model
predicting midterm survival in patients who survived the
postoperative period, stratified by urgency
Variable Hazard ratio P value 95% CI
Incomplete revascularization
Age>80 y 5.7 .003 1.8-17.7
Age<80 y 1.2 .544 0.7-2.1
Comorbid condition 1.74 .017 1.10-2.73
EuroSCORE <.001
3-5.99 1.71 0.96-3.04
6 3.25 1.84-5.73
Male 0.71 .125 0.46-1.10
CI, Confidence interval; EuroSCORE, European System for Cardiac Operative Risk
Evaluation.
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circulation were protective against progression of native
vessel disease whereas bypassed moderate lesions with
saphenous vein caused greater native lesion progression
to severe 40% versus 14% of the time if not bypassed.
Arterial grafting especially with IMAs prevents native dis-
ease progression.23 Because a randomized controlled trial
comparing patients with CR versus ICR is not possible, ev-
idence for rationale of the CR dogma is dependent on
retrospective observational studies. Our study of almost
pure arterial grafting eliminates 1 important variable:
The venous graft.
Early theories of what were appropriate revasculariza-
tions and hence the definition of ICR must by necessity,
change. Before the advent of angioplasty,24 coronary ar-
teries with 50% stenosis were routinely bypassed to avoid
reoperation for disease progression. Venous conduits offer
almost no resistance to flow whereas competitive flow is a
significant factor when using arterial conduits.25 Also, use
of fractional-flow reserve (FFR) has demonstrated that
many lesions26 are not hemodynamically significant. In
the ongoing Evaluation of Xience Prime Everolimus
Eluting Stent System (EECSS) or Xience V EECSS Versus
Coronary Artery Bypass Surgery for Effectiveness of Left
Main Revascularization (EXCEL) trial27 randomizing low
SYNTAX score patients with left main stenosis to PCI or
CABG, CR for the PCI arm favors addressing 70% nar-
rowed coronary arteries, whereas for the CABG arm it is
50% stenosis. Opinion as to the level of significant stenosis
appears to be changing, but should change similarly for both
PCI and CABG. G€ossl and colleagues28 proposed a new
definition for both PCI and CABG: CR complete anatomic
(>50% stenosis;>1.5 mm coronary arteries), ICR anatomic
but functionally adequate (FFR>70%), and ICR anatom-
ical and functionally inadequate (FFR70). This third cate-
gory is probably significant for survival; the authors state:
‘‘.CR based on anatomic criteria alone may soon become
obsolete, emphasizing physiology driven coronary inter-
ventions.’’28 There is even evidence to show that ‘‘over-
grafting’’ may be detrimental.21 However unless FFR
testing becomes routine for pre-revascularization assess-
ment at coronary angiography, perhaps what is simplest is
best: the definition of CR used in our study is the same as
the very first used by McNeer and colleagues1 in 1974: a
revascularization by ‘‘territory’’; that is, 1 bypass for each
territory that has a 70% stenosis in a major branch.
Limitations
Limitations of our study include the relatively small
number of the ICR group, the small number of octogenar-
ians (and older) and the number of factors found to signifi-
cantly influence survival. This real-world, single-center
study evaluating total arterial grafting performed by a single
operator may be advantageous because it provides consis-
tent techniques, skills, and decision making but at the
same time may not be applicable to other centers. Ongoing
use of evidence-based medications for secondary preven-
tion, which is known to affect outcome, was not evaluated
in this study. Finally, we evaluated outcomes out to 4.5 years
but longer follow-up may be required to better evaluate the
consequences of ICR, especially because the advantage of
arterial grafts may last decades.
CONCLUSIONS
Contrary to current beliefs regarding completeness of
revascularization, we have demonstrated that ICR in this
unique series of all-comer CABG with 98% arterial grafts
is not associated with decreased survival perioperatively
and at midterm in patients younger than age 80 years. How-
ever many factors affect survival and may act synergisti-
cally or independently. Use of arterial grafts minimizes
the adverse effects of not grafting the third region.
The authors thank the Alberta Provincial Program for Outcome
Assessment in Coronary Heart disease study for providing support
and thank the cardiac catheterization personnel for performing
data entry.
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Discussion
Dr Philip A. Hayward (Melbourne, Australia). I’d like to
thank the American Association for Thoracic Surgery Committee
for the invitation to discuss this work and also thank Dr Kieser for
supplying me with a draft of the manuscript in a timely fashion.
Dr Kieser, you are to be congratulated on an important study.
You’ve done a sophisticated analysis of your own coronary prac-
tice, and your commitment to arterial grafting and to completeness
of revascularization is impressive.
You state as a limitation that this is a single-surgeon experi-
ence, but in this context this may be 1 of the merits of the study
because it allows us to really tease out the effect of incomplete
revascularization. Other series published can be pools of patients
done by different surgeons, with varying thresholds for grafting
small or poor targets, and it is difficult to tease out the effect
of incomplete revascularization when there have been 2 different
revascularization strategies and thresholds. You have a unifor-
mity of your threshold for revascularization—the same eyes,
the same hands, the same threshold—I think that’s why your
study is unique.
Fractional-flow reserve (FFR) is redefining what we think
needs revascularization now. It’s all about physiology, not anat-
omy, we know that from percutaneous intervention and the
Fractional Flow Reserve versus Angiography for Multivessel
Evaluation study. FFR depends on the volume of distal ante-
grade flow, not just the stenosis. Vessels that are small or
running into scar or that are well collateralized do not have sig-
nificant FFR. About 87% of the vessels you left fall into this
category. I suggest that really your ‘‘incomplete revasculariza-
tion’’ group was in fact functionally completely revascularized
for the most part, and the vessels that you left alone really
were functionally insignificant. And that’s probably why you’ve
not shown any effect on survival from your ‘‘incomplete revas-
cularization’’ and that’s reflected in the lack of a difference in
angina, myocardial infarction, or percutaneous coronary inter-
vention thereafter.
You say that your findings differ from other authors because you
used arterial grafts rather than vein grafts and that you therefore
avoided early vein graft failure. But, of course, you also avoid
the progression of native vessel disease that’s seen primarily after
vein grafts, and it is this progression that can damage the collater-
alization that had been providing protection from the effects of
incomplete revascularization. An all-arterial graft population has
been shown to produce less native vessel disease progression, so
perhaps the collaterals are better preserved and hence your
different findings.
I would like to pose 2 questions: The surprise finding clearly is
the difference in the long-term outcome in the octogenarians who
had incomplete revascularization. Do you really think this is a
different effect of incomplete coronary revascularization in older
people, or is there another factor here—a frailty factor—where
really this was a different pool of frail elderly people where you
lowered your threshold for leaving targets alone, such that really
their poorer survival comes from their frailty rather than the fact
that you decided to leave 1 target?
The second question follows from that. You told us that
incomplete revascularization didn’t affect in-hospital mortality
overall, but was that also true for the octogenarians whose
long-term outcome you say is poorer with incomplete revascu-
larization? Perhaps their long-term outcome is just a reflection
of a turbulent perioperative period. I think that shorter-term
outcome data might influence most surgeons’ practice more
than the long-term survival, because many of us faced with frail
octogenarians are really focused on getting them out of the hos-
pital intact and we tend to lower our horizons. If I’m
faced with that frail octogenarian patient and I want to get
him or her safely through, does complete or incomplete
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revascularization matter in the short term, irrespective of if it
matters in the long term?
Dr Teresa Kieser (Calgary, Alberta, Canada). Your point
regarding FFR is very well taken. Rastan and Fred Mohr had an
article in Circulation in 2009 that spoke to this. They didn’t say
the reason was FFR, but they spoke about vessels that were within
scar, for example. So it didn’t matter if you didn’t completely re-
vascularize them. I think your reason is correct, the FFR would be
insignificant. However, being the bilateral internal mammary ar-
tery graft fanatic that I am, I would still like to invoke the untimely
demise of the vein graft as a mechanism.
With respect to poorer survival coming from surgical frailty or not
wanting to put an older patient through the stress of surgery, I think
the reasons are 2-fold:Operatingon frail people does cause a surgeon
to possibly scale down the operative procedure. But experience has
taught me that when you operate on an 80-year old, everything has
to go correctly. They cannot tolerate the slightest complication the
way a younger patient would. The wheels easily fall off the wagon.
Incomplete revascularization in an octogenarian patient perio-
peratively, you are right, we probably should have included this.
There were only 70 patients older than age 80 years, 53 were
incompletely revascularized, so that’s 76%.
The operative mortality was not different. There were 2 out of
23 incompletely revascularized patients who died, and 3 out of
47 of the completely revascularized patients died—a P value
that was insignificant. We looked at the cause of death of these 5
patients: 1 died from fulminant sepsis at another hospital, very
quickly; another had a massive stroke; another died of necrotic
bowel because he had embolized from a calcified aorta (we had
had to perform the procedure on him off-pump and he was a re-
do). The deaths of 2 patients of the 5 were probably due to graft-
ability issues or graft failure. Incomplete revascularization did not
make a difference in these patients. So the answer is if you can get
a patient—an 80-year-old—out of hospital alive and intact with
incomplete revascularization this is better.
Dr Hayward. That’s a great relief. Thank you.
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 CURRENTOPINION Arterial grafting and complete revascularization:
challenge or compromise?
Teresa M. Kiesera, Stuart J. Headb, and A. Pieter Kappeteinb
Purpose of review
Arterial grafting is superior to venous grafting in coronary artery bypass graft surgery with respect to graft
patency and long-term patient outcome, but it may be difficult to achieve complete arterial
revascularization.
Recent findings
Use of arterial grafts, especially bilateral internal mammary artery grafts, is not common, whereas there are
clear indications that it may increase survival. Definitions of complete revascularization are varied and
confusing, making study comparisons difficult. Technical challenges in complete revascularization with
arterial grafts can be minimized by surgical techniques. Competitive flow in moderately stenosed coronary
arteries grafted with arterial conduits may result in reduced patency. While internal mammary arteries may
be used in arteries with at least 60% stenosis, radial artery and gastroepiploic grafts are best placed onto
coronaries with severe stenosis. Moderate lesions in the left coronary circulation should be bypassed, but
right coronary artery lesions can be left untouched as there is minimal progression over time. Complete
revascularization may not be necessary or possible in every patient because of technical challenges.
Conclusion
Complete revascularization with arterial grafts presents both technical and physiological challenges.
However, with techniques to maximize length of arterial conduits, knowledge of competitive flow and which
moderate lesions should be addressed, complete revascularization with arterial grafts can be accomplished in
the majority of patients, notwithstanding it may not be possible or even indicated for every patient.
Keywords
arterial grafts, CABG, complete revascularization
INTRODUCTION
As stated by a 29-year-old woman after total
arterial coronary artery bypass graft (CABG) surgery
(‘Doctors always question the scar on my wrist and
are astounded to hear that you used an artery in my
heart; it makes only sense’), arterial grafts for CABG
are intuitively the correct conduit. Just the pressure
difference alone between veins (25–30mmHg) and
arteries (mean pressure 70mmHg) should be
evidence enough of arterial superiority. Why then
do only 4% of patients in North America [1] and
10% in Europe [2] receive bilateral internal mam-
mary artery (BIMA) grafting? The reasons are com-
plex and many: non-belief of the evidence to date,
technical and time demands of use of arterial grafts,
fear of deep sternal wound infection [3], lack of
benefit beyond a certain patient age, perceived mis-
match between arterial graft flow and myocardial
demand, and inertia to change. In addition, sur-
geons find it difficult to completely revascularize
patients using only arterial grafts because of tech-
nical (limited length of arterial graft available) and
physiologic factors (competitive flow when moder-
ately stenosed coronary arteries are grafted).
EVIDENCE FOR IMPROVED SURVIVAL
AND GRAFT PATENCY WITH ARTERIAL
GRAFTING
As a result of advancements in operative techniques
and myocardial protection, operative mortality of
aDepartment of Cardiac Sciences, LIBIN Cardiovascular Institute
of Alberta, University of Calgary, Calgary, Alberta, Canada and
bDepartment of Cardiothoracic Surgery, Erasmus University Medical
Center, Rotterdam, the Netherlands
Correspondence to Teresa M. Kieser, Foothills Medical Centre, Room
C814, 1403 29th St NWCalgary, Alberta T2N 2T9, Canada. Tel: +1 403
944 8449; e-mail: t.kieserprieur@ucalgary.ca
Curr Opin Cardiol 2013, 28:000–000
DOI:10.1097/HCO.0000000000000001
0268-4705  2013 Wolters Kluwer Health | Lippincott Williams & Wilkins www.co-cardiology.com
REVIEW
137
Arterial grafting and complete revascularization
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
CE: Alpana; HCO/829; Total nos of Pages: 8;
HCO 829
CABG has reduced significantly (1% in planned
cases) [4] and is no longer in question, but the
longevity of the procedure is. As stated by Barner
[5], ‘Only continued patency of a graft or stent
provides benefit.’ Long-term venous graft patency
is disappointing and has not changed for 44 years:
Fitzgibbon et al. [6] reported in 1996 a series of 5065
grafts from 1969 to 1994 (25 years’ span) with
venous graft patency of 50% for at least 15 years,
and Tatoulis et al. [7] reported in 2011 3238 venous
grafts from 1986 to 2008 (22 years’ span) with a
patency of 50.7% at 15 years.
Use of the internal mammary artery (IMA)
began 66 years ago as a myocardial implant by
Vineberg and Jewett [8] in 1947. Evidence for
superior long-term survival for arterial grafting
was reported by multiple authors in the past years.
Kelly et al., in a study of 8264 patients (13% BIMA),
found that risk-adjusted survival at 10 years was
71% [hazard ratio 0.8; 95% confidence interval
(CI) 0.67–1.00] for BIMA grafts, 66% for single
IMA grafts (reference group) and 58% (hazard ratio
1.42; 95% CI 1.2–1.7) for no IMA graft. Only the
right IMA (noother arterial grafts) conferred benefit
[9
&
]. In another study with 8622 Mayo clinic
patients (overall 12%BIMA), use ofmultiple arterial
grafts compared with left IMA/vein was a strong
predictor of survival at 10 (83 vs. 70%) and 15 (80 vs.
60%) years in matched groups (P¼0.0025) [10].
Kurlansky et al. [11] have reported the longest
follow-up to date in a propensity-matched analysis
of 4584 patients who underwent CABG through
1972–1994. Survival at 25 years of follow-up was
significantly improved in BIMA graft patients as
opposed to those receiving only one IMA (29 vs.
16%, respectively; P<0.001) [11].
Bilateral internal mammary artery grafting in
diabetic patients has gained little traction because
the risk of deep sternal wound complications is
particularly high in this subgroup of patients. How-
ever, use of two IMA grafts in diabetic patients has
been recently shown to also increase late survival,
similar to non-diabetic individuals. Puskas et al.
[12
&
] reviewed 3527 patients operated between
2002 and 2010, and showed that there were no
increased propensity score-adjusted rates of 30-day
mortality and sternal wound complications between
the use of BIMA and single IMA grafts in diabetic
patients; however, 8-year survival was 87.4% vs. only
60.6% in BIMA and single IMA patients, respectively
(P<0.001). Furthermore, Dorman et al. [13
&
], in a
cohort of 1107 consecutive patients with diabetes,
showed that median survival of 646 single IMA
patients was 9.8 years compared with 13.1 years
of propensity-matched patients with BIMA grafts
(P¼0.001).
Also for diabetic patients with complex disease
in the SYNergy between Percutaneous Coronary
intervention with TAXus and Cardiac Surgery
(SYNTAX) trial, CABG is preferred over percutane-
ous coronary intervention (PCI) because of fewer
major adverse cardiac or cerebrovascular events and
less repeat revascularization, in keeping with find-
ings from the Freedom trial [14
&
,15].
Radial artery grafts, easier to harvest and use
than the right IMA (RIMA), have some attrition
beyond the first postoperative year, but remain
stable thereafter up to 20 years: at 1.0, 5.4, 8.3
and 13.1 years, respectively, radial artery graft
patency is 86.2, 81.9, 81.4 and 81.6% [16]. Because
of the susceptibility of radial grafts to the effects of
competitive flow (see below), radial grafts should
only be constructed in areas of severe stenosis. As
stated by Alfieri et al. [17] in their paper entitled
‘Drug-eluting stents or drug-eluting conduits for
multivessel disease’, mammary arteries are the very
best conduits. Tatoulis et al. [7], in a series of 5766
patients with BIMA, reported a 15-year patency of
91.1% for the left IMA, 79% for the RIMA and 50.7%
for saphenous vein; 10-year patency for radial artery
grafts was 78%. It is important to note that the
patency of the right and left IMA is identical when
used to the same vessels [7]. Yet, there are still those
who remain to be convinced . . . The Arterial Revas-
cularisation Trial (ART) trial randomizing 3102
patients to either single IMA or BIMA will be the
deciding vote [18].
KEY POINTS
 Arterial bypasses, especially BIMA grafting,
portend long-lasting graft patency and improved
survival compared with CABG with predominantly
venous grafts. Multiple definitions of complete
revascularization abound and need careful scrutiny to
compare studies.
 Surgical techniques exist to maximize arterial conduit
length to facilitate complete revascularization with the
finite amount of arterial conduit.
 Arterial conduits to moderately stenosed coronary
arteries may suffer from the effects of competitive flow:
guides exist for minimizing this problem.
 The moderately stenosed coronary artery behaves
differently depending whether it is in the left or right
coronary circulation: right-sided lesions do not progress
and hence may be left not bypassed, whereas left-sided
lesions do progress over time and should
be addressed.
 Incomplete revascularization in some patients may be
‘reasonable’ or ‘appropriate’.
Coronary artery surgery
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DEFINITIONS OF COMPLETE
REVASCULARIZATION
Incomplete revascularization (ICR) varies from 9 to
39% from study to study [19]. One of the difficulties
interpreting the literature on this topic is the many
and varied definitions of complete revascularization
(Table 1) [20–27]. The ‘traditional’ definition
defines complete revascularization as placement
of at least one bypass in all diseased arterial systems
and is basically a ‘territorial’ definition. ‘Functional’
complete revascularization most often refers to the
bypassing of all diseased primary coronary seg-
ments, irrespective of size and territory. However,
the term ‘functional’ has also been used to indicate
bypasses into all territories except to those infarct
areas without viable myocardium [22]. This has led
to completely opposite definitions in some papers,
in which traditional is called functional [28]. The
amount of ‘disease’ (50% [20] or 70% stenosis [21])
varies among studies as well.
The definitions ‘conditional’ or ‘unconditional’
reflect revascularizing vessels of a certain size
[>1.5mm for CABG and PCI in the the Bypass
Angioplasty Revascularization Investigation trial
and >2.75mm for PCI in the Arterial Revasculari-
zation Therapy Study (ARTS) trial] or location (main
or branch) [22]. The definition ‘numeric’ refers to
whether the number of distal anastomoses is either
less than, equal to or greater than the number of
diseased coronary segments [24]. One definition
may be labelled the ‘left anterior descending
(LAD) artery definition’: patients are grouped by
whether they have at least two bypasses to both
LAD and non-LAD system, at least two bypasses to
the LAD, at least two bypasses to non-LAD system or
whether no arterial system had multiple bypasses
[24]. For the definition ‘Index of Completeness of
Revascularization (ICOR)’, complete revasculari-
zation is a ratio of the number performed bypasses
divided by the number of preoperatively planned
bypasses and should be at least 1 [25]. This defi-
nition – because of the necessity of forethought –
cannot be retrospectively applied to observational
studies. However, to circumvent this, the definition
has been extrapolated to be: the total number
of distal anastomoses performed divided by the
number of diseased coronary vessels defined on
preoperative angiography [26,27]. Finally, complete
revascularization can be measured by weighting
stenoses in different vessels (extent of disease is a
continuous variable) and may be ‘anatomic’ (irre-
spective of viable myocardium) or ‘functional’
(using the Jeopardy score to calculate the myo-
cardium at risk after revascularization) [22]. Because
of the different techniques by which PCI and
CABG achieve complete revascularization, it is
Table 1. Definitions of incomplete vs. complete revascularization
Principal definitions Description
Traditional ‘Territorial’ all territories diseased receive at least one graft/PCI (stenosis 50% [20] or
70%) [21]
Functional ‘Territorial’ without requirement for non-viable myocardium to be perfused [22]
Functional Also called ‘anatomic’, all primary coronary segments irrespective of size or territory
(SYNTAX trial is an example of this definition) [23]
Numeric Number of stenotic vessels¼ number of distals [24]
‘LAD definition’ 2 distal sites to LAD þ another artery
(Number of distal anastomoses to the
LAD or other coronary arteries)
2 distal sites to LAD
2 distal sites to an artery other than LAD
<2 distal sites to all arteries [24]
ICOR (Index of Completeness of
Revascularization)
Number of bypasses performed/number of bypasses preoperatively planned (should be >1)
[25]
Also, number of bypasses performed/number of stenotic arteries [26,27]
Weighted scoring (continuous variable) Scoring of stenoses in different vessels at different locations with weighting, disease extent is
a continuous variable, treatment is another variable; post treatment score determines
completeness of revascularization [22]
Anatomic Irrespective of viable myocardium [22]
Functional Post-treatment score based on amount of viable myocardium still at risk by Jeopardy score
[22]
Conditional Conditions include specified vessel diameter or location (main or branch), can apply to any
of above definitions [22]
LAD, left anterior descending; PCI, percutaneous coronary intervention.
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questionable whether one definition for both PCI
and CABG is possible or even advisable. Hopefully,
one day, we will reach the utopian goal of no longer
needing comparison of PCI and CABG because the
role for each will be defined; for example, patients
with diabetes [14
&
,15], patients with a SYNTAX score
above and below 33 and so on [29]. This multiplicity
of definitions needs addressing, without which
comparison from study to study is difficult and
may not be meaningful. Forethought and decision
beforehand of vessels potentially treatable by both
the cardiologist and cardiac surgeon of the Heart
Team (as used in the SYNTAX trial) [14
&
], and then
comparingwithwhat was done,may be the best way
to decide completeness of revascularization.
The residual SYNTAX score is a recently pro-
posed definition to grade the degree of complete-
ness of revascularization, adding more detail to
previous dichotomous definitions. It is promising
as a predictor ofmortality during follow-up after PCI
[30
&
,31,32
&
], but has not yet been validated in a
CABG cohort. It will be interesting to see how
it performs, particularly since the original core
SYNTAX score lacks prognostic accuracy [33].
TECHNICAL CHALLENGES IN ARTERIAL
GRAFTING FOR CORONARY ARTERY
BYPASS GRAFT SURGERY
When using venous grafts, one can always ‘go and
get more vein’, whereas with arterial grafts there is
only so much conduit available. A large heart may
require ‘creative arterial grafting’ in which various
segments of arterial conduit are attached to each
other to form a composite graft and reach their
target. Technical tricks include the following:
(1) Skeletonization of the IMAs [34] adds consider-
able length and also facilitates sequential graft-
ing because the correct ‘lie’ of the conduit can be
judged accurately when the whole circumfer-
ence of the IMA is seen (when performing the
side-to-side anastomosis of a sequential graft).
(2) The length of an arterial graft is maximized if
placed ‘as the crow flies’, that is, as direct a route
as possible to the target. For example, for either
the left or right IMA to reach the LAD, one can
bring the conduit through a hole in the pericar-
dium (or make a slit) instead of going ‘up and
over’ the pericardial reflection. First pleural tis-
sue is swept away to avoid entering the pleural
cavity, then cautery is used to make a small hole
in the pericardium, enough to admit two fin-
gers. In order for the RIMA to reach the right
coronary artery (RCA) system, pericardial holes
are made in different locations depending on
the location of the target: for a RIMA graft to the
main RCA or postero-lateral branch of the RCA,
the pericardial hole is made adjacent to the
‘superior vena cava’, and to graft the posterior
descending artery (PDA), the hole is made near
the ‘inferior vena cava’ (personal communi-
cation from Dr Pascal Berdat of Berne, Switzer-
land, July 2003). This route to the PDA is extra-
pericardial (may facilitate re-operation if
needed); the IMA seems longer with this route,
usually reaches the PDA and allows the ‘turn-
point’ of the IMA to be tethered by the pericar-
dial edge, ensuring a correct lie of the distal
segment of the RIMA. This allows no twisting
at the heel.
In the authors’ experience of almost 10 years of
1047 patients with 98% arterial grafts, by using this
technique, the RIMA–PDA was used as a free graft
13% of the time (26/194 RIMA to PDA). For this
same group of 1047 patients, a total of 748 RIMA
conduits included 309 (41%) RIMA conduits to RCA
system and 439 (59%) to left coronary artery (LCA)
system. For the RIMA to the circumflex system, the
most direct route is usually through a hole in the
pericardium just above the superior vena cava and
through the transverse sinus to reach the marginal
branches. A skeletonized IMA beating against an
occluding clip or bulldog wrapped in a vasodilator
solution usually lengthens enough to reach most
branches of the circumflex system in situ. In the
authors’ experience, for this same group of 1047
patients, the RIMA–LCA system was used as a free
graft only 9% of the time (40/439 RIMA-to-LCA
system). Although it may be twice as difficult to
use the RIMA as the left internal mammary artery
(LIMA), patients get close to twice as many grafts at
15 years (90 vs. 50% patent grafts). The radial artery
is almost as easy to use as a saphenous vein and in
factmay be ‘the new saphenous vein’. Onemust just
be cognizant of the native coronary stenosis and use
the radial when appropriate (in coronary arteries
with 90% stenosis or higher, see below).
COMPETITIVE FLOW AND ARTERIAL
GRAFTING
Venous grafts have virtually no resistance (the pres-
sure at the distal anastomosis is nearly equal to the
aortic pressure) and hence are less susceptible to the
adverse effects of competitive flow [35
&&
]. Arterial
grafts ‘auto-regulate in response to demand’ [36];
flow in an arterial graft will rise and fall as is needed.
Arterial grafts have one Achilles heel – competitive
flow if grafted into coronary arteries with moderate
stenosis. Themost severe form of ‘non-requirement’
Coronary artery surgery
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results in a ‘string sign’ – on angiography, the graft
looks like an atretic thread attached to the coronary
artery. Conversely, arterial grafts increase their
diameter over time [35
&&
] and, in particular, left
IMAs have been known to revascularize the whole
of the LCA circulation in cases of isolated/predom-
inant left main stenosis (Fig. 1). IMAs are the arterial
conduit least affected by competitive flow; generally
there is no critical level of stenosis belowwhich graft
flow is compromised [5]. Sabik et al. [37] studied
2121 IMAs from 1972 to 1999, and found that,
although IMA patency diminished as the degree
of coronary stenosis decreased, at no particular
degree of stenosis was there a sharp decline in
patency. Glineur et al. [38] showed that composite
‘Y’ IMA grafting to both the RCA and LCA systems
had a negative prognostic influence on graft func-
tion, with loss of the graft to the RCA system.
Possibly the different diastolic filling of the right
(50%) and left coronary arteries (66%) could explain
this: the RCA segment fails because two disparate
pressure systems are grafted with one inflow.
For the radial artery graft, Barner [5] was the first
to identify the relation of native coronary stenosis
and radial artery patency; he found that patencywas
worse in moderate stenosis (70%) compared with
critical stenosis (90%). Shah’s review showed
radial artery graft patency to be significantly
reduced from 90 to 60% when grafts were placed
to fewer than 70% stenotic arteries [39]. In the
Radial Artery Patency Study, Desai et al. [40] found
that radial grafts to coronary arteries with stenosis
of at least 90% as compared with those with
stenosis of 70–89% were associated with a lower
rate of occlusion (5.9 vs. 11.8%). Composite grafts
using the radial and IMA to the left circulation
therefore need to take this into account as well.
The right gastroepiploic artery, similar to the
radial artery, is recommended to be used only
on severely stenotic coronary arteries [41]. Some
of these guidelines are difficult to implement for
arterial grafting in that the conduit that ‘reaches’
may not be the most appropriate conduit for that
particular coronary [e.g. a long graft (radial) is
needed for two branches on the RCA system, but
the stenoses are only 70%].
WHAT ABOUT MODERATE STENOSIS?
If arterial grafts are better, but are subject to the
vagaries of competitive flow, should moderate
stenosis be left alone? Hayward et al. [42
&&
] answered
this when he studied 386 bypass grafts to moder-
ately (40–69%) stenosed coronary arteries from the
Radial Artery Patency and Clinical Outcomes trial.
During a mean of 6.2 years follow-up in non-
bypassed coronary arteries, moderate lesion pro-
gression differed according to location: only one
in seven moderate lesions in the RCA showed sig-
nificant progression (frommoderate to severe) com-
pared with one in two for left-sided coronary vessels.
Conversely, however, when a moderately diseased
coronary artery in the RCA systemwas bypassed, the
native lesions progressed to severe 40% of the time
vs. 14% of the time if not bypassed. Competitive
flow from grafts seemed to cause greater disease
progression in right-sided vessels than in left-sided
vessels; as well, right-sided grafts tended to have
inferior patency (73.3% at 7 years vs. 83.2% at
8 years; P¼0.051). He concluded that it is advisable
to bypass moderate lesions of the left coronary
system because of the likelihood of progression,
but leave right-sided moderate lesions alone, given
the low risk of progression if left undisturbed.
The use of fractional flow reserve has been
shown to assist in deciding which lesions are best
treated by angioplasty [43]; possibly the same may
prove to be useful in deciding which moderate
lesions should be grafted. With this new knowledge,
that which constitutes ‘completeness of revasculari-
zation’ may need to be rethought.
IS COMPLETE REVASCULARIZATION
ALWAYS NECESSARY?
Reduced survival after CABG is multifactorial and
cannot be attributed solely to incompleteness
FIGURE 1. LIMA graft supplying all of LCA system in a
patient with predominantly left main stenosis. LCA, left
coronary artery; LIMA, left internal mammary artery.
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of revascularization [4]. Also, not all studies have
shown that incomplete revascularization in CABG
results in impaired survival [19,21,44,46–48,51]
Table 2 shows 13 studies [19,21,27,28,32
&
,44–51]
comparing completeness of revascularization at
follow-up times ranging from 2 to 10 years relating
to the amount of arterial grafting.’ In the SYNTAX
trial with 27.6% BIMA [23,51,52], in the CABG
group, no difference in outcomes was seen between
incomplete and complete revascularization groups.
Incomplete revascularization was identified as an
independent predictor of Major Adverse Cardiac
and Cerebrovascular Event (MACCE) in PCI (hazard
ratio 1.55, 95% CI 1.15–2.08, P¼0.004), but not
CABG patients. Rastan et al. spoke about ‘reasonable
ICR’, noting that most often the territory not
bypassed involves either the RCA or circumflex
territory, which may or may not portend worse
outcomes, especially if, as in their study, arterial
grafting was more frequent [19]. Taggart [53
&
] dis-
cussed the ‘appropriateness’ of ICR, noting that
inability to completely revascularize often is a
marker for more severe and diffuse disease. It is
not ‘appropriate’ to place a bypass graft into an
infarct area, or into a small target vessel, risking
graft failure and possible infarct.
CONCLUSION
Arterial grafting is thought to be superior for graft
longevity and patient survival, and we anxiously
await the results of the ART trial to confirm this
[18]. The definitions of ICR are as varied as is the
incidence of ICR in the literature. Although techni-
cally challenging, it is possible to achieve complete
revascularization with arterial grafts, especially if
one skeletonizes the IMAs and as much as possible
follows guidelines correlating the conduit type to
level of stenosis in order to avoid competitive flow.
Moderate lesions on the RCA system should prob-
ably be left alone as they do not progress (one in
seven), whereas those in the left coronary system
should be bypassed because of their progression over
time (one in two). Finally, ‘the enemy of good is
perfect’, and it may not be necessary to achieve
completeness of revascularization each and every
time.
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Table 2. Comparison of studies with differing amounts of arterial grafting
Grafts Author, year
Number of
patients
Length of
follow-up
(years)
Survival
(ICR) (%)
Survival
(CR) (%) Comparison
Venous grafts only McNeer et al., 1974 392 2 75% 83 NS
IMAþ vein Mohammadi et al.,
2012
476 8 49 54 P¼0.40
Kim et al., 2011 514 5 90 87 P¼0.26
Sarno, 2010 567 5 91 93 P¼0.48
Aziz, 2009 580 8 34 44 P<0.01
Lattouf et al., 2008 12812 10 58b– –68b P<0.001;
HR¼0.85 (95%
CI 0.77–0.93)
Kozower, 2005 500 8 25 39 P<0.008
Arterial (more
than usual)
Farooq et al., SYNTAX,
2013a
1541 (22.7% BIMA) 4 88 92 P¼0.039
Vieira et al., MASS II,
2012
198 (36% IMAþradial) 10 88b 91b NS
Girerd et al., 2012 6539 (4.4–10.9% BIMA) 6 82 88 P<0.001
Head et al., SYNTAX,
2012c
870 (27.6% BIMA) 3 93 94 P¼0.60
Rastan et al., 2009 8806 (22–32% TAG) 5 54 61 P¼0.77
Kleisli et al., 2005 1034 5 53 82 P<0.001
aIn comparison with Head et al., this group also includes patients both in the trial and in the CABG registry
bEstimate from survival graphs in paper
cIncludes only trial patients
CABG,coronary artery bypass graft; CR, complete revascularization; HR, hazard ratio; ICR, incomplete revascularization; IMA, internal mammary artery; MASS
II, Second Medicine, Angioplasty, or Surgery Study; NS, not significant.
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Abstract
OBJECTIVES: Skeletonization of the internal mammary artery (IMA) facilitates arterial grafting and has been shown to reduce deep sternal
infection but is more time-consuming and tedious than pedicle harvest. We wished to determine if use of harmonic technology (HT)
facilitates skeletonization of the IMA and is as safe as the conventional technique of skeletonization.
METHODS: In a consecutive series of 1057 patients with isolated coronary artery bypass graft (CABG) surgery from 2003 to 2013, adverse
events and recorded harvest times were compared between harmonic (965 patients) and non-harmonic patients (86 patients).
RESULTS: HT was used to harvest 1640 IMAs in 965 (91%) of 1057 consecutive CABG patients and skeletonization with the traditional tech-
nique (use of an electrocautery tip as a dissector) was used to harvest 147 IMAs in 86 patients. Six patients had no IMA harvested with this
surgery (4 patients had an IMA used from a previous CABG, 1 had no disease of the left anterior descending coronary artery and 1 patient
was in cardiogenic shock precluding IMA use). Excluding patients with single-vessel disease, 730/987 (74%) of patients received bilateral
IMAs. Demographics of patients with and without harmonic skeletonization, respectively, were the following: mean age: 64.7 vs 67.7 years;
diabetes: 33 vs 34%; women: 21 vs 26% and median European System for Cardiac Operative Risk Evaluation: 2.9 vs 3.2. The mean harvest
time for 77 non-harmonic skeletonized mammary arteries (49 surgeries) was 32.2 min (95% confidence interval (CI): 30.1, 34.3), for har-
monic skeletonized arteries after 450 surgeries was 28.4 min, (95% CI: 27.8, 29.1) and in the last 100 IMAs harvested for the isolated
harmonic device use/mammary was 15.4 min (95% CI: 14.0, 16.7). Major adverse events for patients with and without harmonic skeletoni-
zation, respectively, were: reoperation for bleeding: 2.7 vs 3.5% (difference = 0.8%, 95% CI: −3.2, 4.8); damaged mammaries: 0.4 vs 0.7%
(difference = 0.3%, 95% CI: −1.0, 1.7); deep sternal infection: 1.6 vs 1.2% (difference = −0.4%, 95% CI: −2.8, 2.0) and perioperative infarction:
1.7 vs 2.3% (difference = 0.7%, 95% CI: −2.6, 4.0).
CONCLUSION: In this largest series to date of harmonic IMA skeletonization, this technique results in rare damage, is quicker and with a
comparable adverse event rate compared with the non-harmonic method.
Keywords: Harmonic scalpel • Coronary artery bypass graft • Bilateral internal mammary
INTRODUCTION
The internal mammary artery (IMA) is increasingly being acknowl-
edged as the best conduit for replacement of diseased coronary
arteries in the coronary artery bypass graft (CABG) operation.
Even though Lytle et al. [1] pointed out in 1999 that ‘Two internal
thoracic artery grafts are better than one’, bilateral internal
mammary arteries (BIMAs) continue to be used rarely in North
America (4%) and infrequently in Europe (10%). The majority of
patients are still treated with the knowledge that ‘one IMA is
better than none’, a concept proposed 27 years ago by Loop et al.
[2] in 1986. Failure to adopt the ‘Two IMA’ philosophy may be
explained by a number of valid reasons. First, evidence for ‘BIMA
being better’ is at best ‘Level of Evidence C’, which is ‘consensus of
opinion of the experts and/or small studies, retrospective studies,
registries’. Moreover, the only randomized trial to date by Taggart
et al. [3], the arterial revascularization trial, is awaiting 10-year
follow-up results in December 2017. Secondly, because the IMA is
the main blood supply of the sternum, bilateral IMA harvest pre-
disposes patients to an increased risk of failure to heal and/or
deep sternal wound infection. Thirdly, the age until which BIMA
grafting is advantageous is also in question. The average age of
patients for CABG in most reported series ranges from 64 to 66
years. As such, the benefit of performance of BIMA grafting after
the age of 70 is lacking [4]. Finally, technical and time demands are
greater with BIMA use. Nevertheless, there is a preponderance of
data from many observational studies [5–7] and meta-analyses [8],
suggesting a significant long-term benefit with the use of BIMA.
†Presented at the 27th Annual Meeting of the European Association for Cardio-
Thoracic Surgery, Vienna, Austria, 5–9 October 2013.
© The Author 2014. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.
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In this retrospective review, we studied IMA harvest in a skeleto-
nized fashion with harmonic technology (HT). Skeletonization of
IMAs allows for more length of a finite conduit and reduced risk of
deep sternal wound infection and we hypothesized that use of HT
allows for a faster, skeletonized harvest of the IMA with infrequent
damage. The purpose of this study was to (i) compare major
adverse cardiac events (MACEs) related to IMA grafting between
non-harmonic scalpel (HS) and HS patients, and (ii) compare
times of harvest between non-HS harvest and HS harvest.
MATERIALS ANDMETHODS
This study group comprised a consecutive group of isolated CABG
patients from July 2003 to July 2013 in which total arterial grafting
was performed where possible in all patients operated on by one
surgeon, regardless of comorbidities including advanced age,
diabetes, obesity, chronic obstructive pulmonary artery disease
(COPD) and urgency. This retrospective analysis of prospectively
collected data from consecutive patients was undertaken to
compare harvest times of IMAs with and without the HS and also
the following major adverse effects of the two techniques related
to IMA harvest: reoperation for bleeding, deep sternal wound
infection, perioperative myocardial infarction (MI), operative
mortality, need for early reoperation for failed grafts, post-
operative development of angina and need for postoperative per-
cutaneous coronary intervention (PCI) or redo CABG. Mammary
arteries damaged to the point of non-use were recorded pro-
spectively. Harvest times were recorded by nurses as part of
operative routine for 816 mammary artery harvests from 2003 to
2007 and then this routine recording of IMA harvest times
stopped because it was deemed no longer necessary by operating
theatre administration personnel. To have the most recent data,
harvest times (with the harmonic hook blade) of the last 100 IMAs
were recorded from December 2012 to August 2013; also we
noted the number of clips on the IMA branches and the repair
stitches needed.
Surgical details
All operations were performed either with standard cardiopulmon-
ary bypass or off-pump using high spinal anaesthesia (local anaes-
thetic and opioid) and light general anaesthesia. For on-pump
procedures, we used intermittent antegrade warm (initial) and cold
blood cardioplegia for myocardial protection and systemic hypo-
thermia at 32°C. Off-pump CABG was performed with the Octopus
stabilizing device (Medtronic, Inc., Minneapolis, MN, USA).
IMA conduits were harvested in a skeletonized manner either
with the traditional skeletonization technique (with use of the
cautery tip without power as a dissector) or with an ultrasonic
scalpel (Harmonic Scalpel; Ethicon Endo-Surgery, CVD, Cincinnati,
OH, USA) (Fig. 1). The three stages of the harvest comprised: (i) ex-
posing the IMA on the chest wall by sweeping away the lung vis-
ceral pleura (trying to maintain this visceral pleura intact), (ii)
incising horizontally with Metzenbaum scissors in the crevice
between the medial internal mammary vein and the IMA and (iii)
use of the cautery tip or HS to isolate and free the IMA, from its
distal bifurcation into the superior epigastric and musculophrenic
branches to proximally above the first intercostal branch. In the
traditional skeletonization technique, side branches were clipped
and cut and, in the harmonic technique, branches were sealed
using the blunt end of the harmonic device. For harmonic skeleto-
nization, clips were used only if the side branch bled before/after
sealing with the harmonic device.
The left IMA was anastomosed to the left anterior descending
artery and the right IMA was anastomosed to either the left
circumflex or right coronary arteries. IMAs were used mostly as
in situ grafts and were wrapped in papaverine-soaked gauze after
harvesting before use. Intraoperative transoesophageal echocardi-
ography was used, except where contraindicated. Long-acting
nitrates were prescribed postoperatively for 6 weeks in patients
with radial artery grafts.
Data collection
Data from all patients were entered into a province-wide database
(APPROACH: Alberta Provincial Program for Outcome Assessment
in CORONARY Heart disease) [9], which is a prospective data col-
lection initiative in which patients are first enrolled at the time of
initial cardiac catheterization and are followed for life to assess
outcomes. Data from the same patients were also entered pro-
spectively into a surgical database to document demographics
and relevant surgical data. This study was approved by our
Institutional Research Ethics Board. Major adverse cardiac events
considered were operative mortality, perioperative MI, deep
sternal wound infection and reoperation for either bleeding or
failed grafts. The primary outcome was a composite measure indi-
cating that any one of these adverse events occurred. In addition,
we considered the postoperative MACEs of angina, and need for
revascularization with CABG or PCI.
Statistical analysis
Continuous variables were described as the mean and standard
deviation (SD) when normally distributed and the median (25th
percentile, 75th percentile) when not. Categorical variables were
described using percentages. Differences between the HS patients
and the non-HS patients were assessed using unpaired t-tests for
normally distributed continuous variables and the Wilcoxon test
for non-normally distributed variables. Differences in categorical
variables were examined using Fisher’s exact test (FET).
Differences between the HS patients and the non-HS patients
were also described using the standardized mean difference. The
unadjusted risk of the composite adverse event and each individ-
ual MACE was described, using percentages. The unadjusted abso-
lute risk difference between HS patients and non-HS patients was
calculated with exact 95% confidence intervals (CIs). Since this dif-
ference may have been a result of an imbalance of covariates
between the two groups, we performed a propensity analysis to
assess the difference in the composite perioperative adverse
event variable. A non-parsimonious logistic regression model was
used to calculate the propensity score in the iterative manner sug-
gested by Rosenbaum and Rubin [10]. All potential covariates
were entered into the model if they were significant for HS use or
for the composite outcome at P < 0.5. In addition, quadratic terms
for the continuous variables and plausible interactions were
included. The balance between the HS groups was examined both
using boxplots comparing the distribution of the propensity
between HS groups within each quintile of the propensity score
distribution and by calculating the standardized mean difference
of each covariate within quintiles of the propensity score. After
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achieving balance between the groups (standardized differences
< 10% within quintiles), we estimated the difference in the com-
posite adverse event risk stratifying on the quintiles of the propen-
sity score and then obtained estimates of the risk difference from
the coefficients. Standard errors and hence CIs were estimated
using the delta method.
Harvest times were summarized separately for non-HS patients
(Patients 1–49) and the patients recruited since December 2012
using the mean, since, for these two groups, the harvest times were
constant across time. There was evidence of a non-linear effect of
the number of surgeries on harvest times after the HS was intro-
duced. This non-linear relationship was estimated using linear re-
gression in which a log transformation was applied to the number
of surgeries and then the results back-transformed to arrive at the
presented estimates. For both the means and the regression,
standard errors of the estimates were calculated taking into account
the intrasubject correlation between the left and the right IMA
using a generalized estimating equation approach. All analyses were
done using Stata version 13 (StataCorp. 2013. Stata Statistical
Software: Release 13. College Station, TX, USA: StataCorp LP.)
RESULTS
Demographics and arterial graft anatomy
In 10 years from July 2003 to July 2013, 1057 consecutive patients
received 3150 grafts of which 3083 (98%) were arterial in origin,
2205 grafts were of IMA origin [1421 left internal mammary artery
(LIMA) (45%) and 784 right internal mammary artery (RIMA) (25%)]
Figure 1: Harmonic hook blade and generator.
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and the remaining were as follows: 874 Radial (28%), 4 inferior epi-
gastric artery and 67 (2%) vein grafts with an average of 2.98 grafts/
patient. A total of 1640 mammary arteries in 965 patients [940 left
IMAs (57%) and 700 right IMAs (43%)] were skeletonized with HT
and in 86 patients 147 IMAs were skeletonized using the cautery tip
as a dissector (no power; side branches were individually clipped
and cut). Six patients of this consecutive series had no IMA har-
vested with this surgery because IMAs existed from a previous
CABG (4 patients); there was no need of IMA because of non-left
anterior descending artery (LAD) disease with inferior wall scar (1
patient), and prolonged cardiogenic shock precluding IMA use (1
patient). Figure 2 shows a flow chart of the study groups. Excluding
patients with single-vessel disease, 74% of patients received bilateral
IMAs. Baseline variables of patients with and without harmonic ske-
letonization are described in Table 1. HS patients were younger
(P = 0.009), less likely to have hypercholesterolaemia (P = 0.068) and
more likely to have an ejection fraction <30% (P = 0.024). No other
significant differences were observed at P < 0.20.
The majority of right IMA conduits went to the right coronary
artery (RCA) (42%) (322/758) and the circumflex (Cx) (54%) (408/
758) territories; only 3.7% (28/758) went to the LAD/diagonal
system. Seventy-two percent of the right IMA-to-RCA grafts were to
the sub-branches: 64% to the posterior descending artery, 8% to the
posterolateral branch of the RCA; 28% went to the main RCA. In the
majority of right IMA grafts to the RCA and Cx systems, skeletoniza-
tion allowed in situ use: direct anastomosis to the aorta was required
in 11% of right IMAs to the RCA system and 9% to the Cx system.
Skeletonization with harmonic technology
The traditional skeletonization technique for IMA harvest was
used during two time periods: from 18 July to 13 November 2003
on 49 patients and from 11 March to 3 August 2010 on 37 patients
because the HT changed. The first skeletonization of an IMA with
any harmonic device for a patient occurred on 24 November
2003; and although it is usually the surgeon’s preference to con-
tinue a change in technique without breaks, when the first device
was discontinued by the company in 2009, it took 5 months to
discover an adequate replacement. For the first 673 (71%) patients
the HC105 HS (with non-disposable handle and disposable blade
tip) was used and when the nation-wide supply of the blade tip
was exhausted by the first author, in March 2010, for 5 patients
the Harmonic Synergy Curved Blade was trialled. This blade was
3 mm wide compared with the 2 mm width of the HC105 blade,
was sharper and tended to damage the accompanying internal
thoracic veins of the IMA. The resulting bleeding from these
damaged veins frustrated attempts to seal the IMA branches
because of the dry field required. This device was only used in
5 patients before its use for IMA harvest was abandoned. After
this, for a period of almost 5 months the traditional skeletonization
technique was used in 37 patients until the harmonic hook blade
was discovered in August 2010. This device has been used for the
last 269 (28%) patients and has become the authors’ device of
choice for delicate, accurate dissection and speed of harvest of
the IMA.
Major adverse events related to internal
mammary artery harvest
The unadjusted rates of the composite adverse events were
6/86 = 6.98% in non-HS patients and 78/965 = 8.08% in HS
patients with an unadjusted absolute risk difference of −1.1% (95%
CI: −6.76%, 4.55%), FET P = 0.838. We developed a propensity
Figure 2: Flow chart of study patients, grafts, conduits, RIMAs and LIMAs of study groups. CABG: Coronary artery bypass graft; IMA: internal mammary artery;
OR: operation.
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score that adequately balanced the covariates on the quintiles of
the propensity and estimated the adjusted risk difference between
non-HS patients and HS patients, which was −0.79% (95% CI:
−6.73%, 5.14%, P = 0.793). The adjusted risk in the non-HS group
was 7.26% (1.59%, 12.93%) and in the HS group 8.06% (95% CI:
6.34, 9.77%). Individual adverse event rates for patients with and
without harmonic skeletonization, respectively, are seen in Table 2
and were not statistically different. Absolute risk differences are
presented in Fig. 3. With respect to reoperation for bleeding, in
the 10 years of use of the HS, the cause of bleeding was never
from a reopened sealed IMA side branch. In 6 patients, 8 har-
vested IMAs could not be used due to arterial damage and/or fra-
gility: 1/147 non-HS IMAs vs 7/1640 HS IMAs (difference = 0.3%,
95% CI: −1.0, 1.7).
Table 1: Baseline characteristics of the study population of 1057 patients: 86 patients with the conventional skeletonized harvest
technique; 965 patients with harmonic skeletonization; 6 patients with no IMA graft
All patients
(n = 1057a) (%)
Harmonic patients
(n = 965) (%)
Non-harmonic
patients (n = 86) (%)
Standardized
difference
P-value
Demographics
Number of IMA conduits/patient 1787/1057 = 1.7 1640/965 = 1.7 147/86 = 1.7 0.999
SVD 64 (6.1) 57 (5.9) 7 (8.1) −0.087 0.353
BIMA (excluding SVD) 730/987 (74%) 670/908 (74%) 60/79 (76%) −0.050 0.789
Grafts/patient, mean (SD) 2.98 (0.94) 2.98 (0.93) 3.02 (1.07) −0.039 0.685
Off-pump CABG 413 (39%) 377 (39%) 36 (42%) 0.645
Age, mean (SD) 64.9 (10.5) 64.7 (10.5) 67.7 (9.9) −0.302 0.009
Female gender 229 (22%) 206 (21%) 22 (26%) −0.100 0.343
Elective 459 (43%) 412 (43%) 43 (50%) −0.147 0.447
Urgent-in 477 (45%) 441 (46%) 35 (41%) 0.101
Emergency 121 (11%) 112 (12%) 8 (9%) 0.075
EuroSCORE (median quartiles) 3.0 (1.6, 6.4) 2.9 (1.5, 6.3) 3.2 (2.0, 6.2) 0.057 0.262
Comorbidities
Hypertension 729 (69%) 663 (69%) 63 (73%) 0.100 0.465
Hypercholesterolaemia 729 (69%) 658 (68%) 67 (78%) −0.220 0.068
Diabetes mellitus 367 (35%) 316 (33%) 29 (34%) −0.021 0.906
Ever smoked 622 (59%) 573 (59%) 45 (52%) 0.142 0.210
Ejection fractionb >50% 426 (55%) 380 (55%) 43 (64%) −0.198 0.024
Ejection fraction 30–50% 267 (35%) 243 (35%) 23 (34%) 0.011
Ejection fraction <30% 76 (10%) 74 (11%) 1 (1%) 0.390
BMI ≥ 30 340 (32%) 312 (32%) 26 (30%) 0.045 0.720
COPD 133 (13%) 124 (13%) 9 (10%) 0.074 0.614
Cerebrovascular disease 112 (11%) 103 (11%) 9 (10%) 0.007 1.00
Peripheral vascular disease 117 (11%) 108 (11%) 8 (9%) 0.062 0.720
Renal disease Creatinine >200 40 (4%) 36 (4%) 3 (3%) 0.013 1.000
Reoperative CABG 38 (4%) 32 (3%) 2 (2%) 0.060 1.000
aIncludes 6 patients with no IMA harvested/used with this surgery (4 reoperative CABG patients with IMA from previous surgery, 1 patient with no LAD
disease (radial to diagonal and marginal) and 1 cardiogenic shock patient with no IMA).
bEjection fraction known in 73% of 1057 patients.
IMA: internal mammary artery; SVD: single-vessel disease; BIMA: bilateral internal mammary artery; CABG: coronary artery bypass graft; EuroSCORE:
European System for Cardiac Operative Risk Evalulation; BMI: body mass index; COPD: chronic obstructive pulmonary artery disease.
Table 2: Perioperative and mid-term outcomes of non-harmonic and harmonic patients
Outcomes Harmonic patients (n = 965) (%) Non-harmonic patients (n = 86) (%) P-value
Composite perioperative adverse events 78 (8.1) 6 (7.0) 0.838
Reoperation for bleeding 26 (2.7) 3 (3.5) 0.726
Early reoperation for failed grafts 7 (0.7) 0 (0) 1.000
Deep sternal wound infection 15 (1.6) 1 (1.2) 1.000
Perioperative MI 16 (1.7) 2 (2.3) 0.653
Operative mortality total 36 (3.7) 2 (2.3) 0.763
Postoperative adverse events
Angina 59 (6.1) 5 (5.8) 1.000
PCI 30 (3.1) 4 (4.7) 0.353
Late redo CABG 1 (0.1) 0 (0) 0.765
CI: confidence intervals; IMA: internal mammary artery; MI: myocardial infarction; PCI: percutaneous coronary intervention; LIMA: left internal mammary
artery; Operative mortality: in-hospital mortality.
A
D
U
LT
C
A
R
D
IA
C
T.M. Kieser et al. / European Journal of Cardio-Thoracic Surgery 5
153
Harmonic scalpel for IMA skeletonization
Operative time
The traditional technique of skeletonization, with use of the
cautery tip as a dissector (no power) with clips and scissors, had
been used for the previous 3½ years (June 2000 to November
2003). Hence the harvest of the first 77 non-harmonic skeleto-
nized mammaries (49 surgeries) (mean time of 32.2 min) (95%
CI: 30.1, 34.3) was done by a surgeon experienced in this tech-
nique. After introduction of the HS there was a significant
non-linear decrease in harvest time (P < 0.001 controlling for
intrasubject correlation between the left and the right IMA).
Figure 4 illustrates the change in harvest times per IMA by the
number of surgeries performed over time. Initially, for the 50
surgeries using the HS for the first time, the harvest time was
36.2 min (95% CI: 34.2, 38.2). After 100 surgeries the mean time
was 33.7 min (95% CI: 32.3, 35.2) and after 450 surgeries the
mean time was 28.4 min (95% CI: 27.8, 29.1). Times were further
reduced with the addition of an easier-to-use mammary retract-
or (Bugge IMA retractor) and use of the harmonic hook blade.
For the last 60 surgeries (100 IMAs harvested) from 29 December
2012 to 29 August 2013 the mean harvest time for use of the har-
monic device per mammary was 15.4 min (95% CI: 14.0, 16.7)
(16.7 min for the left IMA and 14.1 min for the right IMA). A total
of 75 clips were used (0.75 clips/mammary), less than 1 clip/
mammary. Seven repair stitches were needed to repair small
needle holes or branches that were inadvertently transected
flush with the IMA.
Postoperative events at mid-term follow-up
At a mean follow-up time of 5 years development of angina and
requirement for revascularization (PCI or redo CABG) were no dif-
ferent for the non-harmonic and harmonic group of patients
(P = 1.00, P = 0.353 and P = 0.765) (Table 2).
DISCUSSION
In this consecutive all-comer series of 1051 patients with 1787 skele-
tonized IMAs, we have shown that use of HT to skeletonize IMAs is
safe and efficient with regard to harvest time. Major adverse events
related to IMA use are no different when compared with patients
whose IMAs were skeletonized with the conventional technique; time
for IMA harvest with HT is half of that of harvest with the cautery tip
as a dissector. Also the IMA is rarely damaged and in fact, in those
rare instances that an IMA is not usable (7/1640 mammaries−0.43%),
it is possible that the HS is able to harvest excessively fragile mammar-
ies intact and this fragility comes to light only when one starts to work
with the conduit in the performance of distal anastomoses.
Skeletonization technique for internal mammary
artery harvest
This study also shows that skeletonization of the internal
mammary artery allows for in situ right mammary grafts to reach
Figure 3: Absolute risk differences for major adverse events (actual risks by group are presented in Table 2) between non-harmonic patients and harmonic patients
(with exact 95% CI for the risk differences) in which a positive value represents a beneficial effect of using a HS. This illustrates that there were no substantial differences
in the risk of MACEs between HS patients and non-HS patients.
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branches of the RCA and Cx the majority of the time. By com-
parison, the left IMA usually easily reaches the LAD and/or diag-
onal arteries. Use of the right IMA is largely responsible for the
increased difficulty in use of double IMAs; right IMA in situ
attachment to non-LAD territory arteries such as the distal
branches of the RCA and Cx systems with the right IMA can be
challenging. In our experience, skeletonization allows an easier
‘reach’ to distant distal targets. Although a benefit not easily
quantifiable, a clip-less IMA is much easier to use especially in
sequential grafting. In this series 35% (359/1021) of left IMAs
were used in a sequential fashion and less frequently, 5.3% of
right IMAs.
In 1946, Vineberg [11] was both the first surgeon to pioneer the
use of the IMA in revascularization as an implanted artery into a
tunnel in the myocardium and the first to harvest the IMA in a
skeletonized fashion. None of Vineberg’s early papers actually
describe the technique, but Effler et al. [12] of the Cleveland Clinic,
in a 1963 paper on ‘Vineberg’s Operation’, outlined the technique
in great detail. In 1962, in an attempt to promote collateral circula-
tion in the heart muscle tunnel, Sewell, in animal experiments,
first reported the use of a ‘pedicle’ of the IMA, which included
IMA harvest with the veins and surrounding tissue. Hence, the
most commonly used pedicle technique for IMA harvest today
derives from research intended to improve the Vineberg oper-
ation [13]. In 1987 Keeley [14] introduced skeletonization again
but harvested the IMA first as a pedicle, and then used bipolar
cautery to skeletonize the IMA.
Studies have shown anatomical and physiological differences in
skeletonized IMAs: skeletonization results in a longer conduit by
as much as 4 cm compared with the pedicled conduit [15]. Also
free flow is greater in the skeletonized mammary. In a review by
Athanasiou et al. [16] Grade A evidence was found for ‘skeletoniza-
tion causing less sternal devascularization compared with pedicle
harvest’, and Grade B evidence was found for ‘superior free
flow for skeletonized IMAs’, but all other parameters compared
were Evidence Grade C, which included: ‘damage to the harvested
IMA’, ‘mortality/morbidity improvement with skeletonization’,
‘improved graft patency’, ‘reduction of postoperative respiratory
complications’, ‘reduced postoperative blood loss and
sternotomy-related pain’, and ‘reduction in the incidence of IMA
hypoperfusion syndrome’.
Operative time
Lengthy preparation times with harvesting of bilateral IMAs for
CABG surgery can be a deterrent to performance of bilateral
IMA grafting. Shorter procedures are in everyone’s best interest
—the patient, the team, the surgeon and the hospital adminis-
tration. Harvesting two IMAs by skeletonization may lengthen a
2½ h conventional procedure (one IMA and venous grafts) by at
least 30–45 min for two reasons: first the skeletonization tech-
nique is more meticulous and time-consuming and also IMA
harvest is metachronous by the primary surgeon and not syn-
chronous as with simultaneous vein harvest by the assistant. We
have shown that IMA harvest time can be reduced with use of
HT and, although not as speedy as simultaneous vein harvest, is
quicker than the conventional skeletonization technique. In
principle, techniques that are less damaging usually take more
time; not so with harmonic skeletonization—in this study in
addition to being quicker, it is less damaging to the mammary
artery.
Whereas it would be interesting to try and calculate a ‘learning
curve’ for harmonic skeletonization, there have been too many
variables introduced at different times over the 10-year period to
allow scientific assessment. These variables include: use of three
types of harmonic blades, use of two different mammary retrac-
tors and lack of time recordings for the entire series of IMA har-
vests. From the authors’ personal experience in teaching this
technique to junior and senior cardiac surgical residents as well as
Figure 4: The change of harvest times per IMA by the number of surgeries performed over time. The blue dots represent the first 49 non-HS patients and the green
dots represent HS patients. No time measurements were made between the 519th and 1012th surgeries. The red lines represent the mean values for the non-
harmonic patients and the last 100 IMAs harvested (which do not change over time). There was a significant non-linear decrease in harvest time per IMA (P < 0.001),
which is illustrated by the blue line. Multiple R2 = 0.1473 for surgeries 50–518.
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Harmonic scalpel for IMA skeletonization
to surgeons already in practice, if one is familiar with the skeleto-
nization technique, approximately 10 harvests with the HS gives
one a comfort level with the technique and, if one is not experi-
enced in skeletonization, approximately 20 harvests would be
needed.
Arterial conduit harvest times recorded by other authors
include Matsumoto’s 20–25 min for the pedicle dissection of
IMAs [17], Higami’s 20–25 min for both pedicled and harmonic
skeletonization of IMAs [15] and, in the early years of minimally
invasive CABG, thoracoscopic harvest times were 65 min (range
35–95 min) for the left IMA and 37 min (range 25–45 min) for the
right IMA [18]. Harvest times for other conduits were noted by
Isomura: the gastro-epiploic harvest time was 9 min and that for
the radial artery was 17 min, both with the HS. Use of the HS
decreases harvest time and conduit spasm, and reduces the
number of clips [19]. Prior to the authors’ skeletonization experi-
ence (beginning in June 2000) the average time for pedicle
harvest in the preceding 4 years was 19 min, making the current
time of 15.4 min faster than that for the pedicle harvest. We
believe that the extra time of 15.4 min to harvest the second IMA,
with its potential to endure, is more than justified.
Physiological advantage of harmonic technology
HT in the form of the hook blade was first introduced in cardiac
surgery by R.K. Wolf (with the first human harvest in 1994) and ini-
tially was used for thoracoscopic IMA harvest for minimally inva-
sive CABG [20]. Wolf not only tested early prototypes of the HS for
years in animal studies but also designed the hook blade specific-
ally for IMA harvest, which is still used today. An ultrasonically acti-
vated scalpel seals vessels only by coaptive coagulation and not
by tissue desiccation as with electrocautery. The blade tip vibrates
longitudinally 55 500 times/s with an excursion of 50–100 µm.
Energy propagates only in the direction in which force is applied—
there is very little lateral distribution of energy. Vessels up to
5 mm in diameter are able to be sealed and without tissue desic-
cation or charring. The hook blade design (used in the latter 265
patients of this series) provides coaptive coagulation as well as
haemostatic cutting.
Studies comparing electrocautery, lasers and ultrasonically acti-
vated (harmonic) scalpels have shown that with HT the zone of
thermal injury is greatly reduced because of both decreased
depth of penetration (coagulation) and lateral thermal spread [21].
With electrocautery a coagulation depth of 1 mm is reached
almost instantly, whereas it takes 3 s for an ultrasonically activated
scalpel to achieve the same depth. Similarly, lateral thermal
spread after 1 s of contact by the HT is 0.1 mm compared with
1 mm by electrocautery (i.e. it takes 10 s of HT to cause the same
thermal spread of 1 mm [22]. Thermal degeneration is limited to
the depth of the connective tissue of the tunica externa [23].
Because of the decreased lateral thermal spread, wound repair
is also superior and decreased postoperative adhesions are
described by McCarus [21]
The HS has two cutting mechanisms: the primary is the cutting
effect of the longitudinal vibrating sharp blade (vibrating 55 500
times/s over a distance of 50–100 µm), which incises high-density
tissues such as muscle, and fibrous connective tissue. Cavitational
fragmentation is the second cutting mechanism, which disrupts
low-density tissues such as fat and parenchyma; tissue planes sep-
arate ahead of the blade tip quickly and easily. A dry field is advis-
able for the harmonic blade to function; therefore, blood vessels
must be ‘sealed’ before they are cut. This is done by continuous
pressure on the branch for about 1–2 s until the branch turns
white or black. Harvesting IMAs in patients requiring ongoing
intravenous heparin or who are on Clopidogrel can be challen-
ging, but not impossible: more clips might be needed.
‘Cauterization’ of a bleeding vessel is possible but the bleeding
cannot be brisk and, in the authors’ experience, is most often only
possible in actively smoking patients because of their hypercoa-
gulability.
Histology/pharmacology of harmonic skeletonized
internal mammary arteries
Use of HT does not damage the endothelium [24] but endothelial
relaxation function may be compromised; Matsumoto et al. [17]
found in a study of discarded distal ends of 50 skeletonized and
30 pedicled IMAs that whereas norepinephrine-mediated con-
traction was similar for skeletonized and pedicled IMAs, pedicled
vessels showed greater relaxation responses to acetylcholine
(P < 0.05). A topical vasodilator such as papaverine or nitroglycerin
on the skeletonized IMA may therefore be important. Higami
et al. [25] established the safe distance to seal IMA branches to be
at least 1 mm distal to their origin from the IMA, using the power
level 2 of a maximum level of 5. He also found that 92% of the
sealed branches remained intact when subjected to burst pres-
sures of 350 mmHg.
Limitations of this study
As with all observational retrospective reviews, it was not possible
to control factors which may have changed outcomes in the two
groups of patients. Also the numbers of the two groups are dispar-
ate but this is also in keeping with the nature of observational
reviews. Even though some factors were different for the two
groups, the major adverse events were no different, either before
or after controlling for these factors, establishing that use of HT is
safe and not inferior to the traditional technique of harvest. The
strengths of this study lie in the fact that it is a real-world consecu-
tive all-comer population of almost purely arterial grafting CABG
patients.
CONCLUSIONS
In this study of 1051 consecutive all-comer patients with 2205
IMA grafts from 1787 IMA conduits, we have shown that use of HT
to skeletonize IMAs facilitates the skeletonization technique by
being faster and rarely damaging, needing less clips and having
similar results with respect to reoperation for bleeding, deep
sternal infection and peri- and postoperative MI compared with
conventional IMA harvest by skeletonization. Simply put, use of
HT is quicker than and just as safe as the conventional method of
skeletonization; this easier technique may encourage use of bilat-
eral IMAs. In turn, this may benefit patients in the long term with
regard to improved survival and cardiac problem-free existence.
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APPENDIX. CONFERENCE DISCUSSION
Dr M. Contino (Milan, Italy): First of all, about the cost, can you do a compari-
son between the differences in cost of the two technologies, the Harmonic
technology and the traditional technique?
And the second thing is about the learning curve, because during this study
we see a significant speed-up in the harvesting time of the IMA, but I know that
you also change the kind of instruments during this period. So in conclusion,
how long can we consider the learning curve to be to achieve this very quick
skeletonization time?
Dr Kieser: The cost. Okay. I do know that the disposable hook blade in
Canadian dollars is $314. So clips don’t cost that much, so it is expensive. The
rest of the technology, the blue cord and the generator, often are already in
your hospital because they’re used by general surgeons, specifically thyroid sur-
geons. So the cost is $314 for the disposable handpiece.
Concerning the learning curve, if you already know how to skeletonize, it
probably takes about 10 mammaries. And if you don’t know how to skeletonize,
or you’re not familiar with the technique, about 20 mammaries. But I’ve taught
several residents how to do this and they learn very quickly. And these are not
residents who are experienced. We have young surgeons or young students
coming out of medical school and I start them right away on the internal
mammary harvest, because the way you start is the way you mean to continue.
I don’t want them learning vein, because that’s what they’ll do when they
become staff. So I start them with internal mammary artery harvest right away
with the Harmonic scalpel. Recently I was teaching a young surgeon in Varna,
Bulgaria, and he was a qualified surgeon, he had been in practice for two years,
and after he was harvesting for about 10 minutes, he turned to me and he said,
"This is easy." And I said, "I know." So it’s not so bad.
Dr T. Folliguet (Nancy, France): I have just one short comment. I believe
totally and I agree with you that I don’t use clips, in our unit we don’t use clips,
but you can do the same thing without the Harmonic, you can do the same
thing with the Bovie. You set up at 30 or 20 and you just go down. So I think on
the question of cost, I mean I have no experience with Harmonic, but the
regular Bovie does the job just the same way and you don’t have to use clips. I
think clips, as we see a lot of the time, are pinching, and you sometimes have a
little bit of dimpling on the artery, and this technique allows you to have a
smooth surface. The only thing we have to teach the residents is to be really far
away from the mammary arteries in order not to cauterize, because otherwise
you can get burn injury. Maybe that can be an advantage of the Harmonic, I
don’t know.
Dr Kieser: No, I agree, whatever works for you is a very, very good technique.
The difference between the Harmonic and the cautery is that the lateral
thermal spread is 10 to 1. The lateral thermal spread with electrocautery in one
second is a millimetre, whereas it is 0.1 mm with the Harmonic. So if you’re
teaching it, you have a little more leeway. And if you’re tired, if you’re operating,
you have a little more leeway. But no, the use of cautery is a very valid way.
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Skeletonization of the internal mammary 
artery with the harmonic hook blade
Kieser TM, Narine K
CTSNet Video published on July 12 2012 Website:  
http://www.ctsnet.org/sections/videosection/videos/vg2012_KieserT_Harmonic
CTSNet a world- wide web site that can be joined by all cardiac surgeons in the world, 
currently has 52,000 members of which 35,000 are cardiac surgeons. When a surgical video 
is launched on CTSNet, it is viewed on average 1600 times in the rst month. This video was 
viewed 4609 times in the rst (approximately) 6 weeks.
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This is the script of a video published on Cardio Thoracic Surgery network (CTSNet). 
It describes a method to harvest internal mammary arteries using high frequency 
ultrasound. There are two ways used to harvest internal mammary arteries: either by 
taking a swath of tissue surrounding the internal mammary artery including the ac-
companying veins and some muscle and endothoracic fascia (the pedicle method) or 
by dissecting just the internal mammary artery itself without any accompanying tissue 
(the skeletonization method). In turn, there are two techniques used to ‘skeletonize’ an 
IMA: by either using the cautery tip blade without power, just as a dissector, or with 
harmonic technology. The cautery tip used as a dissector ‘drags’ the surrounding tissue 
from an IMA and may damage a fragile artery. Some surgeons do use low dose cautery 
to harvest IMAs. Harmonic technology uses a device whose tip vibrates longitudinally 
55,500 times/second. The advantage of this technique compared with cautery use is the 
comparative lack of thermal spread. With electrocautery a coagulation depth of 1 mm 
is reached almost instantly, whereas it takes 3 seconds for an ultrasonically activated 
scalpel to achieve the same depth. IMAs are usually 1-2 mm in diameter, therefore use 
of cautery with power could potentially obliterate the lumen of an IMA, precluding its 
use as a bypass.
“SKELETONIZATION OF THE INTERNAL MAMMARY ARTERY WITH THE 
HARMONIC HOOK BLADE”
As results of the SYNTAX trial comparing PCI and CABG surgery for treatment of de novo 
triple vessel and/or left main coronary artery disease are published, CABG surgery is 
enjoying renewed attention. However the preferred mammary artery grafts are avoided 
for many reasons among which include: their nite length, fear of sternal infection, in-
creased technical and time demands, perceived inadequate ow for a specic coronary 
bed or lack of belief in the evidence to date, supporting the use of multiple mammary 
grafting. Many of these issues can be overcome, with use of the skeletonization harvest 
technique of the mammary artery; skeletonization produces longer conduits 1 and 
decreases the risk of DSWI by preserving three of the 6 types of collateral blood supply 
to the sternum.2
However, skeletonization also has issues: the procedure is more time-consuming than 
the standard pedicle technique and there is fear of damage to the mammary when 
harvested directly without its cushion of veins, fascia and muscle.
Use of the harmonic hook blade to skeletonize the mammary artery addresses these 
two factors: it is quicker than skeletonization with the cautery tip used as a dissector 
and much less damaging to the mammary artery; this video shows the technique of 
skeletonization of the mammary artery with the harmonic hook blade.
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After clearing the pleura from the undersurface of the chest wall, without entering 
the thoracic cavity if possible, and insertion of the retractor of choice to harvest the 
mammary artery, the  rst step is to incise the fascia overlying the mammary artery with 
Metzenbaum scissors. This incision is made in the crevice between the medial mammary 
vein and the mammary itself, so that there will be no “over-hang” of tissue precluding 
complete view of the mammary, along its entire length during the course of the dissec-
tion.
The safest start point is the caudal end of the mammary near the level of the xiphister-
num, but the mammary may not always be visible here, hidden by muscle or fascia. The 
mammary is usually easily seen about 1/3 of the distance up from the caudal end and if 
one draws an imaginary horizontal line from where the mammary is seen, to a point at 
the end of the sternum, incising over this imaginary line will expose the mammary artery 
more than 90% of the time; inadvertent damage at this level is usually inconsequential.
Before use, the harmonic hook blade should be positioned for ideal length and ori-
entation: for going from right to left as in harvest of the left mammary, the hook part 
faces opposite to the direction of harvest. The hook part of the blade is very sharp and 
inadvertent movements can cut branches or even the mammary before intended.
The mammary artery is  rst bared over a small area without power to identify its 
borders. One can hold the mammary by the adventitia with delicate forceps, such as 
ringed forceps without fear of damage. Then using the harmonic hook blade on low 
power of 2 (of a possible 5), one “paints” the mammary artery in a sweeping motion 
with the non-hook side of the harmonic. The mammary artery can actually be “touched” 
brie y with this “painting” technique without fear of thermal damage (Figure 1). As long 
as one does not “dwell” on a part of the mammary, the tissues adherent to the mammary 
will part “like the red sea” and quickly expose the branches. Thermal dispersion of the 
harmonic is much less than that of traditional electrocautery; signi cant heat damage 
does not begin until after 3 seconds of harmonic blade contact.3
When coming to a branch, it is easiest if one isolates the branch on either side, so as 
to expose the exact width of the branch one is dealing with. Then using the forceps 
prongs on either side of the branch, and simultaneously depressing the mammary so 
	  
Figure 1. Harmonic hook blade separating (skeletonizing) IMA from chest wall
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as to lengthen the branch, the blunt end of the harmonic hook is used to “sit on” the 
branch, at least 1 mm away from the mammary but at the same time not touching the 
mammary veins, until the branch turns white, or black and then breaks naturally with 
the gentle pressure of the blunt end of the hook. One quickly “learns” the tissues of a 
patient; sometimes only very gentle traction on the branch will result in tearing of the 
branch or an adventitial hematoma, but if one is still at the distal end of the mammary, 
no harm is usually done. I try to resist the temptation to go faster by using the hook to 
cut the branch when I feel it MUST be cooked, I am usually wrong and have to place a 
clip on an otherwise clipless mammary. This brings us to a question most frequently 
asked: do the harmonically sealed branches ever open up and make one take a patient 
back for bleeding? The answer is: in 8 years, for 815 patients with 1363 harmonically 
skeletonized mammary arteries - NO. If a branch is to bleed, it will have done so before 
the end of the case.
Additional advantages of using the harmonic to skeletonize the mammary artery ren-
der it relatively “clip-less”. One can be absolutely sure that wherever one goes to perform 
a side-to-side anastomosis of a sequential graft, there will be a clip. Additionally, when 
the mammary artery dilates (when spasm from the handling is relieved), there are no 
“indents” in the mammary that one may see at a clip location.
Damage to a mammary artery when skeletonized with the harmonic rarely occurs 
(Figure 2): in this author’s experience with the traditional skeletonization technique, an 
average of 1/20 arteries were damaged, whereas 0.4% representing 6 of 1363 (13 hun-
dred 63) mammary arteries were damaged beyond the point of any use. It is the author’s 
surmise that these mammaries were not actually damaged by the harmonic, but rather 
the harmonic does such a good job that these excessively fragile mammaries were taken 
down intact: their excessive fragility came to light, only when used to perform distal 
	  
Figure 2. Harmonically skeletonized Left internal mammary artery graft to diagonal (left forceps tip) and 
left anterior descending artery (right forceps tip)
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anastomoses. Possibly, the “dividing” of tissues by the harmonic rather than the “drag-
ging” of tissues by the cautery tip contributes to decreased injury.
The “smoke” one sees in this video is in fact not smoke, but steam. This steam does not 
carry airborne particles that can be inhaled, as with smoke from traditional electrocau-
tery- a very important factor when surgeons of other specialties operate on cancers.4
This technique of skeletonization with a little practice becomes quicker than the cau-
tery tip method dissection – usually taking 15-18 minutes/mammary. If one has never 
skeletonized before, the learning curve reaches 80% comfort level after approximately 
20 mammaries, if the technique of skeletonization is already known, probably 10 dissec-
tions will aord the same level of comfort.
There can be dicult dissections with the harmonic: in particular patients with a 
bleeding tendency due to Plavix or heparin on board, or fragile elderly tissues, mam-
mary harvest can be tedious and frustrating. When bleeding occurs from a branch, the 
harmonic cannot “coagulate” this branch without damage to the mammary, necessitat-
ing the use of a clip.
Finally, when checking the mammary bed for bleeding at the end of the case, you will 
note the lack of “char”; in fact at times it will appear as if you were never there, the only 
sign is a missing mammary. Although not proven, this lack of burned, dead tissue, can 
only help toward minimization of infection.
To summarize, it is this author’s view: 1) Skeletonization of the mammary artery with 
the harmonic hook blade is a precise and ecient method to harvest the mammary 
artery. 2) Because fewer clips are needed, use of the harmonic facilitates arterial grafting 
and allows easier performance of sequential bypasses. And nally, skeletonization of 
the mammary artery with the harmonic hook blade rarely damages the artery and is the 
most atraumatic and rened way, to harvest this most important artery.
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Chapter 16
Iatrogenic Aortic Root and Left Main 
Dissection in CABG Surgery:  
An Unconventional Fix
Kieser TM, Spence FP, Kowalewski R
CTSNet Video published on Nov 3 2014 Website:
http://www.ctsnet.org/article/iatrogenic-aortic-root-and-left-main-dissection-cabg-
surgery-unconventional-x
This video was published on CTSNet on November 3 2014 and was viewed 1500 times in 
the rst week it was aired, compared with the average of 1600 hits/month on CTSNet. It has 
also been nominated by the CTSNet Co-Editors Professors Joel Dunning and Mark Ferguson, 
as a ‘Best of CTSNet’ submission, for potential inclusion in Interactive CardioVascular and 
Thoracic Surgery because it earned 2,244 pageviews in its rst 30 days of publication. 
Videos published in ICVTS in this way obtain MEDLINE indexing and a second avenue for 
promotion and distribution.
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Complication: aortic root and left main dissection
This is a video of a potentially lethal complication of coronary surgery which had a suc-
cessful outcome due to the use of a novel surgical technique to escape disaster for a 74 
year old patient. The complication was a dissection created by a bypass to a diusely 
diseased marginal coronary artery which went retrograde from the marginal artery to 
include the aortic root and then went anterograde to include the entire LAD system (Fig-
ure 1). Transesophageal echocardiography before trying to come o pump showed an 
akinetic left ventricle. The dissection was reversed by pinning the dissection at a second 
site with another vein bypass on the mid LAD artery, but an oval of calcied coronary 
artery wall (including all three layers – intima, media and adventitia) had to be excised 
to do this (Figure 2). This patient is still alive at age 86 years of age.
	  
Figure 2. Final result
	  
Figure  1. Suspected mechanism of dissection. The 
force from the cardioplegia owing in the vein graft 
into the diseased coronary artery created a dissection 
plane, went retrograde to the left main, involving the 
aortic root and continued down the LAD to the apex of 
the heart (site of LIMA graft).

PART 8
GENERAL DISCUSSION AND CONCLUSIONS
SUMMARY
EPILOGUE

Chapter 17
General Discussion and Conclusions

185
Discussion and conclusions
Hunter S. Thompson, an American journalist and author (1937-2005) said: ‘Anything 
worth doing is worth doing well’. In the case of coronary artery bypass grafting, the 
debatable point is: What is the denition of ‘doing well?’ Is it successfully getting the pa-
tient o the operating table alive, out of hospital alive, or is it giving them an operation 
that aords best long-term results? The mindset of doing ‘just enough to aord patients 
operative survival’ possibly needs revamping to: ‘aording patients long-term survival or 
longest possible ecacy of that procedure’.
Although the evidence of BIMA grafting being benecial for increased patient lon-
gevity and improving quality of life is derived mainly from retrospective and objective 
studies, the volume of these studies is substantial. All too often human nature is such 
that rather than make a change, reasons are sought as to why not make that change.
Use of only one IMA and the rest of bypasses with saphenous vein is a comfortable 
operation and has been the ‘norm’ since since Cosgrove in 1985 and Loop in 1986 re-
ported on the benet of one IMA on patient longevity and quality of life. Is it time to 
move on? At the 83th annual meeting of the American Association of Thoracic Surgery 
in Boston 2003, one of the sessions was given by a cardiologist on drug eluting stents, 
which were just being introduced. Cardiac surgeons were worried about what seemed 
to be an inevitable decline of a principal part of their livelihood - the CABG procedure. 
Vividly remembered is Dr. Bruce Lytle of the Cleveland Clinic saying to the audience 
“Gentlemen, did you think you would be doing the same operation for 100 years?!” Is it 
not time to make an improvement on this operation, now 30 years later?
It is quite possible that surgeons indirectly have been responsible for the develop-
ment of stents, drug-eluting stents (DES) in particular. Saphenous vein disease is very 
dicult to treat. As well, most surgeons prefer not to re-operate on patients with a pat-
ent mammary artery, for 2 other systems to which vein grafts have occluded. DES stents 
were hoped to be able to help to address vein graft disease, however this hope has not 
panned out. [1]
So if surgeons continue in the same vein (so to speak) of one IMA and rest of bypasses 
with saphenous vein, an opportunity will be missed to help thousands of coronary 
artery disease patients. As such, the stage is set for the revival of the CABG procedure.
Why is BIMA grafting not performed more often?
1. Surgeons do not believe the evidence to date.
2. More technically demanding.
3. More time consuming.
4. Fear of Deep Sternal Wound Infection (DSWI).
5. Little benet beyond a certain age.
6. Right IMA won’t reach far enough to branches of right coronary artery (RCA) or 
circumex (Cx).
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7. IMA ow thought to be not enough for certain situations: poor LV function, mis-
match with native coronary arteries (i.e. small IMA on a coronary with large area of 
distribution) or spasm with inotropic agents.
8. Inertia.
RESPONSES TO THE ABOVE STATEMENTS ARE ADDRESSED IN THE CHAPTERS 
OF THIS BOOK:
1. Surgeons do not believe the evidence to date.
‘Those who do not accept the truth do not accept the testament of the truth either. They 
go looking for its defects in order to justify their rejection of it with their conscience. There-
fore always be careful to bear witness to God through a life that is blameless.’ [2] There 
is much evidence to date: when a literature search of the key words of ‘bilateral internal 
mammary artery and survival’ is performed in PubMed, (http://www.ncbi.nlm.nih.gov/pu
bmed/?term=bilateral+internal+mammary+artery+and+survival 15197487) 349 articles 
appear which date from 1973 to 2015. However, all of this work is retrospective and/or 
observational in nature. There is only one randomized clinical trial by Taggart et al [3], in 
which patients were randomized to receive either one or two internal mammary arteries. 
The eagerly awaited 10 year results of this most important trial are due in December 2017.
2. More technically demanding.
It is well known that use of two internal mammary arteries is more technically demanding. 
Other factors also have increased the technical complexity of the CABG procedure over time: 
pre-morbid characteristics of patients have increased, and CAD is more diuse especially 
in diabetic patients. Whereas use of the left IMA, performed in 90% of CABG procedures is 
mastered by most cardiac surgeons easily, use of the 2nd (right) IMA is not. Possibly the left-
sided location of both the heart and the one IMA used to bypass the left anterior descending 
artery (the most important coronary artery) may have something to do with this. However 
there are ‘tips’ and tricks’ on how to achieve bilateral mammary artery grafting safely and with 
relative ease. Chapters 10 (Ways to reduce the incidence of deep sternal wound infection), 
Chapters 13 and 14 (How to skeletonize the IMA with use of harmonic technology) are 
studies to help in this regard. But importantly, there is no substitute for practice: as Malcom 
Gladwell describes in his book ‘Outliers’: ‘In fact, researchers have settled on what they believe 
is the magic number for true expertise: ten thousand hours.’ i.e. If you do anything for 10,000 
hours, you get good at it. [4] ‘Il faut le faire.’ - One just has to do it.
When a procedure is more technically demanding, the success of the procedure may 
be hindered due to the increased complexity. Up until recent years the CABG procedure 
was the only operation/procedure on arteries that did not have an ‘intra-operative veri-
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cation’ of the procedure performed. For example as in the case of PCI, a cardiologist need 
only inject more radiopaque dye after a coronary stent is deployed to verify that there 
is relief of the coronary obstruction. Chapter 8 is a study of the use and ecacy of one 
such intra-operative ‘safety-check’- the use of transit-time ow measurement. This study 
has been appreciated internationally in that it has been quoted in three Guidelines. [5-7]
One method to maximize the nite length of arterial grafts, is to perform sequential 
grafting -the use of one arterial conduit for multiple coronary arteries. Because of the 
nite length of arterial conduits, knowledge of sequential grafting is essential. However 
a danger of sequential grafting is the loss of the second anastomosis in preference to the 
rst, which is outlined in Chapter 15 – a study of sequential vein grafts. This is a useful 
concept to be aware of when doing sequential arterial grafting.
Another aspect of arterial grafting was studied in Chapter 11. If one of the benets of 
arterial grafting is the longevity of the arterial graft and one of the drawbacks of venous 
grafting is the early (venous) demise, possibly the accepted axiom that patients with in-
complete revascularization do not fare as well may be in question. Chapter 11 explored 
this concept  –  if a patient undergoing CABG has all arterial conduits, in the majority 
of patients we found that incomplete revascularization (with one of three territories 
not revascularized) did not reduce survival at midterm. The concept that incomplete 
revascularization being responsible for reduced mid or long-term survival, came from 
studies of patients with predominantly vein grafts (only one IMA). Given that vein grafts 
have reduced survival compared with arterial grafts, a patient with only 2 of 3 terri-
tories revascularized with one IMA and one vein graft would then progress to double 
vessel disease from single vessel disease if/when the vein graft would fail. As is known 
from many studies the occlusion rate of saphenous vein grafts is approximately 12% at 
early post op (3 weeks) and 25% at 1 year and 60 % at 12.5 years. It may be therefore 
reasonably concluded that patients with incomplete revascularization by way of one 
missed territory might become even more ‘incompletely revascularized’ with 2 missed 
territories when a saphenous vein graft would fail as soon as 3 weeks in 12% and 25% in 
1 year. Two of three territories without blood supply would undoubtedly aect survival. 
Notwithstanding, complete revascularization may be more challenging in total arterial 
CABG – a concept explored in Chapter 12.
Chapter 16 outlines a novel technique of how to deal with arteries that have signi-
cant proximal stenosis, but are circumferentially calcied for most of their lengths but 
still have a good lumen.
3. More time consuming.
Use of a second IMA takes approximately an extra 20 minutes – principally the harvest 
time. However what is an extra 20 minutes to use the extra IMA, for maybe an extra 20 
trouble free years for a patient? This is discussed in Chapter 6. In addition Chapters 13 
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and 14 describe an IMA harvest technique with harmonic technology that is not only 
quicker than the traditional method, but also safe for the patient and the IMA. The usual 
way to perform the skeletonization harvest technique of an IMA is by using the cautery 
tip (without power) as a dissector. However this technique takes often more than twice 
as long as the ‘pedicle’ technique. One of the deterrents to use of bilateral IMA grafting 
is the extra time taken for the operation: use of the harmonic scalpel to skeletonize as 
described in Chapters 13 (manuscript format) and Chapter 14 (video format) not only 
expedites IMA harvest, and damages the IMA infrequently.
4. Fear of Deep Sternal Wound Infection and Sternal Dehiscence
The internal mammary arteries are a major source of blood supply to the sternum. One 
real fear of bilateral IMA usage is devascularization of the sternum predisposing the 
patient to sternal instability/dehiscence and/or deep sternal wound infection (DSWI). 
Chapter 10 outlines 12 sequentially added ‘layers of protection’ in the form of wound in-
fection prevention techniques to reduce the incidence of DSWI to near zero all the while 
maintaining a high level of bilateral IMA grafting (73% in this group) in all patients. This 
manuscript was the subject of an editorial in the same issue of the Journal of Cardiovas-
cular and Thoracic Surgery. Paul Kurlansky, author of this editorial commented: ‘….the 
authors chose to chronicle their eorts to eliminate DSWI in the face of a dedicated and 
unusual commitment to bilateral internal thoracic artery (BITA) grafting, even in diabetic 
patients. …Kieser and colleagues were not satised to merely accept the risks of DSWI, but 
rather embarked on a journey to eliminate them, without compromising the integrity of the 
revascularization oered to the patient.’ The closing sentences of this editorial state: ‘The 
true message of Kieser and colleagues – aside from the denitively actionable information 
related to minimizing the risk of DSWI while maintaining a commitment to arterial revascu-
larization – is that it is ultimately the dedication to clinical improvement through rigorous 
self-examination and evidence-based programmatic adaptation that will drive surgical 
quality. Both her professional colleagues and her patients are the true beneciaries’. [8]
Another way to prevent sternal dehiscence is discussed in Chapter 9. This study 
describes a way to solidify the sternum in very short time (24 hours) with the use of 
biological glue.
5. No benet beyond a certain age.
The 2014 ESC/ESCTS Guidelines on myocardial revascularization are the rst guidelines 
to accumulate evidence pertaining to a possible age cut-o up to which use of bilateral 
internal mammary artery can be of benet. One of the papers quoted in these guidelines 
is included in this thesis – Chapter 7 on ‘Outcomes associated with bilateral internal tho-
racic artery grafting: the importance of age’. From this and other papers, BIMA grafting 
is thought to be eective for increased survival up to age 70 years. If BIMA grafting was 
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only performed in this ≤ 70 age group, more than 50% of patients would receive BIMA 
grafting – 10 times that which is performed now in North America.
6. Right IMA won’t reach far enough to branches of RCA or Cx
One of the diculties of using only arterial conduits for coronary surgery is their nite 
length, especially in the case of the mammary arteries. One cannot just ‘go and get more 
artery’ as one can do with saphenous vein. (The legs of patients are quite a bit longer 
than their sterna.) One way to maximize the length of IMAs is to skeletonize the artery. 
Most cardiac surgeons take a ‘pedicle’ of tissue with the IMA harvest believing that this 
technique has less risk of damage to the IMA. Although this may be true, the ‘pedicled’ 
IMA is quite a bit shorter than the ‘skeletonized’ IMA and is not as easy to use to reach 
far corners of the heart and especially harder to use for multiple grafts as in sequential 
grafting. Skeletonization of the IMA maximizes the use of IMA grafts and there is always 
the possibility of attaching the ITA directly to the aorta, to the LITA or another conduit. 
Chapters 13 and 14 outline/demonstrate the skeletonization method of the IMA with 
harmonic technology.
7. IMA ow thought to be not enough for certain situations: poor LV function, 
mismatch with native coronary arteries (i.e. small IMA on a coronary with large 
area of distribution), or spasm with inotropic agents.
This is a subjective area and there is not much research on this topic, only some papers 
with IMA grafting on poor LV’s, small ITA etc. The author has rarely seen “IMA-Coronary 
artery mismatch” in a series of 3333 arterial grafts (77% BIMA) in 1125 patients since 
2003. A simple remedy to this problem, if it occurs, is use of the intra-aortic balloon 
pump. Though not needed often, (IABP in 2% of 1125 CABG) it may help release the 
spasm not only of the conduit but of the coronary bed. When mismatch is suspected, 
graft patency should rst be veried. It is more likely that a suboptimal graft anastomo-
sis or damaged conduit may be responsible for the inadequate graft ow; certainly a 
small IMA is more dicult to use. In addition, IMA ow rises dramatically within hours 
to meet the demand – one only has to measure graft ow in take-backs for bleeding to 
realize this. When ow is re-measured at this time using transit-time ow measurement, 
it is always much greater, rivaling that of vein grafts.
8. Inertia
Human Nature and change often do not mix. Understandably, it can be very dicult to 
leave the comfort zone of ‘One-IMA-rest-vein-graft’ CABG and go to a longer, more dif-
cult procedure with increased risks. And as Bruce Lytle recently said ‘…cardiac surgeons 
are greatly incentivized to function extremely well in regard to short-term outcomes but 
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do not practice the same scrutiny regarding long-term outcomes. The only advantages 
of a complex ITA grafting operation are improved long-term outcomes.’ [9]
The very best way to counteract ‘inertia’ is to never let it take hold. If one remains a 
‘life-long learner’, it is much easier to change. Failing this, another way is to start with the 
younger generation of cardiac surgeons and to never teach them how to use vein grafts…
However, this may not be practical. Perhaps the best way is to target young surgeons 
at the beginning of their training and perhaps teach them harvest of the IMA before 
they are taught how to harvest saphenous vein. One day when teaching a new rst year 
resident in Cardiothoracic surgery how to skeletonize the IMA with the harmonic scal-
pel, (he had been a nal year medical student two weeks before), a surgical colleague 
said: ‘When I was at that level of training, I had to harvest a thousand miles of saphenous 
vein before I was allowed to touch a mammary artery.’ Maybe this is part of the problem. 
My dear Mother always used to tell me: ‘Start the way you mean to continue.’ Perhaps 
if young cardiac surgeons-to-be started with IMA harvesting instead of vein conduits, 
maybe this would be the way they would continue? They would ‘imprint’ on internal 
mammary arteries as conduits instead of saphenous vein. This has already been seen 
with one of our now senior residents who when allowed to perform a case on his own, 
uses as much BIMA grafting as he is able.
To summarize this last paragraph: from Proverbs 22:6: ‘Train up a child in the way he 
should go; even when he is old he will not depart from it.’ comes the modern-day saying: 
“Get them young and train them right.”
This Chapter will close with a favorite quote from the movie – ‘Field of Dreams’. In this 
movie, a 1989 American fantasy-drama lm based on the novel Shoeless Joe by W.P. Kin-
sella, Kevin Costner plays Ray Kinsella, a novice Iowa farmer who while walking through 
his corneld one evening, hears a voice whispering, ‘If you build it, he will come.’ By 
building a baseball diamond in their failing corneld and after many adventures and 
twists of fate, Ray fullls his young daughter’s prophecy of:
 “Build it [a baseball diamond] and they [famous baseball players passed-on] will come”
Using this movie theme as an analogy in cardiac surgery, in cardiac surgery terms we 
can say:
“Do the optimal operation and patients will come for CABG”
 or
“Use mammary arteries and they will come.”
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PART 1: INTRODUCTION
Chapter 1 identies the physical and psychological burden with which patients who 
have coronary artery disease must live. It also outlines the responsibility of health care 
professionals looking after these patients to help them to ameliorate their plight to the 
best of their ability especially with respect to the performance of mammary artery graft-
ing CABG.
Chapter 2 explains the focus and goal of the subsequent chapters, which is to facili-
tate the use of mammary artery grafting and increase the safety for patients when mam-
mary arteries are used more liberally. There are many obstacles both real and feared to 
the performance of BIMA grafting which with this thesis it is hoped that will promote 
a mindset of the necessity to overcome these obstacles and liberalize the use of BIMA 
grafting.
PART 2: RATIONALES FOR USE OF BILATERAL INTERNAL MAMMARY ARTERY 
GRAFTING IN THE MAJORITY OF CORONARY ARTERY BYPASS GRAFT 
PATIENTS
Chapter 3 describes the history and evolution of the coronary artery bypass graft proce-
dure now 51 years of age, and also includes an overview of outcomes – post-operative, 
short and long-term and the determinants of these outcomes.
Chapter 4 describes contemporary CABG techniques, types of conduits used, and 
current methods of quality assurance that have come to make this procedure as safe as 
it is today.
Chapter 5 is a ‘Letter to the Editor’ about arterial grafting which poses the question 
as to whether the radial artery should supplant the vein graft as a superior conduit and 
be the ‘third choice’ conduit given that the best conduits are the left and right internal 
mammary arteries.
Chapter 6 is an editorial point of view regarding use of BIMA vs saphenous vein graft-
ing and reasons are postulated as to why they are used or not.
PART 3: PATIENT’S AGE OF BENEFIT FOR BILATERAL INTERNAL MAMMARY 
ARTERY GRAFTING
Chapter 7 examined retrospectively three groups of patients receiving no, one or two 
internal mammary arteries with a view to dening an age cuto at which BIMA grafting 
was not of benet. The data nding of a statistical trend of the age cuto of 70 years has 
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been accepted by international experts in this eld; this paper is referenced in the recent 
ESC and EACTS Guidelines of Myocardial Revascularization (Oct 2014).
PART 4: REDUCING THE RISKS ASSOCIATED WITH BILATERAL INTERNAL 
MAMMARY ARTERY GRAFTING
Chapter 8 retrospectively reviewed the use of intra-operative transit-time ow mea-
surement (TTFM) to assess the function of bypass grafts in the rst 336 patients and 
found that when only the TTFM was abnormal (no other signs of graft malfunction such 
as EKG changes, regional wall motion abnormalities on echo or hemodynamic compro-
mise) and the graft was not revised, these patients had a signicantly higher chance of 
morbidity and especially mortality. This study has been referenced in three guidelines 
for myocardial revascularization: in the ESCS/EACTS 2010 and 2014 Guidelines for Myo-
cardial Revascularization and in the Medical Technology Guidance ‘The VeriQ system 
for assessing graft ow during coronary artery bypass graft surgery’ for the National 
Institute for Health and Clinical Excellence (NICE) for the National Health Service, UK in 
November 2011.
Chapter 9 describes a pilot study of a novel adhesive-enhanced closure of the ster-
num after cardiac surgery. Use of this biocompatible glue (Kryptonite) confers a solid 
sternum at 24 hours after application of the glue between the sternal halves at the time 
of surgery, instead of the 3 month requisite time to heal any broken bone.
Chapter 10 describes 12 sequentially added infection reduction techniques/pro-
cedures over several years in a group of 1001 consecutive CABG operations with the 
ultimate goal to reduce one of the most dreaded complications of CABG procedure, 
deep sternal wound infection to near zero. This study was also chosen as a topic for an 
editorial by Professor Paul Kurlansky in the same volume.
PART 5: COMPLETENESS OF REVASCULARIZATION AND BILATERAL INTERNAL 
MAMMARY ARTERY GRAFTING
Chapter 11 challenges the concept that incomplete revascularization in CABG surgery 
results in reduced survival. Midterm follow-up of 1000 patients with 98% arterial grafts, 
(if under the age of 80 years) showed similar survival whether they had incomplete or 
complete revascularization. We postulated that all previous studies showing the reduced 
survival of incompletely revascularized patients were in CABG patients with either only 
one or no arterial bypasses. Vein graft occlusion occurs in 12% of the bypasses early (3 
weeks) 25% at 1 year. Between 5 and 10 years postoperatively, FitzGibbon et al reported 
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an unexpected increase in vein graft abnormality, which they termed ‘the 7.5 year 
phenomenon’. [1] However 85-95% of arterial grafts are patent at 10 years. If a patient 
loses one of three bypass grafts  –  this patient essentially has single vessel disease; if 
they lose two, now with ‘double vessel disease’ their survival would be much more likely 
be aected than with just single vessel disease. To put this simply, because vein grafts 
occlude at a faster rate than arterial grafts, if patients start out with one (or two) less 
bypass grafts than they should have and then lose the vein graft(s), they are more than 
likely will suer the consequences – myocardial infarction and reduced survival.
Chapter 12 is a review article exploring the challenge of complete revascularization 
when using arterial grafts. Factors hindering this include the nite length of arterial 
conduits, (the length of the sternum for mammary arteries and of the forearm for radial 
arteries), competitive coronary ow and technical challenges using arterial grafts.
PART 6: FACILITATING SURGICAL USE OF BILATERAL INTERNAL MAMMARY 
ARTERY GRAFTING
Chapter 13 examines the use of the harmonic scalpel to skeletonize 1640 internal mam-
mary arteries in 965 patients. One drawback to performance of routine bilateral internal 
mammary artery grafting is increased operative time on two levels: 1) harvesting two 
IMAs doubles the conduit harvest time (saphenous vein harvest is simultaneous whereas 
double IMA harvesting is metachronous) and 2) skeletonization of the internal mam-
mary artery (which facilitates arterial grafting,) also is more time intensive compared to 
the more common pedicle technique. We found that mean harvest skeletonization time 
of the IMA without harmonic technology was 32.2 minutes. When experienced with the 
use of the harmonic scalpel, the harvest times dropped to 15.4 minutes/IMA. This reduc-
tion in harvest time could therefore potentially reduce each operation by 30 minutes. 
As cardiac surgeons usually perform 2 procedures per day, this would reduce the whole 
day operative time by 1 hour; nishing a day at 18:00 hours instead of 19:00 hours has 
signicant benecial implications for the whole operative team. Use of harmonic tech-
nology is not only faster than the conventional method of skeletonization; damage to 
the mammary (to beyond its use as a conduit for bypass) occurs infrequently (7/1640 
mammaries – 0.43%).
Chapter 14 is the script of a video published on Cardio Thoracic Surgery network 
(CTSNet) a world- wide web site. This 9 minute video shows the technique of skeleton-
izing internal mammary arteries using harmonic technology.
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PART 7: SPECIAL TECHNIQUES IN THE USE OF ARTERIAL GRAFTING
Chapter 15 is a publication (1986) on the use of sequential venous grafting. This was a 
futuristically important paper because i) the study found that the second anastomosis 
of a sequential venous graft was more likely to occlude, ii) the second anastomosis was 
usually to the more important vessel – the left anterior descending artery (LAD) and iii) 
sequential grafts are a major technique used by arterial grafting surgeons because of 
the limited and nite length of arterial conduits. It will be very interesting to perform a 
similar study with arterial grafts to see if the second anastomosis loss occurs with arterial 
conduits as it does with venous grafts, giving one more reason for the reluctance to 
perform much arterial grafting.
This manuscript was co-authored with Dr. Gerald M. FitzGibbon who was an Irish 
cardiologist working in Canada for the Canadian Military. He is responsible for the ‘A, B, 
O’ classication of bypass graft patency that is still used today. I had the great fortune to 
work for 2 years with Dr. FitzGibbon at the military hospital, National Defense Medical 
Centre (NDMC) to fulll my obligation to the Canadian Military for nancially supporting 
me during medical school.”
Chapter 16 is the script of a video published also on CTSNet and describes a rare 
complication of coronary artery surgery – dissection of the whole left coronary system 
and aortic root which originated from a bypass graft to the circumex system. Usually 
lethal, disaster was averted by i) carving an oval opening in the calcied anterior LAD 
coronary artery wall which allowed ii) insertion of an additional graft placed to the true 
lumen of the dissected coronary artery (sutures placed through full wall thickness). This 
resulted in: i) closure of the dissection in the LAD at the graft site, ii) perfusion of the 
complete LAD system from the added graft and hence iii) reversal of the dissection in 
the left coronary and the aorta by obliteration of the false lumen. By closing the dis-
section locally at mid LAD level and with the forward ow in the new LAD graft, the 
dissection process was reversed restoring coronary ow to the left ventricle (LV) and 
hence function of the LV. The case by itself is dramatic, but the true importance of this 
report is that it has led to the incorporation of this technique of creating an oval opening 
for patients with densely calcied arteries. If such calcied coronary arteries have an 
acceptable lumen, this procedure will allow bypass grafting in patients that otherwise 
could not be done.
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DEEL 1: INLEIDING
Hoofdstuk 1 beschrijft de fysieke en psychologische belasting, waarmee patiënten met 
coronair arterie ziekte moeten leven. Het hoofdstuk omschrijft voorts de verantwoor-
delijkheid van de gezondheidszorg-beroepsgroep, die voor deze patiënten zorgdraagt, 
om hen naar beste vermogen te helpen deze last te verlichten met name met betrek-
king tot het uitvoeren van coronaire bypass chirurgie (CABG) met behulp van de arteriae 
mammariae internae (IMA).
Hoofdstuk 2: verklaart van de volgende hoofdstukken zowel het focus alsook het 
doel, namelijk het gebruik van IMA bypass-grafts te faciliteren en de veiligheid voor 
patiënten te vergroten wanneer IMA grafts meer vrijelijk gebruikt worden. Het gebruik 
van bilaterale IMA bypass-grafts (BIMA) ontmoet vele -zowel reële alsook vooral ge-
vreesde- belemmeringen. Het is de hoop van de auteur dat dit proefschrift een ‘mindset’ 
van collegae zal bevorderen dat het nodig is deze belemmeringen te overkomen om 
BIMA-CABG frequenter toe te passen.
DEEL 2: REDENEN VOOR TOEPASSING VAN BIMA BYPASS-GRAFTS IN DE 
MEERDERHEID VAN CABG PATIËNTEN
Hoofdstuk 3: geeft een overzicht van geschiedenis en ontwikkeling van de nu 51 jaar 
oude CABG procedure met inbegrip van een overzicht van de resultaten I) direct post-
operatief ii) op korte termijn en iii) op lange termijn alsook de bepalende factoren voor 
deze resultaten.
Hoofdstuk 4: beschrijft de hedendaagse CABG technieken, de aard van het gebruikte 
vat voor de bypassgraft, en de huidige methoden van kwaliteitsgarantie die deze proce-
dure inmiddels zo veilig hebben gemaakt als hij heden ten dage is.
Hoofdstuk 5: is een ‘Letter to the Editor’ over arteriële grafts, die stelt dat de linker 
IMA en de rechter IMA de beste bypassvaten zijn en dat de Art. Radialis superieur is als 
bypass vat aan de Vena Saphena Magna. De ‘Letter’ stelt derhalve als vraag: ‘dient de Art. 
Radialis de Vena Saphena Magna als derde keus voor bypassvat te vervangen?’.
Hoofdstuk 6: behelst een editorial standpunt betreende BIMA versus Vena Saphena 
Magna bypassvaten en postuleert redenen waarom deze bypassvaten al dan niet ge-
bruikt worden.
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DEEL 3: DE LEEFTIJD VAN DE PATIENT WAARBIJ BIMA-CABG HET MEESTE 
BAAT HEEFT
Hoofdstuk 7: bestudeert in een retrospectieve studie drie patiëntengroepen, die i) 
geen ii) een of iii) twee IMA bypassvaten ontvangen hadden teneinde te bepalen of er 
een leeftijdsgrens is waarbij BIMA bypassvaten geen extra baat meer voor de patiënt 
oplevert. De gegevens toonden een statistische trend voor de leeftijdsgrens van 70 
jaar; deze grens is nu geaccepteerd door internationale experts in het vakgebied en het 
artikel wordt gerefereerd in the recentelijk gepubliceerde ESC en EACTS Richtlijnen voor 
Revascularisatie van het Myocard (Oktober 2014).
DEEL 4: REDUCTIE VAN DE RISIKOS DIE SAMENHANGEN MET BIMA-CABG
Hoofdstuk 8: geeft een retrospectief overzicht van het gebruik van intra-operatieve 
meting van intravasculaire stroomsnelheid met behulp van de transit time techniek 
(TTFM) om de functie van bypassvaten te evalueren in de eerste 336 patiënten. De 
resultaten toonden aan, dat wanneer de TTFM abnormaal was -zonder andere tekenen 
van malfunctie van het bypassvat zoals ECG afwijkingen, regionale wandbewegings 
abnormaliteiten op het echocardiogram of gecompromitteerde hemodynamica- en het 
bypassvat niet gerevideerd werd, dat deze patiënten een signicant grotere morbiditeit 
en mortaliteit hadden. Deze studie is gerefereerd in the drie gepubliceerde ESC en 
EACTS Richtlijnen voor Revascularisatie van het Myocard (2010 en 2014) en in de ‘Me-
dical Technology Guidance’ getiteld:” The VeriQ system for assessing graft ow during 
coronary artery bypass graft surgery” voor the National Institute for Health and Clinical 
Excellence (NICE) voor the National Health Service, UK in November 2011.
Hoofdstuk 9: beschrijft een pilot studie van sluiten van het sternum met behulp van 
een adhesie-versterkte methode. Het gebruik van de bio-compatible lijm Kryptonite 
geeft een soliede sternum in 24 uur na het aanbrengen van de lijm tussen de helften 
van het sternum ten tijde van de operatie, in plaats van de verwachte 3 maanden voor 
het helen van willekeurig welk gebroken bot.
Hoofdstuk 10: beschrijft in detail 12 infectie reductie technieken/maatregelen die 
in een groep van 1001 achtereenvolgens uitgevoerde CABG operaties over de jaren 
werden toegevoegd met het uiteindelijke doel om de meest gevreesde complicatie van 
de CABG operatie –i.e. ‘deep sternal wound infection’- te elimineren. Deze studie werd 
gekozen voor een editorial door Professor Paul Kurlansky (zie de appendix).
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DEEL 5: VOLLEDIGHEID VAN REVASCULARISATIE MET BIMA BYPASSVATEN
Hoofdstuk 11: daagt het concept uit dat incomplete revascularisatie leidt tot vermin-
derde postoperatieve overleving. Een ‘midterm’ vervolg studie van 1000 patiënten met 
98 procent arteriële bypassvaten (indien zij minder dan 80 jaar oud waren) toonde 
gelijke overlevingspercentages onafhankelijk van de vraag of zij compleet of incom-
pleet gerevasculariseerd waren. We veronderstelden dat in vroegere studies de lagere 
overlevingspercentage gevonden waren in incompleet gerevasculariseerde patiënten 
met een CABG zonder of met slechts één arterieel bypassvat. Occlusie van een veneus 
bypassvat treedt op in 12% van de bypasses in 3 weken en in 25% na een jaar. FitzGib-
bon et al. rapporteerden een onverwachte toename in veneuze bypass abnormaliteit na 
5 tot 10 jaar en noemden dit het ‘7.5 jaar fenomeen’ [1] Van de arteriële bypassvaten is 
daarentegen 85-95% open na 10 jaar. Als een patiënt één van drie bypassvaten verliest 
heeft de patiënt in essentie één-vat coronair ziekte. Als de patiënt twee vaten verliest 
heeft de patiënt twee-vaten coronair ziekte met als gevolg een beduidend ernstiger 
prognose dan één-vat coronair ziekte. Omdat veneuze bypasses sneller dan arteriële by-
passvaten occluderen, staan patiënten met incomplete revascularisatie waarbij veneuze 
bypassvaten gebruikt worden simpelweg bloot aan een grotere kans op verlies van een 
bypassvat en lopen dus een groter risico van een hartinfarct en hebben een derhalve 
gereduceerde overlevingskans.
Hoofdstuk 12: is een review dat de uitdaging van de noodzaak to complete revas-
cularisering middels arteriële bypassvaten evalueert. Factoren die de volledigheid van 
arteriële bypass procedure beperken zijn i) de lengte van het arteriële bypassvat (i.e. de 
lengte van het sternum voor de IMA en de lengte van de onderarm voor de Art Radialis 
bypass), ii) competitieve coronaire bloedstroom en iii) technische problemen bij het 
gebruik van arteriële bypassvaten.
DEEL 6: FACILITEREN VAN HET UITVOEREN VAN CABG MET BIMA BYPASS 
VATEN
Hoofdstuk 13: Onderzoekt het gebruik van de harmonic scalpel teneinde 1640 IMA’s in 
965 patiënten te skeletonizeren . Een nadeel van routinematig gebruik van BIMA grafts 
is de toegenomen operatietijd door twee oorzaken: 1) het oogsten van twee IMA vaten 
vergt tweemaal de tijd van de veneuze bypassoogst omdat de vene synchroon met 
de thoracale procedure plaatsvindt terwijl de IMA daar metachroon mee plaatsvindt; 
2) skeletonizeren van de IMA vergemakkelijkt weliswaar de graft procedure aanzien-
lijk, maar is tijdrovender dan de meer gebruikelijke ‘pedicle’ techniek. De gemiddelde 
oogsttijd van één IMA, inclusief het skeletonizeren, zonder de harmonische scalpel 
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technologie bleek hier 32.2 minuten te zijn. Het gebruik van het harmonisch scalpel in 
ervaren handen reduceerde de oogsttijd tot 15.4 minuten/IMA, hetgeen derhalve de to-
tale operatieduur met een half uur kan reduceren. Aangezien hartchirurgen gewoonlijk 
twee procedures per dag verrichten maakt deze reductie het mogelijk een operatie dag 
om zes uur in plaats van om zeven uur in de namiddag te beëindigen met aanzienlijke 
voordelen voor het hele operatieve team. Voorts is het gebruik van de harmonische 
technologie niet alleen sneller dan de conventionele technologie van skeletonizeren 
maar ook vindt zodanige beschadiging van de IMA , dat geen enkel deel meer bruikbaar 
is als bypassvat, slechts sporadisch plaats (7/1640 IMAs ofwel 0.43%).
Hoofdstuk 14: is de tekst bij een video-opname (9min), die gepubliceerd is op het 
Cardio Thoracic Surgery netwerk (CTSNet). De video toont de techniek van het skeleto-
nizeren van de IMA met het harmonisch scalpel.
DEEL 7: SPECIALE TECHNIEKEN GEBRUIKT BIJ ARTERIËLE BYPASSVATEN
Hoofdstuk 15 is een publicatie uit 1986 over het gebruik van sequentiële veneuze 
bypasses. Dit artikel was van futuristisch belang omdat: i) the studie beschreef dat de 
tweede anastomose van een sequentiële veneuze graft een grotere waarschijnlijkheid 
van occlusie vertoonde, terwijl ii) de tweede anastomose gewoonlijk een belangrijkere 
coronair arterie betrof -de Linker Art. Descendens Anterior (LAD) en iii) sequentiële 
grafts vaak worden als techniek gebruikt door coronair chirurgen als oplossing voor het 
probleem van de beperkte lengte van arteriële bypassvaten. Het is waarschijnlijk dat een 
soortgelijke studie van sequentiële arteriële grafts boeiende gegevens zal opleveren 
over de vraag of de tweede anastomose zal occluderen zoals gebeurde bij sequentiële 
veneuze grafts. Dit is van belang omdat vroegtijdige occlusie van de tweede sequentiële 
arteriële anastomose een extra reden zal vormen voor de -al bestaande- huiver voor het 
gebruik van arteriële grafts.
De co-auteur van dit manuscript was Dr. G.M. FitzGibbon, een Ierse cardioloog die 
in Canada voor het Canadese leger werkte. Hij is de auctor intellectualis van de ‘A, B, O’ 
classicatie voor de doorgankelijkheid van coronaire bypasses, die heden ten dage nog 
steeds in gebruik is. Ik had het grote voorrecht om twee jaar lang met Dr. FitzGibbon in 
het militaire ziekenhuis ‘National Defense Medical Centre’ te werken om mijn verplich-
tingen na te komen voor de nanciële steun van het Canadese leger gedurende mijn 
medische studie.
Hoofdstuk 16: is de tekst van een video die ook op het CTSNet gepubliceerd is, die 
een ongebruikelijke complicatie van coronair chirurgie beschrijft: dissectie van het 
gehele linker coronair arteriële system inclusief de stam van de aorta uitgaande van de 
graft op een de Art. circumex. Gewoonlijk is dit een lethale complicatie; in dit geval 
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kon een ramp voorkomen worden door: i) een ovale opening uit de verkalkte anterieure 
wand van de LAD uit kerven en ii) daarna een additionele graft aan te sluiten met ge-
bruik hechtingen die de gehele wand van de blootgelegde LAD passeerden. Als gevolg: 
i) werd de dissectie in de LAD lokaal afgesloten en ii) het linker coronair systeem werd 
nu geperfundeerd vanuit de toegevoegde graft iii) hetgeen de dissectie keerde in het 
linker coronair systeem en de aorta door obliteratie van het valse lumen. Hoewel de 
casus op zich dramatisch is, ligt het werkelijke belang in het principe van het ‘kerven 
van een ovale opening’ uit de coronair arterie wand ten behoeve van patiënten met 
zwaar verkalkte coronair arteriën -met niettegenstaande een goed lumen-, die anders 
ongeschikt lijken om bypass te accepteren.
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